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Abstract 
 
 
More than 11 million people worldwide are diagnosed with cancer every year. New cancer 
drugs are required that are more effective and selective. Nitrogen mustard alkylating agents 
crosslink DNA inhibiting transcription and replication. Use of the mustard pharmacophore 
as part of a macrocycle allows metal complexation and produces a prodrug. Hypoxic 
tumour cells have increased concentrations of reductase enzymes which could lead to 
reduction of the complex in situ and release of a cytotoxic drug. 
Human African Trypanosomiasis is commonly known as Sleeping Sickness and affects 
over 36 countries of sub-Saharan Africa. It is transmitted to humans by the tsetse fly which 
carries the parasitic subspecies Trypanosoma brucei rhodesiense and Trypanosoma brucei 
gambiense. Any compounds synthesised would also be tested to assess their potential as 
anti-parasitic agents. 
 
Parker synthesised a range of polyazamacrocycles. Testing of compound A in vitro gave 
highly efficient DNA crosslinking activity. Copper complexes were formed of the 
macrocycles and B was found to be 24 times more toxic against hypoxic cells than oxic 
cells thus exploiting tumour hypoxia and creating a selective drug. Jones synthesised a 
range of oxaazamacrocycles such as C which when tested in vitro exhibited comparable 
cross-linking activity to the azamacrocycles although it proved impossible to synthesise the 
corresponding copper complexes. 
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It was decided to vary the leaving group on the alkylating arms to see if the DNA 
crosslinking results could be improved. Eight carbamates and the corresponding copper 
complexes were synthesised. The R-groups were alkyl and aromatic. Anti-cancer DNA 
crosslinking and hypoxia selectivity results were disappointing however, a number of 
compounds displayed significant activity when tested against T. brucei.  
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A range of thiaazamacrocycles would complete the set of heteroatom-containing 
macrocycles (N, O, S) and might produce good DNA crosslinking results. It might also be 
possible to synthesise the corresponding copper complexes producing prodrugs. Six 
thiaazamacrocycles were synthesised and 2-hydroxyethyl arms were attached. However it 
proved impossible to isolate the desired alkylating agents with the 2-chloroethyl arms. 
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In the body, the p53 protein activates the transcription of specific genes. In healthy cells, 
the levels of p53 have to be kept to a minimum to allow the normal running of the cell, e.g. 
growth and replication. This function is carried out by the HDM2 protein, which forms an 
auto-regulatory feedback loop with p53. In some tumours, the p53 function is disrupted 
due to genetic mutations of p53. However other tumours possess ‘wild type’ p53 – this 
type of p53 has lost the ability to respond to oncogenic stress due to over-expression of 
HDM2. Drugs that inhibit HDM2 should cause stabilisation of p53 and induce apoptosis in 
cancer cells.  A small library of 5-deazaflavins were synthesised and biologically tested 
producing some interesting biological results. 
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abs.   absolute 
AcOH   acetic acid 
ADEPT  antibody directed enzyme prodrug therapy 
ADP   adenosine diphosphate 
AIDS   autoimmune deficiency syndrome 
ALDH   aldehyde dehydrogenase 
ARF   auxin reponse factor 
aq.   aqueous 
BBB   blood brain barrier 
BC   before Christ 
BCEA   N,N-bis(2-chloroethyl)amine 
Boc   tert-butoxycarbonyl 
bs   broad singlet 
oC   degrees Celsius 
CDCl3   deuterated chloroform 
CI   chemical ionisation 
CML   chronic myeloid leukaemia 
CNS   central nervous system 
conc.   concentrated 
cyclen   1,4,7,10-tetraazacyclododecane 
d   days or doublet 
dd    doublet of doublets 
DMF   N,N-dimethylformamide 
DMSO   dimethylsulfoxide 
DNA   deoxyribose nucleic acid 
EC50   concentration of a drug to inhibit 50% of growth 
EI   electron impact ionisation 
EPO   erythropoietin 
Et   ethyl 
EtOH   ethanol 
eq.   equivalents 
FAB   fast atom bombardment 
g   gram 
GDEPT  gene directed enzyme prodrug therapy 
6 
h   hours 
HAT   Human African Trypanosomiasis 
HBr   hydrobromic acid 
HCl   hydrochloric acid 
HDM2   human double minute gene 2 
HEK   human embryonic kidney 
HIV   human immunodeficiency virus 
HPDC   hypoxia activated prodrugs of diffusible cytotoxins 
HPLC   high performance liquid chromatography 
HSC   hypoxia selective cytotoxin 
Hz   hertz 
IC50   concentration of a drug to inhibit 50% of growth 
IR   infra-red 
J   NMR spectra coupling constant 
kDa   kiloDalton 
kg   kilogram 
L   litre or ligand 
µL   microlitre 
Leu   Leucine 
lit.   literature 
m   multiplet 
M   molar or metal centre of complex 
λmax   maximum UV absorbance 
MDM2  mouse double minute gene 2 
Me   methyl 
MeOH   methanol 
mg   milligram 
MHz   megaHertz 
mmol   millimole 
mM   millimolar 
µM   micromolar 
mL   millilitre 
mp   melting point 
Ms   methanesulfonyl 
MSF   Médecins Sans Frontières 
NMR   nuclear magnetic resonance 
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ODC   ornithine decarboxylase 
P   partition coefficient 
Ph   phenyl 
Phe   phenylalanine 
q   quartet 
RPE   primary human pigment epithelial cells 
RT   room temperature 
s   seconds or singlet 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SN1   nucleophilic primary substitution 
t   triplet 
T   temperature 
T.b.g.   Trypanosoma brucei gambiense 
T.b.r.   Trypanosoma brucei rhodesiense 
TEBA   triethylbenzyl ammonium chloride 
TETA   triethylene tetraamine 
THF   tetrahydrofuran 
TLC   thin layer chromatography 
Try   Tryptophan 
Ts or tosyl  para-toluenesulfonyl 
UV   ultraviolet 
WHO   World Health Organisation 
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1 Cancer 
Cancer is defined in the Oxford English Dictionary as ‘a malignant growth or tumour in 
different parts of the body, that tends to spread indefinitely and to reproduce itself, as also 
to return after removal; it eats away or corrodes the part in which it is situated, and 
generally ends in death.’1  
Mitosis is the name for the process by which a cell replicates, i.e. the division of a cell to 
produce two identical daughter cells. Cancer occurs when there is uncontrolled cell 
division and the normal processes of mitosis such as initiation, control and termination 
cannot occur - generally this is due to genetic mutations.  This uncontrolled cell division 
results in the growth of a tumour.2 There are two categories of tumour: benign and 
malignant. A benign tumour will not spread to other parts of the body and rarely causes 
death. A malignant tumour can metastasise; this means that the cancer can invade other 
tissues.  
One in three people from the western world will contract cancer at some point in their lives 
and one in four will die as a result of the disease.2 Although cancer is considered to be a 
disease of the modern world, the first reference to it appeared in an Egyptian papyrus 
dating from 3000-1500 BC that mentions breast tumours.2 Cancer is not just confined to 
humans, since animals and plants have demonstrated tumorigenesis.3 
1.1 Cancer Treatments 
Modern medicine has made huge advances towards the treatment of cancer. There are four 
main treatments used. Generally a combination of the treatments is given to ensure that the 
patient receives the best outcome. 
1.1.1 Surgery 
Surgery was once considered to be the only option, and indeed can completely ‘cure’ 
cancer by the removal of cancerous tissue. If the cancer has been diagnosed early then 
surgery can be the most effective treatment; however the problem is metastasis. Nowadays 
tissue biopsies are essential for diagnosis and surgery is carried out in 90% of cancer 
patients.2 
Jennifer M. Wilson, 2007   Chapter 1, 12 
1.1.2 Radiotherapy 
Radiation therapy can stop cell proliferation and disrupts atoms within tumour cells. The 
cell DNA is damaged beyond repair.2 However the radiation can’t distinguish between 
healthy and cancer cells – especially rapidly dividing cells such as bone marrow and hair 
folicles so patients suffer from side-effects. Doses can be given internally or externally and 
advances in technology mean that the radiation can be targeted more precisely to the 
desired area increasing dose efficiency and diminishing damage to healthy cells. 
1.1.3 Biotherapy 
The cancer is controlled by the body’s natural defence system. Immunotherapy or 
biotherapy uses the body’s immune system to fight cancer.2 It is designed to repair, 
stimulate or enhance the body’s immune response. The treatment should stop, control, or 
suppress processes that permit cancer growth by making cancer cells more recognizable, 
and therefore more susceptible, to destruction by the immune system. Biotherapy can also 
block or reverse the process that changes a normal cell or a pre-cancerous cell into a 
cancerous cell.  
1.1.4 Chemotherapy 
Chemicals are used to kill cancerous cells by damaging the cell proteins or the cell DNA. 
The aim is to cause apoptosis (cell suicide).2 Cytotoxic drugs such as antibiotics, 
antimitotics, hormones, antimetabolites, inorganic compounds and alkylating agents are 
currently used as chemotherapeutic agents. Chemotherapy cannot distinguish between 
healthy and cancerous cells so side effects are then experienced.  
1.2 Alkylating Agents 
Alkylating agents are the best known anticancer cytotoxic therapeutic agents available for 
use in oncology departments today due to their effectiveness in cross-linking DNA, thus 
inhibiting cell growth and ultimately leading to cell death. Covalent bonds are formed 
between the DNA strand and the alkylating agent causing intermolecular cross-linking; cell 
death occurs because the DNA can no longer unwind and replicate. 
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The anticancer properties of alkylating agents were discovered after the use of mustard gas 
in World War I – casualties developed a profound fall in their white cell count with 
damage to marrow and lymphatic tissue.  
 
Sulfur gas 1 was first synthesised in 1860 by Frederick Guthrie using ethylene and sulfur 
dichloride4 (Scheme 1), although the idea was first developed by M. Depretz in 1822.5 In 
its pure form, mustard gas is a colourless, odourless, viscous liquid. However the warfare 
agent was used impure as a yellow/brown substance with an odour similar to mustard 
plants (it is not related to culinary mustard), garlic or horseradish.  
 
+   SCl2 S ClCl
1
 
Scheme 1 
Other names for 1 include HD, sengas, sulfur mustard, blister gas, s-lost, Kampstoff LOST, 
yellow cross liquid and yperite. The LOST part of the name comes from a reference to 
Lommel and Steinkopf who developed a process for mass producing the gas for war use by 
reacting thiodiglycol with HCl.6 
 
Sulfur gas is a strong vesiccant (blister causing agent). Upon exposure there are no 
immediate symptoms. Within 4-24 h of exposure any area of skin that comes into contact 
with the agent will develop deep itchy burning blisters and eyes will become sore and 
swollen leading to conjunctivitis or blindness. Inhalation of the agent leads to respiratory 
problems such as mucous membrane damage and pulmonary oedema. If more than 50% of 
the body surface area is exposed then the result is usually fatal.7 Sulfur gas was first used 
effectively in 1917 by the Germans on Canadian soldiers during WW1. It has since been 
used in several conflicts including the Iraq-Iran war (1981-1988).5 
 
The therapeutic effects of mustards were discovered in 1943 in the port of Bari, Italy when 
a U.S. stockpile of mustard gas was bombed exposing thousands of civilians and 628 
Allied troops to the effects of the warfare agent. Medical workers discovered that white 
cell counts of exposed victims were decreased. Dr Cornelius Packard Rhoads thus 
investigated the use of mustards as treatment for Hodgkin’s lymphoma.8 Two American 
pharmacologists (Goodman and Gilman from Yale) were also investigating nitrogen 
mustards around the same time.9 This was essentially the birth of anti-cancer 
chemotherapy. 
Jennifer M. Wilson, 2007   Chapter 1, 14 
Alkylating agents are themselves carcinogenic as they damage the genetic material of the 
cell and the consequences of this genetic change can be the conversion of a normal cell 
into a cancerous cell. Fortunately the benefits of alkylating agents far outweigh the 
possibility that they will induce the development of a second cancer.  
 
Nowadays, alkylating agents are designed to form reactive intermediates with certain 
characteristics such as electron deficiency because these reactive electrophiles will be 
readily attacked by nucleophilic sites on biological molecules thus forming covalent bonds. 
Nucleophilic groups such as amino, carboxyl, sulfhydryl or imidazole moieties in proteins 
and nucleic acids can be alkylated. The intermolecular cross-link (Figure 1) generally 
occurs at the N-7 position on guanine.10 Two different nucleophiles on separate DNA 
strands attach to the alkylating agent preventing the unravelling of the DNA.  
 
N
R
 
Figure 1 
 
The spacing between the nucleophilic sites on each DNA strand and the number of carbon 
atoms between the two electrophilic sites on the alkylating agent are crucial. Ideally the 
two DNA strands will become locked in position to prevent replication. Cross-linking can 
occur on single strands on DNA – unfortunately this scenario is not serious and the DNA 
will repair itself. Bifunctional alkylating agents are responsible for forming rigid cross-
links between the two strands of DNA – these drugs are known as major groove-binders as 
a link is formed in the major groove of DNA. 
Jennifer M. Wilson, 2007   Chapter 1, 15 
 
1.2.1 Classifications of Alkylating Agents 
1.2.1.1 Nitrogen Mustard Derivatives 
There are four main nitrogen mustard derivatives – all four possess the same 
pharmacophore. The pharmacophore is an N-chloroethyl group that can attach itself to 
DNA. All the nitrogen mustards possess two chloroethyl groups, hence are bifunctional 
and able to crosslink DNA. This occurs by the release of a chloride ion as the molecule 
undergoes a first order reaction forming a positively charged reactive intermediate – an 
aziridinium ion. This intermediate covalently binds to the N-7 group on guanine, which is 
nucleophilic. The second ‘arm’ of the drug then undergoes similar reaction with the base 
on a separate strand of DNA forming the crosslink (Scheme 2).11 Several of the nitrogen 
mustards are discussed below. 
 
NR
Cl
Cl
NR
Cl
Nuc
NR
Nuc
Cl
NR
Nuc
Nuc
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Scheme 2 
Mechlorethamine12, commonly known as Mustargen 2, has a half-life of approximately one 
minute under physdiological conditions so it must be administered intravenously for the 
drug to have an effect. This drug is used to treat lymphomas. 
 
Cl N Cl
CH3
2
 
 
Chlorambucil13 3 has a half-life of twenty minutes which means that it can be taken orally 
in tablet form. Although 3 is insoluble in water, passive diffusion acts as the transport into 
cells. This drug exists mainly as a zwitterion – this means that the molecule is ionically 
doubly charged. This is not the reactive form of the drug because the nitrogen is protonated 
and unable to form the reactive intermediate. 
N
Cl
ClHO
O
3
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To increase the stability of nitrogen mustards, ring structures were added to the molecule. 
This increases the stability by decreasing the number of unwanted side reactions as the 
nucleophilicity of the nitrogen is reduced, for example an aromatic ring withdraws 
electrons from the nitrogen thus reducing the nitrogen’s ability to displace one of the 
chloride ions. Chlorambucil 3 is used to treat chronic lymphocytic leukaemia, ovarian 
cancers, trophoblastic neoplasms and Waldenström macroglobulinaemia as well as being 
used as an immunosuppressant.  
 
Melphalan13 4 exists as a highly charged species due to the fact that two nitrogens and one 
carboxylic acid are present. The uptake of the drug by cancer cells after oral administration 
is controlled by an amino acid active transport system. A drawback to use of this drug is 
the build up of resistance due to a mutation that leads to a change in the transport system. 
Melphalan 4 is used to treat multiple myeloma, malignant myeloma and ovarian cancer. 
One major drawback to the use of Chlorambucil 3 and Melphalan 4 is their minimal 
specificity, which means that they can be very toxic to healthy cells in the body, e.g. bone 
marrow cells. 
 
N
Cl
Cl
4
NH2HO
O
 
 
Cyclophosphamide14 5 was one of the first nitrogen mustard prodrugs to be synthesised. It 
was thought that tumours were rich in phosphoramidase which would convert the drug into 
its active form.  
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Scheme 3 
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Scheme 3 shows what actually happens. The drug 5 is oxidised by enzymes in the liver 
producing the active metabolite 4-hydroxycyclophosphamide 6 and its tautomer 7 which 
can react with aldehyde dehydrogenase (ALDH) forming phosphoramide mustard 8 that 
can crosslink with DNA. A side product is acrolein 9 which is toxic to the bladder 
epithelium.  
1.2.1.2 Alkyl Sulfonates 
The most common alkyl sulfonate is Busulfan15 10 which is also a bifunctional alkylating 
agent. It is used to treat chronic myeloid leukaemia (CML) and other cancers. It can be 
taken orally or intravenously.  
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1.2.1.3 Nitrosoureas 
The two main compounds that fall under this category are Carmustine (BCNU) 11 and 
Lomustine (CCNU) 12.16 Decomposition occurs in aqueous conditions. 
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Scheme 4 
These compounds are used for the treatment of brain tumours as they are extremely 
lipophilic so can easily pass through the blood-brain barrier (BBB).17  
1.2.1.4 Ethyleneimines 
As the classification name suggests, these drugs contain the three-membered ring moiety 
that appears as an intermediate during the DNA alkylation process. TEPA 13 was the 
initial compound synthesised although it turned out to be chemically unstable so 
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ThioTEPA 14 was produced.18 ThioTEPA is used to treat breast, ovarian and bladder 
cancer and is given intravenously. 
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1.2.1.5 Triazenes 
Triazenes are used to treat malignant melanomas and Hodgkin’s lymphomas. This group of 
compounds produces the same intermediates after following different physiological 
pathways in the body. Scheme 5 shows two examples, temozolomide 15 and dacarbazine 
16 breaking down to form the same intermediate 5-(3-methyltriazen-1-yl)imidazole-4-
carboxamide (MTIC) 17 which then breaks down to form amine-imidazole-4-carboxamide 
(AICA) 18 and the DNA-alkylating methyldiazonium ion 19.19 
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2 Hypoxia and Cancer 
The majority of solid human tumours contain areas deficient in oxygen and, cells in this 
condition are referred to as hypoxic.20 Hypoxia occurs when there is an insufficient amount 
of oxygen reaching tissues. Hypoxic cells have been found in cervical cancers, squamous 
cell carcinomas of the head and neck, melanoma, breast and prostate cancers. There is no 
regularity between individual tumours and there is no way of predicting the levels of 
hypoxia in a tumour.21 
Hypoxia is associated with the poor prognosis of cancer. Clinical and experimental 
evidence show that hypoxia is one of the major causes of resistance to treatment as well as 
encouraging tumour growth and possibly increasing malignant cell progression. In head 
and neck cancer there is evidence that the extent of hypoxia is associated with the overall 
survival of a patient.20 
The detection of the level of hypoxia present in a cancer patient may be beneficial for 
designing a patient-specific treatment course. In particular the assessment of early tumour 
response to treatment as well as examining long-term tumour response is an important area 
of research. Unfortunately, data on hypoxia in human tumours is scarce due to technical 
and experimental limitations. The oxygenation pattern of cells and the occurrence of 
hypoxia does not correlate with the stages of tumour growth.21 It is impossible to predict 
the oxygenation status of individual cells in tumours before therapy. Therefore, to design 
tumour specific treatments the tissue oxygenation of individual tumours must be evaluated. 
Hypoxic cells are intrinsically more resistant to treatment. Generally the amount of 
ionising radiation required for the destruction of hypoxic cells is three times that for 
oxygenated cancer cells.22 The resistance to chemotherapy in hypoxic cells is partially 
caused by reduced toxicity due to the absence of molecular oxygen. Some cancer agents, 
such as bleomycin23 20, require free radicals for the cell killing mechanism to be activated. 
Without molecular oxygen this mechanism cannot occur. Other problems occur due to the 
hypoxia-induced inhibition of the cell cycle. Several chemotherapeutic agents target high-
proliferating cells. However the rate of proliferation decreases in hypoxic cells due to the 
reduction in oxygen concentration.20 Toxicity of cancer agents also decreases the further 
the distance the tumour cells are from blood vessels. Simply put, the effective dose of a 
drug to hypoxic cells will be much less than that to other parts of the tumour. 
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2.1 The Problems Hypoxia Creates 
2.1.1 Metastasis20 
There is scientific evidence that shows the association of tumour hypoxia with metastasis – 
this is the spread of cancer from one part of the body to another. The promotion of tumour 
metastasis by hypoxic cells occurs in two ways: firstly by inducing the expression of 
certain gene products involved in the metastatic cascade; and secondly by selecting a more 
aggressive phenotype. 
The initiation of metastasis occurs by three major processes.24 The first step involves the 
degradation of the basement membrane and extra-cellular matrix of the cell. This is 
followed by the modulation of cell adhesion molecules resulting in cell migration - the 
cancer is now ‘moving’. 
2.1.2 Angiogenesis20,25 
The formation of new blood vessels, known as angiogenesis is required for tumour 
progression to occur. The expanding tumour mass requires nutrients and the removal of 
catabolites, which are produced by the breakdown of complex organic molecules into 
simpler components, accompanied by the release of energy. The process of angiogenesis is 
also required for the efficient dissemination of primary tumour cells during metastasis. 
The initial stages of both metastasis and angiogenesis are almost identical as both 
processes involve the degradation of the extra-cellular matrix and the directed migration of 
cells. Angiogenesis also requires proliferation of migrating endothelial cells. Therefore it 
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would be logical to think that molecules that aid tumour metastasis are also involved in 
angiogenesis and thus must also be regulated by hypoxia, i.e. matrix metalloproteinases, 
the urokinase-type plasminogen activator system and cell adhesion molecules. 
Tumours require an expansion of the blood supply to provide all nutritional requirements 
and a sufficient oxygen supply. Tumour cells adjacent to capillaries are adequately 
oxygenated and are therefore capable of normal aerobic metabolism and cell division. 
Oxygen must be carried by diffusion to cells not directly adjacent to a capillary and the 
oxygen tension diminishes with increasing distance from a blood vessel. Hypoxic cells 
present at the interface between well-oxygenated cells and necrotic tissue rely on anaerobic 
glycolysis26 (the process by which the normal pathway of glycolysis is routed to produce 
lactate) for energy production. These cells are ‘dormant’, dividing more slowly but 
remaining viable. 
Angiogenesis in a tumour produces vessel architecture that is disproportionate and 
inadequate as well as structurally and functionally different from normal tissue.  A 
consequence of this is the high rate of endothelial cell proliferation, which offers two ideas 
for the treatment of the cancer – anti-angiogenesis and vascular targeting. Distorted 
vasculature is also a problem as the drug delivery to hypoxic areas is challenged. 
2.2 Strategies for the Treatment of Cancer by Exploiting 
Hypoxia 
It has already been established that hypoxia is detrimental to cancerous cells as it 
encourages metastasis as well as other processes linked to the worsening of a patient. 
However, hypoxia can be exploited to our advantage especially if a treatment can be found 
that will differentiate between hypoxic and normal cells. 
2.2.1 Anti-angiogenesis27 
The idea behind this treatment is to stop the tumour developing new blood vessels. This is 
a complex biological process where the target population of cells consists of actively 
dividing and migrating vascular endothelial cells from established host and tumour vessels. 
Strategies involve the blocking of angiogenic growth factors and the suppression of 
endothelial cell recruitment through small molecule receptor blockers, specific antibodies, 
or the use of inhibitors. 
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In 2004, Bevacizumab28 (Avastin) became the first anti-angiogenesis drug to be approved 
for the treatment of cancer. The compound is a monoclonal antibody directed against 
vascular endothelial growth factor. The clinical trials carried out showed that people who 
took the drug as well as a course of chemotherapy lived longer (approximately five 
months) than patients who were just following a course of chemotherapy. However this 
drug does not seem to be a cure for cancer. 
2.2.2 Vascular Targeting29 
As explained before, solid tumours require a blood supply to provide oxygen and nutrients 
essential for growth. The growth of a tumour can be described as chaotic and the tumour 
vasculature results in the formation of subpopulations of hypoxic cells.  
Vascular targeting would use agents that exploit vasculature features that are unique within 
a tumour. There are advantages with this concept such as efficacy against any solid tumour 
because the endothelial cell lining is targeted, as well as no resistance being built up 
against the treatment – this is because endothelial cells are genetically stable. There is also 
easy accessibility of the drug to the target and the potential exists for the death of 
thousands of tumour cells due to vessel damage and subsequent nutrient deprivation. It is 
hoped that this technique will result in the death of hypoxic cells at an intermediate level, 
particularly those resistant to classical treatments. 
Generally tumour hypoxia is an independent predictor of the outcome of a tumour, as it 
does not depend on tumour size, clinical stage, histological type, and extent of necrosis or 
haemoglobin levels in the patient.20 Hypoxia has been assigned multiple roles in the whole 
process of cancer – it can induce angiogenesis, apoptosis and metastasis. The induction of 
these chemical changes results from changes in the gene expression that accompany 
hypoxia. The body does try and fight back by expressing genes to counteract hypoxia by 
increasing oxygenation or by mediating cell death signals and inducing cell death. 
2.2.3 Improving Oxygenation 
The main interest in this area involves the administration of hyperbaric oxygen, hypoxic 
cell sensitisers and erythropoietin (EPO - Figure 2) to improve the haemoglobin level and 
avoid repeated blood transfusions.30 
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Mixed results have been achieved from these studies. The best result was in head and neck 
cancers where analysis of a large number of trials showed that oxygen modification 
resulted in a significant improvement in local control and survival. 
 
Figure 2 
Erythropoietin is a glycoprotein hormone that stimulates red blood cell production.  It is 
produced in the kidneys in response to tissue hypoxia in the bone marrow. The structure is 
made up of one hundred and sixty five amino acids in a circular form. Two disulfide bonds 
tether the molecule together between cysteines 29 and 33 and cysteines 6 and 161. Three 
N-linked sugars are present at asparagines 24, 38 and 83, and one O-linked sugar is present 
at serine 126.  
This protein can be applied to a tumour model especially in anaemic patients where tumour 
hypoxia may occur due to low haemoglobin levels.31 There is active interest in using 
recombinant human EPO in order to improve tumour oxygenation. Haemoglobin 
concentration has been shown to be an important factor for the outcome of various cancer 
types that are conventionally treated by radiotherapy.  
2.2.4 ARCON32 
Accelerated radiotherapy combined with carbogen and nicotinamide is currently 
undergoing clinical assessment. Both agents have different roles for the treatment of 
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cancer. Carbogen (95% O2 and 5% CO2) reduces diffusion-limited or chronic hypoxia 
whereas nicotinamide 21 reduces acute hypoxia from vascular shutdown. Simultaneous use 
of these agents has increased the radiation damaging effect in rodent models.33 
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2.2.5 Exploitation of the Microenvironment 
There are three main ways that hypoxia can be exploited. Firstly the known molecular and 
cellular biological responses to hypoxia can be targeted. Secondly, the unique features of 
tumour vasculature (already discussed) which are responsible for, as well as a consequence 
of, tumour hypoxia, can also be exploited. Finally the lack of oxygen can be used to our 
advantage by the administration of bio-reductive drugs. 
2.2.5.1 Exploitation of Biological Responses20 
Gene expression is altered by the presence of hypoxic cells. These changes in expression, 
in turn, cause a cellular and tissue response that affects the processes occurring in the cell, 
be it angiogenesis, metastasis or sensitivity to treatment. If the activation of the early steps 
of these processes can be targeted, specific and effective types of gene therapy can be 
developed. The idea of this concept is to transfer genetic material to the tumour cell in 
quantities sufficient to obtain a therapeutic level of expression. To date, research carried 
out has been unsuccessful due to deficiencies in the delivery systems being used. However 
a current area of research involves the targeting of anaerobic bacteria that will infect the 
hypoxic/necrotic areas of tumours. 
Various biological responses to hypoxia can be seen in a generalised pathway consisting of 
four steps. Firstly an oxygen sensor is activated – an oxygen sensor is capable of sensing 
and responding to reduced oxygen levels. Then the activation of this sensor leads to a 
molecular response, which is quickly followed by a cellular response. The culmination of 
these steps is a tissue or tumour response.  
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2.2.5.2 Bio-reductive Drugs34 
These are inactive compounds that can be reduced by enzymes in the body revealing toxic, 
active metabolites. They are designed so that this metabolism occurs preferentially in the 
absence of oxygen making them good agents for targeting hypoxic cancer cells. Used in 
combination with existing cancer treatments this strategy has potential for improving 
treatment outcome by targeting the hypoxic fraction of the tumour. Hypoxic cells are also 
found in a number of different medical conditions including rheumatoid arthritis, diabetes 
and stroke – thus non-cytotoxic delivery of the therapeutic agent would be preferred.  
Bio-reductive drugs are also known as hypoxia-selective cytotoxins (HSCs).35  
Conceptually, HSCs consist of three domains: a trigger that undergoes hypoxia selective 
(oxygen inhibited) reduction; an effector which is activated following reduction of the 
trigger; and a linker which connects the other two domains and communicates the change. 
The trigger must undergo efficient and selective metabolism in the hypoxic cells to 
generate a toxic effector. Prodrugs are often classified by the nature of the trigger unit. The 
effector should be potent and able to kill cells in all proliferative states. Ideally it should be 
able to diffuse back to kill surrounding cells. Therefore, the effector requires good 
diffusion properties and an appropriate half-life. The linker deactivates the prodrug but 
must rapidly transmit an activating signal for the metabolism of the trigger. 
Bio-reductive drugs should fulfil several requirements. In hypoxic cells the compound 
should be converted into a stable persistent cytotoxin. The active product should bind non-
covalently to DNA with a reasonable affinity to produce cytotoxicity but with enough 
stability to allow slow diffusion and subsequent cytotoxicity in proximate tumour cells 
irrespective of the oxygen levels. The HSC must also be easily oxidised back to the parent 
compound if it comes into contact with an oxygenated cell. 
Nitro-aromatic heterocycles and indoloquinones have been studied for use as prodrugs.36 
There is significant interest in the design of a prodrug that when reduced will release, as 
well as an active drug, a bioreductive agent that itself will show therapeutic efficacy 
towards tumour cells (perhaps another population of tumour cells). Quinones release their 
active drug by a mechanism involving bio-reduction followed by intramolecular 
cyclisation (Scheme 6). The benzoquinone acts as the trigger and the propionic moiety acts 
as the linker.37 This effectively masks the drug until it is released in hypoxic tissues. The 
bulky ‘dimethyl lock’ imparts steric hindrance upon the molecule and this aids the 
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lactonisation (Thorpe-Ingold effect38). After reductive activation, intramolecular 
lactonisation occurs resulting in the elimination of the drug. 
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Scheme 6 
Bio-reductive drugs can also form adducts with DNA via attack by a nucleophilic moiety 
on DNA itself, i.e. the action of alkylating agents. This idea uses a synergistic approach for 
the killing of tumour cells – delivery of the drug as well as the concomitant activation of 
another cytotoxic agent. 
Another idea is to incorporate a nucleophile within the bio-reductive molecule that will 
react intramolecularly after bio-reduction and drug release, effectively inactivating the 
compound (Scheme 7).39 
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Scheme 7 
Vitamin E (tocopheryl quinone TQ 22) can be cyclised in a redox driven manner (Scheme 
8).40 The hydroxyl group is ejected upon reduction of TQ 22. Looking at this mechanism 
via a prodrug approach, the conjugation of a chemotherapeutic agent via the hydroxyl 
group would result in the ejection of the drug under favourable conditions.  
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Scheme 8 
Radio-sensitisers20 such as gemcitabine 23,41 are agents designed to mimic the effects of 
oxygen during radiation delivery. They perform two tasks – increasing DNA damage as 
well as restoring radio-sensitivity - and can be effective as this type of cancer agent. 
Unfortunately the compounds developed thus far could not be administered to patients at 
effective concentrations with acceptable toxicity. 
Two of the best ‘prodrugs’ are Tirapazamine 2442 (TPZ) and AQ4N 2543. TPZ is the 
leading compound in this class of drug and has been studied in clinical trials, especially the 
use of the drug in conjunction with cisplatin and/or radiotherapy. In fact a synergistic effect 
can be seen when the drug is used in conjunction with cisplatin. The release of the toxic 
moiety occurs by an enzymatically catalysed one-electron reduction of TPZ yielding a 
reactive hydroxyl radical capable of causing cell death through DNA damage.44 A strong 
oxidising species must be formed as TPZ causes double-strand breakage of DNA under 
anoxic conditions and these effects correlate with the cytotoxicity. In the presence of 
oxygen, this radical is transformed back into the non-toxic parental compound – thus 
oxygenated tissues are protected and toxicity is minimised. 
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TPZ causes several side effects including neutropaenia (an abnormally low level of 
neutrophils in the blood), fatigue, muscle cramps, nausea and vomiting. The mechanisms 
of these side effects are not fully understood. They could arise from aerobic redox cycling 
which leads to a reactive oxygen species or the TPZ radical forming in normal tissues. 
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In the case of AQ4N 25,43 a stable product AQ4 27 is released from the compound by a 
reduction process (Scheme 9) – this mechanism occurs via an obligate mono-N-oxide 
intermediate, AQ4M 26. AQ4 intercalates within the DNA strand and blocks 
topoisomerase II action. The AQ4 released is stable and diffusion to oxygenated cells can 
occur where it acts producing a ‘bystander’ effect – this occurs when cells produce 
damage-response signals that are communicated to their unaffected neighbours.  
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Scheme 9 
AQ4N 25 is the N-oxide of AQ4 27. AQ4 27 has a high DNA affinity constant which 
stabilises the DNA double helix as measured by a large increase in the DNA melting 
temperature. The DNA binding of the AQ4 chromophore is greatly facilitated by the 
electropositive nature of the alkylamino side chains in the protonated form of the drug – 
this allows for the critical electrostatic interaction with the phosphates of the DNA 
backbone.  
Nitro-heterocycles can act as mimics of molecular oxygen and can be effective as radio-
sensitisers of hypoxic cells.45 Although a correlation between the one-electron reduction 
potential of such compounds and their efficiency as sensitisers of hypoxic cells does exist, 
compounds have been recently identified that are markedly more potent than their 
relatively negative one-electron reduction potentials would suggest. 
Misonidazole 2846 was the first electron-affinic radio-sensitiser to receive extensive clinical 
study although it was established that it was not possible to administer a sufficient dose to 
achieve radio-sensitisation of tumours. 
The second generation of this class of compounds were 1-substituted-2-nitroimidazoles 
such as etanidazole 29,47 pimonidazole 3048 and RSU 1069 31,49 which are selectively toxic 
towards hypoxic cells because the 2-nitroimidazoles are bio-reduced in cancerous cells to 
form a specially designed electrophile that will avoid neuro-toxicity by being highly polar 
and thus less able to cross the ‘blood-brain barrier’. Pimonidazole 30 bears a tertiary amine 
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designed to be selectively absorbed by acidic regions of tumour tissue and thus has a 
higher potency. RSU 1069 31 is a ‘dual-function’ agent with electrophilic groups. The 
compound proved potent as a radio-sensitiser in experimental systems but elicited dose-
limiting gastro-intestinal toxicity in clinical trials. RB6145 3250 employs additional DNA-
alkylating functionalities in order to produce a toxic bi-functional DNA cross-linking 
species. At this point it could be seen that general toxicity of the compounds was hindering 
the development of a selectively bio-reductive cytotoxic species so attention was turned to 
producing bis(nitroimidazoles) - like compound 33.51 
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Using bis(nitroimidazoles), both of the nitro groups could be reduced providing a bi-
functional cytotoxin which was more toxic than the non-reduced species. However the 
kinetic data collected although consistent with a bi-reduced cytotoxic species, showed that 
the compound does not act as a DNA cross-linking agent. There were also two important 
limitations with this class of agent. The dose range could not be evaluated properly due to 
lack of aqueous solubility and the full hypoxic selectivity was only seen after exposure of 
several hours. This is presumed to be a consequence of the less electrophilic 5-
nitroimidazole moiety. 
Nitro-benzyl mustard quaternary salts are a new class of HSCs, which show very high 
hypoxic selectivities in vitro.52 The proposed products for this class of compounds are 
shown in Scheme 10. A one–electron reduction of the nitro-aromatic compounds is 
induced by cellular enzymes to give the nitro radical anion. This mechanism is controlled 
primarily by the reduction potential of the compound and will occur in both oxygenated 
and hypoxic cells. The following step depends on the nature of the cell. In an oxygenated 
cell, molecular oxygen will re-oxidise the radical anion producing the parent compound. 
However, if the cell is hypoxic, fragmentation of the initial radical anion will occur 
producing a benzyl radical and a reactive nitrogen mustard, such as mechlorethamine 2.  
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Scheme 10 
There is published evidence that closely related nitro-benzyl salts and nitro-benzyl 
quaternary salts do fragment following a one–electron reduction and that the nitro radical 
anions of such compounds are readily re-oxidised by oxygen. Other studies involving 
cyclic voltammetry and direct observation of the absorption spectra of both the transient 
radical anion and the resulting benzyl radical provide further evidence for the suggested 
mechanism. The observation that these compounds fragment efficiently using radiolytic 
reduction also suggests that the drugs could be reduced using radiotherapy rather than 
enzymatic reduction. The only drawback to this idea would be the need to use more potent 
cytotoxins for the concept to be therapeutically useful. 
Radiation-activated prodrugs use the aquated electron from the radiolysis of water as the 
reducing agent.53 The hypoxic selectivity is achieved by the redox cycling of the initial 
electron adduct in the presence of oxygen. Again it must be reinforced that highly potent 
cytotoxins are required to compete with endogenous electron acceptors in the body for the 
radiation-induced reductants.  
The positive charge on the quaternary salt ensures a high degree of deactivation of the 
mustard and excellent water solubility of the compound as well as a reduction potential 
within the range expected to be suitable for metabolic activation. It is now known that the 
extent to which toxicity is masked by a prodrug is not directly related to the reduction 
potential. However it is thought that the charge will slow the cellular uptake rate of the 
drug.51 
Mechlorethamine 254 is the best mustard so far found to be formed from the fragmentation 
of the drug. It possesses a half-life long enough for back-diffusion into other tumour cells 
to occur. The release of mechlorethamine has been confirmed by the trapping of the 
nitrogen mustard with diethyl dithiocarbamate and HPLC analysis. 
The main problem with nitro-benzyl quaternary salts is their aerobic toxicity as this totally 
negates the idea of a prodrug. Aerobic toxicity is not thought to be caused by the reductive 
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activation of the drug unless the reduced intermediate is not as stable as thought. Other 
possible theories indicate the slow release of the nitrogen mustard by direct nucleophilic 
displacement during the drug exposure phase. This potentially could occur chemically or 
enzymatically. Generation of a reactive oxygen species could also contribute to the aerobic 
toxicity through redox cycling. The main conclusion to be taken from these studies is that 
quaternising a mustard does not mask all its toxicity. 
Another potential strategy for the design and synthesis of prodrugs involves N-oxidation.55 
The electron density on the nitrogen of the mustard is significantly decreased and the pKa 
value is lowered by about 5 log units. Molecular oxygen inhibits the metabolic reduction of 
the tertiary amine N-oxides and the N-oxide derivative of mechlorethamine, nitromin 34, 
has been reported to have modest hypoxia selectivity in cell cultures. 
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Several different nitrogen mustards that were already used as therapeutic agents were 
transformed into their N-oxides using peracetic acid followed treatment with by sodium 
bicarbonate (Scheme 11).56 
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Scheme 11 
However, aliphatic N-oxides can rearrange in aqueous solution via a cyclic intermediate to 
form tri-substituted hydroxylamines (Scheme 12).57 Comparison of the 1H NMR spectra of 
the product with 35 showed that the chlorambucil N-oxide had indeed rearranged. The 
decomposition products were also tested but chlorambucil N-oxide was the most cytotoxic 
species present. 
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Scheme 12 
The development of related tetrahydroisoquinoline quaternary salts has also been carried 
out.35 The provision of a second, non-cleavable linking chain between the nitro-benzyl 
chromophore and the quaternary leaving group ensures that the released mustard and the 
benzyl radical remain linked. A mono-functional mustard will be generated and it is hoped 
that the simultaneous generation of a linked reactive centre generated from the attached 
benzyl radical will not hinder the toxicity. 
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The three isomers of 36 that were synthesised were less toxic than mechlorethamine – this 
is due to the powerful deactivating effect of the permanent positive charge of the nitro 
group. Preliminary studies also show that these compounds inhibit [14C]-choline uptake. 
This strongly suggests that the major mechanism for the uptake of these compounds is via 
the choline transport pathway instead of passive diffusion.58 Further work is being carried 
out to study factors such as radical lifetime or the ability of the drugs to be transported via 
the choline carrier pathway. 
Carmethizole 37 is a novel bis-carbamate alkylating agent, which forms DNA-protein and 
DNA-DNA crosslinks in vitro.59 It has in vivo anti-tumour activity against murine 
leukaemias, solid tumours and human tumour xenografts. 
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By adding electron-donating substituents at the 2-position the anti-tumour activity was 
enhanced whereas with electron-withdrawing groups the compounds became inactive.  
This observation is probably explained by the stabilisation of the transition state of the 
SN1-type activation of the hydroxymethyl groups that will lead to DNA alkylation. Two 
different strategies could be employed. Firstly, the bis-hydroxymethylimidazole nucleus 
derived from carmathizole could be used as the alkylating unit with 2-nitrogen substituents 
added to deactivate the alkylating units. Secondly the substituted hydroxymethylimidazole 
ring could be used as a trigger unit rather than an alkylating unit. 
Using the first strategy, 38 (when R = NH2) is expected to be more reactive than 
carmethizole. This is not useful for a prodrug so by changing the amino group to an azide 
or a carbamoyl group (i.e. considerably less electron donating substituents) a more useful 
compound would be produced. Azides are known as masked amine functions and the 
metabolism of aryl azides to amines has been demonstrated.60 
The second approach involves the reduction of the trigger group leading to activation of a 
separate alkylating moiety attached via a deactivating carbamoyl linker. The electron-
withdrawing substituent on the imidazole ring could be bio-reduced to a more electron-
donating moiety that would activate the carbamate unit to nucleophilic attack with the 
subsequent fragmentation of the resulting carbamic acid, releasing a secondary amine as 
the cytotoxic effector. The alkylating agent selected was N,N-bis(2-chloroethyl)amine 
(BCEA) and nitro and sulfoxide substituents were selected as suitable electron 
withdrawing substituents to place in conjugation with the methyl carbamate. The results 
showed that there is potential in the further study of these compounds especially for the use 
as trigger units for the release of secondary amino cytotoxins.59 
Transition metal complexes have demonstrated cytotoxicity in cell culture and/or anti-
tumour activity in tumour-bearing animals.61 The metals used include Ag(I), Cu(I) and 
Cu(II), Zn(II), Hg(II), Rh(II), Ru(II) and Ru(III), Pd(II), Pt(II), Co(III) and Fe(III). 
Platinum complexes are currently in routine clinical use.62 
The classical inorganic anticancer agent cis-diaminedichloroplatinum(I), cisplatin 39 forms 
coordination bonds with cellular targets and is classified as an anti-tumour alkylating 
agent. Other complexes that bind specifically to sites on DNA are chiral Co(III) tris-
phenanthroline molecules. 
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Cobalt (III) complexes are kinetically inert coordination complexes. The inertness is due to 
the d6 low spin electron configuration of the trivalent cobalt. This inertness is the main 
reason why cobalt complexes have potential as prodrugs. The biological consequence of 
the inertness is that the complex will remain intact when added to a culture medium or 
injected as a drug. The drug should arrive at its cellular targets intact with its original 
ligand configuration.  
The complexes 40 and 41 are interesting as targets for bio-reductive drugs.60 The bulky 
pyridine ligand in 41 is similar in size to the BCEA ligand possessed by many alkylating 
agents such as 40, although the bifunctional alkylating ability is not present. The Co(III) in 
both compounds could also be reduced to Co(II) thus releasing BCEA. The lone pairs on 
the nitrogens in the Co(III) complexes 40 and 41 are deactivated because they are 
complexed to the metal. 
These drugs are known as HPDCs – hypoxia activated prodrugs of diffusible cytotoxins. 
They are used as a solution to the problem of cells with intermediate oxygen 
concentrations. Bio-reductive drugs are only activated at very low oxygen concentrations 
and therefore many tumour cells are sufficiently hypoxic to be radio-resistant even though 
the prodrug will not be activated. Thus, prodrugs were developed with an appreciable 
diffusion range – HPDCs. Activation of the drug is confined to regions of very low oxygen 
tension. 
There are other strategies including ADEPT63 and GDEPT,64 which use prodrugs. ADEPT 
is antibody directed enzyme prodrug therapy and GDEPT is gene directed enzyme prodrug 
therapy.  
ADEPT involves a group of drugs called monoclonal antibodies, which recognise certain 
proteins that are found at the surface of some cancer cells. ADEPT is a targeted therapy – 
the antibody is attached to a specific enzyme. The monoclonal antibody recognises the 
protein and locks on to it. A prodrug is then given and cell death should occur. 
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GDEPT operates in the same way except that a gene for the expression of the prodrug 
activating enzyme is delivered to the cells. The prodrug becomes activated by the foreign 
enzymes present in the cancerous cells. 
2.3 Conclusion 
To date, there is no prodrug that has shown sufficient clinical activity to achieve 
registration for general use. A drug has to be designed that will reach remote hypoxic cells, 
i.e. the diffusion of the drug should be more efficient. The activated effector must possess a 
better ‘bystander’ effect so that the ‘killing zone’ is expanded. A more deliberate design 
process must be developed allowing the synthesis and biological testing of a drug that will 
selectively kill cancer cells. 
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3 Human African Trypanosomiasis65 
3.1 Human African Trypanosomiasis 
Human African Trypanosomiasis (HAT) is more commonly known as African Sleeping 
Sickness. The disease is carried by parasites of the Trypanosoma genus and is transmitted 
by the bite of a tsetse fly (Glossina genus – Figure 366). The tetse flies themselves acquire 
the infection from mammals (human beings or animals) harbouring the pathogenic 
parasites. Tsetse flies are found exclusively in Africa in a belt that stretches south of the 
Sahara and north of the Kalahari desert. 
 
Figure 3 
The protozoa belong to a family comprised of parasites of insects, plants, fish, amphibians, 
reptiles, birds and mammals.67 The parasites generally infect most vertebrate genera and 
are likened to cancer cells due to their capacity for growth.68 Only two forms of 
trypanosomes cause significant human disease. Trypanosoma brucei (Figure 469) is found 
in sub-Saharan Africa and causes HAT. The parasites are known as salivaria as the disease 
is transmitted in tsetse fly saliva. Trypanosoma cruzi is found in America, primarily in 
South America, but it presents a potential hazard in Mexico through blood and organ 
donations. T. cruzi causes Chagas’ disease and the parasites are known as stercoraria 
because transmission is via vector faeces. Both forms of the parasite are single-celled 
flagellates that are transmitted by insect vectors. The parasites undergo phases of local 
multiplication followed by dissemination and localisation in target organs where they cause 
lethal damage. Both vector groups that transmit the diseases are known as K-strategists.70 
They have a low reproductive rate complemented by a high survival rate adapted to exploit 
their habitats. 
It has been shown that humans have been exposed to T. brucei during the course of 
evolution whereas T. cruzi evolved independently, only coming into prominence with the 
appearance of man on the American continent within the past 12,000 years. 4000 year old 
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mummified remains from South America have been identified as possessing T. cruzi 
DNA.71 
 
Figure 4 
There is one reported case of HAT being transmitted sexually.72 A 30 year old Portuguese 
woman presented herself at hospital with HAT symptoms. She had never visited Africa, 
although her Brazilian partner had been on a military mission to Angola three years 
previously. He was identified as a symptom free carrier. Both were successfully treated for 
HAT. 
HAT affects 36 countries of sub-Saharan Africa (Figure 573) and occurs in remote rural 
areas where health systems are weak or non-existent and it mainly strikes the active adult 
population. Epidemics are currently rife in the Democratic Republic of Congo (DRC), 
Angola and Sudan. Other infected countries include Uganda, Central African Republic, 
Congo Republic and Tanzania.74 60 million people are at risk from HAT.75 The number of 
cases is difficult to estimate. In 1998, 40,000 cases were reported but it is believed that the 
real number of sufferers was in the region of 300,000-500,000 due to cases being 
undiagnosed and therefore untreated.  
 
Figure 5 
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Surveillance of the disease is being reinforced and the number of cases reported has been 
substantially reduced. It is still difficult to assess the current situation due to lack of 
surveillance and diagnostic expertise. The disease was nearly eliminated during the 1960s. 
However the disease has recently been on the increase due to war, population movements 
and the collapse of health systems. The disease is the major cause of depopulation of large 
tracts of Africa. Fear has led to abandonment of fertile land and is an impediment to 
development.65 
There are two stages to the disease.65 After the host has been bitten by the tsetse fly, the 
parasites proliferate at the site of infection, leading to an inflammatory nodule or ulcer. The 
parasites then spread to the draining lymph node and reach the bloodstream, initiating the 
haemolymphatic phase. The sufferer will experience fever, headaches, joint pains and 
itching. As the disease progresses past the blood-brain barrier, the parasite infects the 
central nervous system and the second stage known as the neurological phase begins. The 
sufferer will experience confusion, sensory disturbances, poor coordination and 
disturbance of the sleep cycle – hence the common name of the disease. How and why the 
parasites infect the CNS is not clear. 
There are two forms of HAT depending on which specific parasite is involved. 
Trypanosoma brucei gambiense (T.b.g.) occurs in west and central Africa and accounts for 
90% of reported cases. The disease is a chronic infection and the patient can be infected for 
several months without showing any symptoms. As symptoms do appear the disease will 
be in the advanced stages with the central nervous system affected. The other form of the 
disease is Trypanosoma brucei rhodesiense (T.b.r.) which affects east and southern Africa, 
although this accounts for less than 10% of the reported cases. This form of the disease is 
acute and the first symptoms will appear after a few weeks. The disease will develop more 
rapidly in the later stages. Without treatment HAT is fatal. 
The diagnosis relies on detecting parasites in the patient’s blood or lymph nodes. If there is 
a positive test for parasites, a lumbar puncture is performed to identify if the disease has 
progressed onto the second stage. Current diagnostic methods are invasive, difficult to 
carry out and require highly trained staff. 
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3.2 Trypanosomes’ Life Cycle76 
The tsetse fly becomes infected when taking a blood meal from an infected mammalian 
host (Figure 676). The parasites transform into procyclic trypomastigotes and multiply. The 
parasites leave the midgut and transform into epimastigotes that reach the fly’s salivary 
glands and continue mulitiplying. 
The infected tsetse fly has a blood meal on a mammalian host and injects metacyclic 
trypomastigotes into the skin tissue. The parasites enter the lymphatic system and pass into 
the bloodstream. Inside the host, they transform into bloodstream trypomastigotes and are 
carried to other sites of the body. Continuous replication occurs. 
 
Figure 676 
3.3 Treatment of HAT77 
The type of treatment a patient receives depends on the stage of the disease. If caught early 
during the first stage, the drugs used are less toxic, easier to administer and more effective. 
However, if the disease has developed into the later stages the success of the treatment 
relies on the drug crossing the blood-brain barrier. Such drugs are toxic and complicated to 
administer. 
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3.3.1 Pentamidine 
Pentamidine 42 was first used in 1941 to treat first stage T.b.g. and is well tolerated by 
patients.78 The aromatic diamidine must be injected into the muscles. Diamidines work 
directly against the parasites. 
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Pentamidine 42 was developed after the observation that a related compound, synthalin, 
that induced hypoglycaemia in mammals also displayed trypanocidal activity.78 The 
diamidines are dications at physiological pH and they interact with a number of cellular 
anions. They are known to bind tightly to the minor groove of DNA inhibiting 
replication.79 
3.3.2 Suramin 
Suramin 43 was first developed in 1921 by German chemists and is used to treat T.b.r., 
although the drug does produce undesirable side effects in the urinary tract and also 
stimulates allergic reactions.80 The drug is given to humans and camels. The treatment 
course takes five weeks which causes problems due to the lack of resources in infected 
areas.  
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The drug is a colourless, polysulfonated symmetrical naphthalene derivative. Other 
naphthalene dyes were initially developed for their marked trypanocidal activity. At 
physiological pH, the drug bears six negative charges and it inhibits many enzymes by 
electrostatic interactions. It has been shown to block the specific cell surface binding of 
various growth factors81 and inhibits tyrosine phosphorylation.82 
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Suramin 43 inhibits reverse transcriptase which is a key enzyme of the human 
immunodeficiency virus (HIV).83 The drug had no impact on the progression of AIDS. 
Suramin 43 has recently been used in clinical trials against hormone-refractory prostate 
cancer and other human malignancies as it inhibits angiogenesis.82,83  
3.3.3 Melarsoprol 
Melarsoprol 44 was first used in 1949 and was developed from arsenic. It is known to 
corrode plastic syringes.84 The compound 44 is synthesised by complexing melarsen oxide 
with the metal-chelating drug dimercaptol. In trypanosomiasis, 44 reversibly inhibits the 
cellular enzyme glutathione reductase and NADPH oxidase.85 
The melaminophenyl-based organic arsenical 44 induces many different side effects. One 
of the more serious is encephalopathic syndrome which will kill 3-10% of patients. 
Statistics show that one in 20 patients treated with melarsoprol will die.  
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One Médecins Sans Frontières doctor working in Uganda has been quoted as saying 
‘Melarsoprol is a terrible drug – you don’t feel proud injecting it. It is caustic, it burns and 
you don’t know if you are going to save your patient or kill him!’ 
The disease can also build up resistance against the drug and around 30% of patients 
treated will not be cured. This resistance has mainly been observed in central Africa. The 
drug is accumulated by an unusual amino-purine transporter and loss of this transporter 
leads to drug resistance. T. brucei contain multiple purine transporters at their plasma 
membranes. Trypanosomes like all protozoan parasites are auxotrophic for purines and rely 
entirely on salvage from the host environment for their purine supply.86  
It is generally accepted that the toxic species of the arsenicals is the trivalent oxidation 
state of the arsenic. Trivalent arsenicals react quickly and reversibly with vicinal thiol 
groups in proteins such as trypanothione and so many enzymes can be targeted for 
inhibition. Cell death is rapid. 
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3.3.4 Eflornithine 
Eflornithine 45 was first registered in 1990 to treat T.b.g. although the drug was initially 
designed to be an anti-cancer agent. Clinicians are still deliberating about the malignancies 
for which it is best suited.87 The compound is a derivative of ornithine. The regimen is 
extremely strict and difficult to apply as slow drip infusions are administered every six 
hours for fourteen days. 
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It is reported that uptake occurs via passive diffusion across the plasma membrane. The 
compound inhibits ODC. 
3.3.5 Nifurtimox 
Nifurtimox 46 is normally used to treat Chagas’ disease and has been used with limited 
success to treat arsenical-resistant HAT.88 The drug contains a nitro group that is essential 
for activity. Uptake is reported to occur via passive diffusion. One electron reduction of the 
nitro group generates a free radical which in turn generates reduced oxygen metabolites 
such as superoxide, hydroxyl free radical and hydrogen peroxide all of which can cause the 
death of the parasite.89 Mammalian cells have better protection against oxidative damage so 
the compound is generally parasite selective.  
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3.3.6 Megazol 
1.3.7Megazol 47 has shown good activity against T. brucei.90 The 5-nitroimidazole possesses 
the same motif recognised by the transporter responsible for the uptake of several anti-
trypanosomal drugs. It was thought that megazol 47 would be of limited use against 
arsenical-resistant trypanosomes. However it would appear that this drug enters the cell by 
passive diffusion as opposed to the transporter thus supplying an alternative drug to use 
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against arsenical-resistant parasites.91 A combination treatment of megazol 47 and suramin 
43 appears to eliminate trypanosomiasis of the CNS.85 
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3.3.7 Treatment of Cattle 
Domestic cattle can be affected by the disease too although it is referred to as ‘Nagana’. 
This word literally means ‘depressed’. There are several drugs that can be used to treat 
infected livestock such as berenil 48 and cymelarsan 49.78 These drugs are based on the 
human alternatives. Berenil like pentamidine has two positive charges at pH 7.4. 
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Once cured, the cattle must not be slaughtered for human consumption for several months 
to ensure that the drug is totally excreted. 
1.3.83.3.8 Vector Control 
During the colonial era, great efforts were made to eradicate HAT by clearing large areas 
of land of any vegetation and removing large wild mammals that would act as a reservoir 
for the disease.92 This proved very effective but due to the huge resurgence of the disease 
this is now not practical. 
Nowadays, insecticides have proved very successful. The lower parts of trees are targeted 
for spraying as resting flies can be found there in infested areas.93 Unfortunately ecological 
considerations mean that the use of insecticides is becoming more restricted. 
Tsetse traps and baits are very useful (Figure 7). Trap efficiency depends on the different 
species of tsetse fly. The traps are baited with odours and impregnated with insecticides. 
The flies are also attracted to visual aides such as large expanses of black or blue cloth. 
Acetone is sometimes used as this is the tsetse-atttracting component of cattle breath. 
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Figure 7 
A much publicised approach to controlling tsetse numbers involves the release of sterile 
male flies that will mate unproductively with females.94 
3.4 Potential Drug Uptake Pathways95 
Trypanosomes live freely in the bloodstream and cerebral spinal fluid of their mammalian 
hosts and not intracellularly. They are fully exposed to the host’s immune response. The 
parasite remains protected from the immune response by a dense, highly immunogenic 
glycoprotein coat.96 Up to 1000 genes code for these surface glycoproteins and sequential 
expression of these genes produces antigenically distinct parasite populations allowing 
survival in the mammalian host.97 Due to this antigenic variation, the prospects of vaccine 
development are poor. 
Drugs need only cross one membrane in order to reach the trypanosomes’ interior which 
can offer a means of selectively targeting drugs to these cells. Potential drug targets could 
be designed from biochemical pathways common to the parasites but absent in mammalian 
hosts.98 As explained before the only barrier between the parasite and its host is the plasma 
membrane. Transporters are used for the uptake of nutrients by the parasites. If vital 
transporters were blocked the parasites would die. Nutrient transporters represent excellent 
drug targets.99 
3.4.1 Glucose Metabolism 
Trypanosomes are dependent on glycolysis for energy production. The first seven enzymes 
found in this pathway reside within unusual organelles known as glycosomes.100 There are 
several structural and functional features of trypanosome glucose transporters that 
distinguish them from mammalian counterparts.101 The transporters possess a relative 
insensitivity to various pharmacological reagents such as cytochalasin B. The transporters 
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also have a substrate recognition profile which includes the ability to transport D-
fructose.102 
3.4.2 Pentose Phosphate Pathway 
Many enzymes of the pentose phosphate pathway (Figure 8) are related to cyanobacterial 
isoforms rather than to those of eukaryotes.103 6-Phosphogluconate dehydrogenase (3rd 
enzyme of the pathway) is essential for trypanosomal survival.  
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Figure 8 
There are specific structural differences when compared to the mammalian counterpart and 
this has been exploited in the design of new selective inhibitors.104 
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3.4.3 Thiol Metabolism 
The role of glutathione in trypanosomes is undertaken by trypanothione 50 (N,N-bis-gluta-
thionylspermidine) which is a low molecular weight thiol consisting of two glutathione 
molecules linked by spermidine.105 Enzymes involved in trypanothione metabolism have 
been identified as good candidate targets.  
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Design of new targets should take into account that the interaction between trypanothione 
50 and the enzyme appears to occur via a heteroatom of the enzyme that bonds with the 
free thiol groups of the two cysteines present in the co-factor.106 Therefore the central atom 
of any new lead compounds should show a great affinity towards sulfur. 
3.4.4 Polyamine Metabolism 
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Figure 9 
By synthesising synthetic analogues of key biosynthetic enzymes, drugs can be directed to 
specific targets. Ornithine and methionine are essential for the trypanosomes’ polyamine 
biosynthetic pathways (Figure 9).107 Eflornithine 45 is the only drug used to treat HAT for 
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which a mode of action has been identified. As explained before eflornithine 45 is an 
inhibitor of ornithine decarboxylase (ODC).  
The polyamine metabolic pathway is also a target for anti-cancer chemotherapy due to the 
central role of these metabolites in cell proliferation. 
3.4.5 Lipid and Sterol Metabolism 
Lipids play a central role in biological membranes as well as participating in cell 
signalling. Sterol biosynthesis has been targeted for use against fungi which have similar 
pathways to trypanosomatids. Therefore drugs designed to use against fungi could also be 
potential anti-parasitic candidates.108 
3.5 Future of HAT Treatments 
It is difficult to encourage pharmaceutical companies to carry out research on anti-parasitic 
agents as there is no monetary incentive for them. Most sufferers live in developing 
countries. In May 2001, after pressure from several governments and non-governmental 
organisations, Aventis, MSF and WHO set up a project to produce pentamidine 42, 
melarsoprol 44 and eflornithine 45 for at least five years. Bayer and Bristol-Myers Squibb 
also got involved in the production of sleeping sickness drugs.  
A consortium of researchers funded by the Melinda and Bill Gates Foundation have 
identified prodrug DB289 51 (2,5-bis[4-amidinophenyl]furan bis-O-methyl amidoximine) 
as a future HAT treatment.109 The compound is absorbed across the intestinal epithelia and 
is converted into a trypanocidal dicationic form. 
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This is the first ‘new’ HAT drug for almost 50 years. More research is required to design 
better drugs. Major pharmaceutical companies must be encouraged to play a greater role in 
developing new drugs for this developing world disease. Meanwhile it is mainly University 
researchers who carry out research into the development of new and better anti-parasitic 
agents. 
48 
4 Previous Work within the Robins Group 
4.1 Piperidines 
The Robins group first started researching alkylating agents in the early 1990s. Henderson 
synthesised a series of bifunctional mustards based on piperidine such as 52. The aim of 
the research was to investigate whether aziridinium ion formation was possible if 
conformational restrictions were imposed on the molecule. Prodrugs were developed in the 
form of N-oxides 53. The free bases such as 52 showed good activity in two human 
carcinoma cell lines (IC50 values ~8 µM); however the N-oxides such as 53 were inactive 
in oxic and hypoxic conditions.110 It is thought that the reduction potentials of the 
compounds were outside the range needed for bioreduction. 
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4.2 Bispiperidines 
Henderson then investigated variation of the alkylation selectivity using bispiperidines 
such as 54. The piperidines were separated by a chain of varying length to ascertain the 
optimum distance between the two heterocycles. The derivatives synthesised showed 
greater selectivity of alkylation at N-7 of guanine over melphalan and were cytotoxic in 
three cisplatin-resistant cell lines.111 A relationship between linker chain length and 
compound reactivity was observed. When n = 2, compound 54 was twice as reactive as 
longer chain analogues. 
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4.3 Bispyrrolidines 
Anderson carried out further investigation into the length of the linker chain and varied the 
size of the heterocycle by producing a series of homochiral bispyrrolidines such as 55. 
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Compound 55 with 2-, 5- and 6- carbon linker chains gave the best alkylating results. 
Examples of 55 with 3- and 4- carbon linker chains showed no cross-linking activity. A 
range of alkyl linear 56 and cyclic mustards 57 were also prepared but showed no 
cytotoxicity in a useful range (IC50 values > 100 µM) when tested against  human colon 
carcinoma cell lines.112 
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4.4 Azamacrocycles 
Robins’ group research then moved away from heterocyclic mustards towards macrocyclic 
nitrogen mustards. There were several reasons for this. Firstly the macrocycles would still 
allow for multiple alkylating arms to be incorporated into the drugs. Secondly the 
architecture of the compounds would be defined yet chain lengths could still be varied. 
Finally, and most importantly, bioreducible prodrugs could be synthesised due to metal ion 
chelation. Inorganic chemists have long studied macrocyclic polyamines as ligands for 
chelation.113  
NN
NN
Cl
Cl
Cl
Cl
R
R R
R NN
NN
Cl
Cl
Cl
Cl
n
N
N N ClCl
Cl
58 R = H
59 R = Me
60 n = 1
61 n = 2 62
 
Compound % DNA cross-linking at 0.1 µM IC50 µM 
58 100 22 
59 64 10 
60 94 8 
61 100 9 
62 30 13 
Table 1 
Lacy synthesised a cyclen derivative 58 which showed extremely promising cross-linking 
results compared to chemotherapeutic agents currently in use.114 The compound was 104 
times more effective at DNA crosslinking than chlorambucil and 2000 times better than 
melphalan. IC50 values for the set of compounds ranged from 6 to 25 µM (chlorambucil – 
45 µM and melphalan – 8.5 µM). Anderson synthesised a range of poly-2-chloroethylated 
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azamacrocycles 59-62.114 These compounds showed promising biological results. Table 1 
shows a summary of the biological results for this set of compounds. 
Due to difficulties experienced during the synthesis of the previously discussed 
azamacrocycles, Parker investigated the development of a flexible, reliable method for the 
synthesis of azamacrocycles with varying linker chain lengths. Parker also developed the 
synthesis of copper(II) complexes of the macrocycles thus producing potentially 
bioreducible prodrugs.115 Complex 63 showed no hypoxia selectivity, however complex 64 
displayed reversible redox behaviour and showed excellent hypoxia selectivity. When 
tested against human chronic myeloid leukaemia cell line K562, complex 64 was 24 times 
more toxic under hypoxic conditions than in oxic conditions.  This provided the evidence 
that further investigation into this area of research would be beneficial. 
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Jones investigated the synthesis of oxaazamacrocycles and azamacrocycles of varying size 
and shape to discover if this affects their alkylating ability.116 Compound 65 proved to be 
the most toxic (IC50 – 4.0 µM) of all the compounds prepared so far. It was unfortunate 
that it proved impossible to synthesise the corresponding copper complex.  
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Reid developed a reliable synthesis of substituted tetraazamacrocycles such as 66. R 
groups were aromatic or heteroaromatic producing a range of compounds with varying 
electronic demand.117 However, it proved difficult to attach the alkylating arms onto the 
macrocycles so unfortunately the desired alkylating agents were not prepared. The parent 
macrocycles were tested against the parasite Trypanosoma brucei. Analogue 67 was the 
most toxic and underwent in vivo testing although a dose of 20 mg/kg did not cure 
trypanosomiasis. 
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4.5 Aims of the Project 
It was thought that the favourable results from compounds 64 and 65 could be improved. 
So far only mustards bearing a 2-chloroethyl alkylating arm have been produced. It would 
be interesting to investigate varying the leaving group R (see 68). The aziridinium ion 
formation could turn out to be more efficient producing better biological activity. A 
selection of R groups attached to the cyclen skeleton would be desirable. These compounds 
would then be sent for biological testing to assess DNA cross-linking ability, hypoxia 
selectivity and anti-parasite activity. 
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It would be sensible to complete the ‘set’ of heteroatom-containing macrocycles by 
synthesising thiaazamacrocycles containing N, O, and S such as 69. Multiple alkylating 
sites would still be available and there is literature evidence that sulfur binds to copper(II) 
more strongly than oxygen which may overcome the problems experienced during the 
synthesis of the copper complexes of the oxaazamacrocycles. 
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5 Synthesis of Azamacrocyclic Mustard 
Derivatives 
5.1 Synthesis of Cyclen 
The first aim of the project was to investigate a quick and reliable synthesis for compound 
70 – commonly known as cyclen. Cyclen has been used as an intermediate for the 
synthesis of diagnostic and therapeutic agents.118 The tetraazamacrocycle is involved in the 
development of magnetic resonance imaging contrast agents119 and more recently as a 
chelating agent for use against targeted cancer agents.120 Cyclen 70 is commercially 
available but is expensive. There are several ways of synthesising cyclen but in each case 
reaction conditions favour intramolecular cyclisation over intermolecular cyclisation.  
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5.1.1 Template Synthesis121 
This synthesis is an established procedure within the Robins Group, based on published 
work and can be carried out on a multigram scale (Scheme 13). The three step synthesis 
uses a carbon template around which the macrocycle is built and the two carbon 
infrastructure is then removed leaving the tetraazamacrocycle. Starting from 
triethylenetetraamine (TETA) 71, this synthesis exploits the reactivity of formamide 
acetals forming bis-imidazoline 72. Cyclisation occurred by reacting 72 with 1,2-
dibromoethane to give the monoimidazolinium compound 73. The desired macrocycle 70 
was obtained after alkaline hydrolysis with potassium hydroxide. The disadvantage to 
template synthesis is that it cannot be used to synthesise a range of macrocycles with 
varying ring size and heteroatom content. It was decided to attempt other cyclen syntheses 
that could provide the opportunity to vary the range of compounds synthesised. 
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Scheme 13 
5.1.2 Richman Atkins Cyclisation 
Before the 1970s, the most efficient method for the synthesis of polyazamacrocycles was 
by Stetter and Roos.122 By combining terminal dihalides and bis-sulfonamide sodium salts 
under high dilution conditions, the protected product was isolated in poor to moderate 
yields. Although this procedure was versatile with respect to ring size, there were 
disadvantages such as excessive use of solvent, poor yields and long reaction times. In 
1974 Richman and Atkins published a letter detailing a procedure with improved 
cyclisation yields without high dilution conditions (Scheme 14). Nine to 21 membered 
macrocycles could be prepared using DMF as a dipolar aprotic solvent.123  
NHHN
NHHN
NTsTsN
NTsTsN
NTs
NTs
NTs
Na
Na
R
TsN
R
DMF Deprotection
74 75 76 70
 
Scheme 14 
More recently, this reaction was carried out between the dianion of bis-toluenesulfonamide 
and bis-tosylated derivatives in DMF. The dianion was created either by addition of 
sodium hydride or more recently in situ by addition of caesium carbonate.124  
The tosyl groups are essential for the success of the reaction. Not only do they render the 
amine hydrogens more acidic to aid deprotonation but their steric bulk encourages the 
intermediate to undergo intramolecular cyclisation rather than oligomerisation by adopting 
a pseudo-Thorpe Ingold effect (Figure 10).125 The distance between the reacting termini is 
decreased by the bulk of the tosyl groups pushing the termini closer together. 
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Figure 10 
5.1.3 Phase Transfer Cyclisation 
Lukyanenko published work describing the synthesis of azamacrocycles and 
oxaazamacrocycles using a biphasic system.126 Bis-sulfonamides were reacted with 
dibromides or ethylene glycol bis-(toluene-4-sulfonyl) derivatives in a toluene and aqueous 
alkali mixture.  
Quaternary ammonium salts were used as phase transfer catalysts. The charged centre of 
the salt allows the compound to dissolve in an aqueous environment and the butyl groups 
permit the compound to solubilise in an organic medium. Scheme 15 shows the 
mechanism for the cyclisation. The alkali deprotonates a sulfonamide producing an anion 
that exchanges cations with the catalyst. The ionic species formed undergoes alkylation in 
the organic phase. The alkylated species then undergoes deprotonation once more forming 
another ionic precursor that undergoes intramolecular cyclisation completing the process. 
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Scheme 15 
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5.1.4 Synthesis of Tosylated Cyclen 
5.1.4.1 Tosylation of Precursors 
The starting materials for both the Richman-Atkins cyclisation and the phase-transfer 
cyclisation require the corresponding amine or diol to be tosylated. Well known procedures 
previously used by members of the Robins group were applied successfully. 
Scheme 16 shows the reaction of diethylene triamine 77 with tosyl choride – these reaction 
conditions require vigorous stirring and product 78 was produced in very high yield.127  
H2N
H
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99%
 
Scheme 16 
Scheme 17 shows that different conditions were required when tosylating diethanolamine 
79.128 Triethylbenzylammonium chloride (TEBA) was used as a phase transfer catalyst. 
Product 80 was prepared in good yield.  
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Scheme 17 
5.1.4.2 Cyclisation 
Both the Richman Atkins and the phase-transfer reactions were carried out to compare 
yields. As Scheme 18 shows both reactions produced the desired macrocycle 76 in good 
yield. The phase transfer procedure does have advantages over the Richman Atkins 
cyclisation. The main one is the length of time required for the reaction to go to 
completion. To achieve optimum yields with the Richman Atkins procedure the reaction 
mixture must be left stirring for two weeks as opposed to an overnight reaction using the 
phase transfer procedure.  
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Scheme 18 
5.1.5 Deprotection of Tosyl Groups 
The final step required to achieve cyclen 70 is the removal of the tosyl groups. There are 
many examples in the literature that include conc. sulfuric acid,129 sodium/mercury 
amalgam,130 potassium fluoride on alumina,131 lithium aluminium hydride132 and 
hydrobromic acid in varying concentrations of acetic acid solution.125,133 All of these 
conditions are harsh and generally low yielding. 
Several procedures were investigated. The first reaction involved reacting the tosylated 
macrocycle with HBr-AcOH 45% and phenol (Scheme 19).133 The protected amine 
becomes protonated resulting in attack by a bromide ion producing tosyl bromide. In order 
to prevent this by-product from re-attaching to the macrocycle, phenol was added to ‘mop 
up’ any by-product. The intermediate formed at this point is the hydrobromide salt. The 
free base 70 was isolated either by using ion exchange chromatography or by using sodium 
hydroxide and a Dean-Stark apparatus. Although this reaction was successful, there were 
impurities present which could affect future reactions. 
The second method applied involved heating the protected macrocycle under reflux in 
conc. sulfuric acid for 40 hours (Scheme 19).133 Pure 70 was isolated, however the yield 
was poor. 
The final procedure attempted involved heating the macrocycle in conc. sulphuric acid at 
165 oC for 10 minutes (Scheme 19). This black solution was cooled and then added 
dropwise to an ethanol/diethyl ether mixture from which a solid precipitated. This solid 
was dissolved in a minimum volume of water and an equivalent volume of hydrobromic 
acid was added dropwise until crystals were observed. This hydrobromide salt was heated 
under reflux overnight with sodium hydroxide solution in toluene using a Dean-Stark 
apparatus producing the pure free base 70 in good yield.134 
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Scheme 19 
5.2 Alkylation of Cyclen 
In order to synthesise the desired mustard pharmacophore, a two carbon chain must be 
added to the amine groups. Parker initially synthesised chloroacetamides which were 
subsequently reduced (Scheme 20) and this method was particularly effective for 
triazamacrocycles.135 However a more efficient route was then discovered using ethylene 
oxide.115  
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Scheme 20 
Alkylation using ethylene oxide is clean and high yielding although a high yield is 
dependent on the purity of the parent macrocycle. Reaction conditions must be carefully 
monitored to prevent the formation of unwanted side-products such as over-alkylated and 
polymerised species. Optimum reaction conditions involve the use of water as the reaction 
solvent and the reaction temperature must be maintained for three hours at 0 oC. Gaseous 
ethylene oxide was added to the reaction mixture with the use of a cold finger condenser 
and addition funnel to ensure accurate volumes of reactant were added. Once the reaction 
was complete excess ethylene oxide was removed by rotary evaporator yielding pure 83 – 
no further purification was required (Scheme 21). The 2-hydroxyethylated compound 83 
provides the precursor required to attempt the synthesis of a range of compounds with 
different leaving groups present on the mustard functionality.  
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Scheme 21 
In order to synthesise the chlorinated mustard 58, the 2-hydroxyethylated macrocycle 83 
was reacted with thionyl chloride (Scheme 22).115 The mustard 58 was isolated as the 
corresponding stable dihydrochloride salt which prevents immediate activation as the lone 
pairs on the nitrogens are protonated and aziridinium ion formation cannot occur.  
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Scheme 22 
Copper complexation occurred quantitatively by treating the hydrochloride salt 58 with 
anhydrous copper (II) chloride in hot methanol.115 The complex 64 precipitated from the 
solution upon cooling, producing the prodrug.  
5.3 Synthesis of Carbamates 
It was decided to form carbamate groups on the macrocyclic skeleton in the same way as 
the Robins group had previously synthesised carbamate derivatives that showed cytotoxic 
activity.111 Carbamates are also generally crystalline so purification is easier and they are 
reasonably stable although it is hoped that they will be displaced under physiological 
conditions. 
5.3.1 Route I 
The phenyl carbamate 84 was synthesised in quantitative yield using a procedure involving 
the 2-hydroxylethylated macrocycle 83, pyridine and phenyl isocyanate (Scheme 23).136 
This compound was crystallised and an X-ray structure was obtained (Figure 11). 
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Compound 84 crystallises in the monoclinic space group P21/a and the structure clearly 
shows the formation of the macrocyclic ring and four carbamate side-chains. 
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Scheme 23 
 
Figure 11 
Due to the success of this reaction, substituted phenyl carbamates were targeted, e.g. 4-
nitrophenyl, 4-bromophenyl and 4-methoxyphenyl. However it was impossible to isolate 
the desired compounds and the only products observed in the 1H NMR spectra were the 
corresponding aromatic amines produced after hydrolysis of the isocyanates. 
The synthesis of alkyl carbamates was also attempted using the same procedure. The 
isopropyl derivative 85 was isolated in a poor yield (11%), however it proved impossible to 
synthesise the ethyl derivative. 
Jennifer M. Wilson, 2007   Chapter 5, 60 
5.3.2 Route II 
A different procedure was used to try and synthesise a range of carbamates. A method 
using the 2-hydroxyethyl precursor 83, an isocyanate and dibutyl tin diacetate in 
dichloromethane was attempted (Scheme 24).137  
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Scheme 24 
The two previously obtained macrocyclic carbamates were synthesised again by stirring 
the reaction mixtures at room temperature for two days. The phenyl derivative 84 was 
again produced quantitatively and the isopropyl derivative 85 was obtained in a good 60% 
yield. It was also possible to crystallise 85 and an X-ray crystal structure was obtained 
(Figure 12). As before this compound crystallises in the monoclinic space group P21/a and 
shows successful formation of the macrocycle and four side-arms. 
 
Figure 12 
Using the same reaction conditions, it proved impossible to synthesise the propyl 86 and 
the 4-methoxyphenyl 87 analogues. The reactions needed to be heated under reflux 
conditions overnight and these two compounds were successfully isolated in moderate 
yields. By studying reaction conditions and the number of equivalents of isocyanate used, 
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it proved possible to synthesise a range of substituted carbamates. The reaction conditions 
required and yields are summarised in Table 2. 
Cpd No. R Eq. RNCO T Yield 
84 
 
40 RT 100% 
85 
 
40 RT 60% 
86 
 
40 reflux 41% 
87 
OMe
 
40 reflux 56% 
88 
Br
 
40 reflux 64% 
89 
NO2
 
10 reflux 64% 
90 
NO2
 
10 reflux 46% 
91 
NO2
 
10 reflux 60% 
Table 2 
The mechanism of the reaction is assumed to proceed as shown in Scheme 25.137 A lone 
pair of electrons from the alcohol attacks the carbonyl of the isocyanate which in turn 
attaches itself onto the dibutyl tin diacetate with loss of an acetate group. The acetate group 
reattaches onto the tin moiety reforming the catalyst and resulting in the formation of the 
desired compound. 
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Scheme 25 
5.4 Synthesis of Copper Complexes 
In order to transform the macrocycles into prodrugs, copper complexes had to be formed. 
Using the same procedure previously described in Scheme 22,115 eight copper complexes 
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were synthesised from the corresponding macrocyclic carbamates using one equivalent of 
copper(II) chloride (Scheme 26). Yields are summarised in Table 3.  
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Scheme 26 
Cpd No. R Yield 
92 
 
100% 
93 
 
58% 
94 
 
64% 
95 
OMe
 
23% 
96 
Br
 
39% 
97 
NO2
 
18% 
98 
NO2
 
74% 
99 
NO2
 
80% 
Table 3 
Characterisation using mass spectrometry and UV-vis spectrometry proved that the 
complexes had been successfully formed. It has been reported that the λmax for the d to d 
transition of CuCl2 occurs at 810 nm. Upon complexation of amine ligands to the copper, 
the λmax for the d to d transition dropped to 690 nm.138 Parker obtained a λmax of 622 nm for 
mustard 64. Similar results were obtained for the macrocyclic copper-complexed 
carbamates 92-99 and are detailed in the Experimental chapter. It was unfortunate that 
crystals of the complexes could not be grown as X-ray crystal structures would have been 
desirable. 
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5.5 Unsuccessful Attempts at Formation of Other Leaving 
Groups 
Although the carbamate synthesis was successful, many unsuccessful attempts were made 
to attach different leaving groups onto the cyclen macrocycle. 
5.5.1 Sulfonamides 
It was desirable to synthesise a mustard derivative with tosyl groups attached to the 
alkylating arms as this functional group is considered to be a good leaving group. Several 
procedures were attempted using different solvents, bases and reaction conditions (Scheme 
27).139 It proved difficult to produce the tetratosylated macrocycle. A mesylation was also 
attempted but again isolation of the desired compound was unsuccessful.140  
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Scheme 27 
It is thought that the product is so reactive that aziridinium ion formation occurs and the 
molecule then breaks itself apart. In order to prevent this happening it was decided to form 
the copper complex of the 2-hydroxyethylated macrocycle 83 as the nitrogen lone pairs 
would then be bound to the copper and aziridinium ion formation should not occur 
(Scheme 16). 
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Scheme 28 
The copper complex 100 was successfully synthesised using the procedure previously 
discussed. Tosylation was then attempted using tosyl chloride and pyridine (Scheme 28).141 
Only starting material was recovered although there had been solubility issues with the 
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reaction. The reaction was modified to use DMF as a co-solvent which resulted in 
complete dissolution of the starting material. Unfortunately the desired product was not 
produced and it was not possible to obtain starting material from the reaction mixture. 
5.5.2 Chloroacetamides and Bromoacetamides 
Parker had used a successful strategy for the alkylation of triazamacrocycles using 
chloroacetyl chloride (Scheme 20).142 The carbonyl groups could then be reduced leaving 
the desired alkylating agent. By using bromoacetyl bromide it was hoped that a 
bromosubstituent could be synthesised as previous work carried out on the bromo-
derivative had been unsuccessful.143 
Both the chloro- and the bromo-derivatives were synthesised using a mixture of cyclen 70 
in dichloromethane with triethylamine and the corresponding haloacetyl halide (Scheme 
29). The yields for both reactions were poor but the desired precursors were produced. 
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Scheme 29 
Reduction of the carbonyl groups was attempted using BH3.THF.144 However the desired 
compounds appeared to have degraded and could not be isolated. A procedure involving 
lithium aluminium hydride was then tried although this resulted in the same conclusions 
that the product, if formed at all, had degraded.145 
5.5.3 Finkelstein Reaction 
A commonly used reaction for the exchange of halides, a Finkelstein reaction, was 
attempted using 2-chloroethylated mustard 58, sodium bromide and acetone.146 Again it 
appeared that there was degradation of the product. Perhaps the molecule is once again too 
reactive and aziridinium ion formation occurs. 
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Scheme 30 
5.5.4 Carbonates 
As it had been possible to synthesise a range of carbamates 84-91, it was thought that it 
would be possible to synthesise a range of carbonates. These should be easier to cleave 
under physiological conditions to produce aziridinium ions. The precursor is the 2-
hydroxylethylated macrocycle 83. 
The first attempt involved the procedure used to synthesise the carbamates with phenyl 
chloroformate used instead of phenyl isocyanate (Scheme 31).137 However the desired 
compound could not be isolated and it looked as though the starting material had degraded 
as seen before during the development of the carbamate synthesis. 
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Scheme 31 
The next protocol tried, used alkyl bromide, phase transfer catalyst, potassium carbonate as 
base and DMF under a carbon dioxide atmosphere that was obtained by dissolving dry ice 
in the reaction mixture and sealing the vessel.147 It proved impossible to extract anything 
resembling the desired product. 
Several other attempts were made to synthesise a carbonate derivative. The first involved 
using phenyl chloroformate with pyridine as solvent and base.148 The second used DCM as 
the solvent and this time no extra additives were added. The only reagents were the alcohol 
precursor and the phenyl chloroformate and the reaction was carried out at -40 oC.149 A 
final attempt used sodium methoxide in toluene with phenyl chloroformate.150 
Unfortunately the product was not obtained using any of these methods.  
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5.6 Biological Results 
5.6.1 Anti-Cancer Test Results 
The series of carbamates 84-91 were sent to Prof. John Hartley at University College, 
London to establish the DNA-crosslinking and cytotoxicity of the uncomplexed mustards 
against the human chronic myeloid leukaemia cell line K562.151 The copper complexes 92-
99 were sent to Prof. Ian Stratford at the University of Manchester for aerobic and 
anaerobic testing against the lung-derived tumour cell line A549.152 
Unfortunately the range of compounds 84-91 proved to be too stable to be efficient DNA 
cross-linkers. Aziridinium ion formation did not occur. There are no quantitative data for 
this range of compounds (XL50 > 1 mM and IC50 > 100 µM) but Figures 13 and 14 show 
that after one hour or two hour incubation with the drug, there is no significant cross-
linking even at high concentrations. No hypoxia selectivity was thus observed with the 
corresponding copper complexes due to the lack of activation of the prodrugs. The data for 
84-86 is not shown but similar results were obtained. 
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Figure 13 
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Figure 14 
5.6.2 Anti-Parasitic Test Results 
The carbamates 84-91 were sent to Dr Mike Barrett in the Department of Parasitology at 
the University of Glasgow for anti-parasitic testing against Trypanosoma brucei (Alamar 
Blue assay).153 Polyamine analogues have shown the ability to disrupt natural polyamine 
metabolism and transport, thus inhibiting parasitic growth. As explained before Reid had 
synthesised a range of azamacrocycles which displayed good results (EC50 values as low as 
1.26 µM).117 
The compounds were also tested against HEK cells which should show if the compound is 
selective towards the parasites.154 A selective drug would show EC50 values of 1-2 µM 
against Trypanosoma brucei but would be inactive against the HEK cell lines. 
The Alamar blue results (Table 4) show that the ortho-, meta- and para-nitrocarbamates 
are the best trypanocides. The meta-derivative is also significantly less active against the 
HEK cells which is required for the drug to be useful as an anti-parasitic agent. 
Fluorescence was measured for the three best compounds. However none of the 
compounds seemed to fluoresce. The compounds kill the cells but don’t rupture the cellular 
membrane. 
91 
88 
90 
89 
87 
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Cpd no. R Est. log P T. brucei EC50 (µM) 
HEK 
EC50 (µM) 
84 
 
4.66 9.22 56.6 
85 
 
1.11 16.9 152 
86 
 
1.40 10.1 ≥200 
87 
OMe
 
4.98 4.00 20.4 
88 
Br
 
8.22 5.81 26.0 
89 
NO2
 
6.24 0.463 * 
90 
NO2
 
6.24 2.00 79.1 
91 
NO2
 
6.24 0.916 23.0 
Table 4 
* shows a gradual decreasing of fluorescence with a biphasic curve: at lower drug 
concentrations (0.1-0.78 µM) there is a slight cytostatic effect, while at the higher doses 
there is a toxic effect. 
 
Log P is the ratio of concentrations of a compound in the two phases of a mixture of two 
immiscible solvents at equilibrium (octanol and water).155 The estimated log P values are 
included in the table (obtained from an online programme156) as Lipinski’s rules state that 
the optimum log P values for a drug should be between 1 and 3.157 The compounds 
synthesised by Reid that showed good activity all possessed log P values that fell into this 
category.117 It should be noted that the compounds 89-91 that showed good activity all 
possess log P values greater then 3. These log P values mean that the drug structures would 
have to be modified for optimum uptake of the drug by the body. These compounds are 
quite insoluble and it was difficult to dissolve the compounds in DMSO to perform the 
assays. It is therefore unrealistic to expect that these compounds would be easily taken-up 
into the body and would cross the blood brain barrier. 
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5.7 Synthesis of Carbamates to Investigate Structure- 
Activity Relationships 
It is unknown whether the mechanism of action of the drugs on the T. brucei involves the 
cyclen moiety or the carbamate side chain. In order to assess the structure-activity 
relationships, it was decided to synthesise a set of carbamates without the cyclen 
macrocycle. These contained the functional groups that had given the best biological 
results from the macrocycles that had been tested – e.g. ortho-, meta- and para-nitrophenyl 
and para-methoxyphenyl derivatives.  
5.7.1 Piperazine Based Bis-Carbamates 
Henderson had previously synthesised a range of piperazine-based carbamates.137 In fact it 
was a procedure developed by Henderson that had been used to synthesise the range of 
macrocyclic carbamates 84-91. It was decided to synthesise a range of piperazine-based 
carbamates. The compounds would still incorporate a heterocycle. They should be useful 
for comparison purposes with the macrocyclic carbamates. As the precursor to the desired 
compounds was commercial, only one synthetic step would be necessary (Scheme 32). 
Using the same general procedure described for the synthesis of the other carbamates, four 
piperazine derivatives 103-106 were successfully produced and the yields are summarised 
in Table 5.  
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Scheme 32 
Cpd no. R Yield 
103 
NO2
 
68% 
104 
NO2
 
55% 
105 
NO2
 
90% 
106 
OMe
 
99% 
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Table 5 
5.7.2 Linear Carbamates 
It was also decided to synthesise a linear compound that would have four arms, similar to 
the tetraazamacrocyclic cyclen moiety. 2-Hydroxyethyl arms were added to ethylene 
diamine 107 producing the tetraol 108 required for carbamate formation (Scheme 33). The 
next step was the addition of the carbamate functionality to the four side arms. The same 
procedure and reaction conditions were attempted as for the macrocyclic carbamates, 
unfortunately it proved impossible to form the desired compounds. It was decided to test 
biologically the four piperazine derivatives that had been successfully produced. 
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Scheme 33 
5.8 Biological Results 
The four piperazine based derivatives 103-106 were tested as before against Trypanasoma 
brucei and HEK cells. The results are summarised below (Table 6). 
Cpd no. R Est. log P T. brucei EC50 (µM) 
HEK 
EC50 (µM) 
103 
NO2
 
3.23 >100 >200 
104 
NO2
 
3.23 16.6 14.1 
105 
NO2
 
3.23 1.31 >200 
106 
OMe
 
2.61 >100 >200 
Table 6 
The biological results show that 103 and 106 have no trypanocidal activity or any activity 
against the HEK cells. However the corresponding cyclen derivatives 87 and 89 with the 
same functional groups in the same positions do show activity against trypanosomes, 
therefore the cyclen ring of the macrocycles is responsible for some of the activity. The 
Jennifer M. Wilson, 2007   Chapter 5, 71 
derivative 104 with the nitro group in the meta position displays low trypanocidal activity, 
however this compound seems to be toxic to HEK cells. It appears to act more as a 
cytostatic than a toxic drug. The best results occur with the para-nitro derivative 105. 
Strong trypanocidal activity is displayed however the compound does not seem toxic to 
HEK cells.  
It is not understood why moving the nitro group around the aromatic ring displays such an 
array of results. The results do not help explain the structure-activity relationship for the 
azamacrocycles in any more detail. 
5.9 Conclusions  
A short efficient synthesis of a range of eight macrocyclic carbamates was developed and 
the corresponding copper complexes were successfully synthesised as alkylating agents 
disguised as pro-drugs. Unfortunately the compounds synthesised proved to be too stable 
to be activated as aziridinium ions and the corresponding copper complexes were therefore 
unselective towards hypoxic cells. Further work is necessary to design successful anti-
cancer prodrugs. 
 It would appear that the eight macrocyclic carbamates provide a good model for the 
development of anti-parasitic drugs as they gave promising results when tested against 
Trypanosoma brucei. The structure-activity relationship for the eight macrocyclic 
carbamates was unclear so a range of piperazine carbamates were synthesised to 
investigate whether the activity of the compounds is due to the cyclen moiety or the 
carbamate functional group. Initial biological results show that the nitro group in the para-
position of the piperazine carbamates produces the best anti-parasitic activity for these 
compounds. Futhermore, it is evident that the macrocyclic cyclen ring does confer 
significant anti-parasitic activity. Futher work is required to determine the mode of action 
of the macrocyclic compounds. In addition, the structures of the compounds needs 
modified to enhance their solubility. It is hoped that the transport of these compounds 
through the parasite plasma membrane will be better understood by studying the different 
carbamates that have been synthesised. There is a realisitic prospect of developing more 
potent and selective analogues. 
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6 Synthesis of Thiaazamacrocycles 
As previous members of the Robins group had synthesised a range of azamacrocycles115 
and oxaazamacrocycles116 such as 58 and 65, it was decided to synthesise a range of 
thiaazamacrocycles to complete the set of macrocycles containing the common heteratoms 
of N, O and S.  
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The previously synthesised oxaazamacrocycles were promising alkylating agents, and 
compound 65 displayed the most potent cytotoxicity of any macrocycle synthesised to 
date.116 It was therefore planned to make a range of thiaazamacrocycles (Figure 15). They 
might display different biological results to the oxaazamacrocycles. It should be noted that 
it was impossible to synthesise the corresponding pro-drug of 65 by complexing the 
macrocycle to copper, although there is literature precedent for the complexation of copper 
to ligands containing oxygen and nitrogen.158 It is well-documented that 
thiaazamacrocycles complex to copper159 and the proposed thiaazamacrocycles should 
form the desired pro-drugs with copper(II) and might produce hypoxia selective 
compounds. 
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Figure 15 
Extreme caution would have to be exercised during the synthesis of the thiaazamacrocycles 
to ensure that at no time would a sulfur mustard be formed as an intermediate. If the 
pathway used to synthesise the azamacrocycles115 and oxaazamacrocycles116 was modified 
to synthesise the sulfur derivatives, several sulfur mustards might be required as precursors 
or intermediates. It was decided that it would be prudent to find a synthesis of a 
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thiaazamacrocycle that was designed in such a way that epi-sulfonium ion formation could 
not occur – i.e. the C-2 of the 2-chloroethyl arm (or corresponding leaving group) was 
protected so that the lone pairs on the sulfur could not activate the mustard mechanism 
(Figure 16). 
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Figure 16 
6.1 Amide Strategy 
A literature search provided the necessary solution to the problem. There are multiple 
examples in the literature of the synthesis of thiaazamacrocycles by forming amide 
bonds.160 The carbonyl group present on the β-carbon to the sulfur provides protection 
against epi-sulfonium ion activation. Once the macrocycle is formed, the carbonyl groups 
would be reduced leaving the desired parent macrocycle. At this stage epi-sulfonium ion 
formation cannot occur. There were many literature precedents available for the reduction 
of the carbonyl groups.159,161 Not only would this pathway (Figure 17) to new macrocycles 
produce the desired compounds safely, it would also eliminate the difficult low yielding 
de-tosylation step and reduce the number of synthetic steps required to synthesise the 
compounds. Once the reduced macrocycle was obtained, the alkylating arms of the 
compound would be added using ethylene oxide. Again, there are literature examples 
detailing the 2-hydroxyethylation of thiaazamacrocycles.162 Chlorination would then take 
place producing the desired mustard. Copper complexation would be the final synthetic 
step required to produce the prodrug. 
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Figure 17 
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6.1.1 Formation of Amide-Protected Macrocycles 
The first step of the reaction involves the synthesis of the sulfur-containing acid chloride 
that is the precursor for the amide bond formation. This was simply prepared by stirring 
thiodiglycolic acid 109 in thionyl chloride at room temperature overnight (Scheme 34).160c 
The acid chloride 110 was isolated by removing the excess thionyl chloride under vacuum. 
This product was not purified but used directly in the next reaction. Quantitative 
conversion was assumed. 
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Scheme 34 
Formation of the macrocycles occurred using a high dilution simultaneous drop-wise 
addition of thiodiglycolic acid chloride 110 and a diamine.160c The product precipitated 
from the reaction mixture. Three macrocycles 111-113 were synthesised using commercial 
diamines (Scheme 35). These reactions work very well and quantitative yields were 
achieved for the three macrocycles 111-113. 
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Scheme 35 
In one case, it was necessary to synthesise the diamine precursor 116 required to carry out 
the cyclisation. There are several procedures in the literature to synthesise sulfur-
containing diamines.163 It was decided to use a process that involved reacting cysteamine 
hydrochloride 114 with 2-chloroethylamine hydrochloride 115 in a sodium ethoxide 
solution.164 The desired amine 116 was successfully formed and was subsequently reacted 
with the thiodiglycolic acid chloride 110 producing the desired macrocycle 117 in 
excellent yield (Scheme 36). 
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Scheme 36 
It should be noted that NMR spectroscopic characterisation carried out on the macrocycles 
corresponded to literature data. However it proved very difficult to obtain any mass 
spectrometry data for any of these macrocyclic amides (111-113, 117). 
6.1.2 Reduction of Carbonyl Groups 
Four amide-protected macrocycles (111-113, 117) had been successfully synthesised. The 
next step involved reducing the amide functional groups. The use of 1M borane in 
tetrahydrofuran solution as the reducing agent was reported in the literature.160 
Macrocycles 111 and 112 were heated under reflux in borane solution for four hours 
(Scheme 37). The compounds did not dissolve and grey suspensions were observed. The 
excess borane was quenched and the reaction mixtures were concentrated. The resulting 
residues were heated under reflux in 6M hydrochloric acid for two hours. However, after 
basification and extraction according to literature procedures, only trace amounts of 
material were isolated. The aqueous phases were concentrated and re-extracted but nothing 
was recovered. It was assumed that the borane solution had degraded or that the starting 
materials had broken apart due to harsh reaction conditions.  
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Scheme 37 
The reactions were repeated using new borane reagent and the reaction mixtures were 
vigorously stirred to aid dissolution of the starting materials. Again only small amounts of 
crude material were recovered. Perhaps heating the compound under reflux in acid during 
the work-up was too harsh and the macrocycle was degrading. 
Jennifer M. Wilson, 2007   Chapter 6, 76 
The solubility of the starting materials could be an issue. The reaction mixture was 
sonicated in an attempt to encourage the starting material to dissolve in the tetrahydrofuran  
solution. The macrocycles 111 and 112 are extremely insoluble so that no common organic 
solvents can be used ruling out the use of other well-known reducing agents such as 
lithium aluminium hydride.  
It was decided to continue developing the borane reduction and instead of heating under 
reflux in 6M hydrochloric acid as a work-up, the corresponding hydrobromide salt was 
formed. No basic work-up was performed as it was felt that the free base could be isolated 
by carrying out anion exchange column chromatography. Preliminary results looked 
promising but the isolated material was a mixture of compounds which proved difficult to 
purify. In certain cases the recovered products were the diamines used to form the 
macrocycle. Thus, the skeleton of the macrocycle had broken apart into several fragments. 
Dean-Stark conditions were also applied to isolate the free base from the hydrobromic salt 
but no product was isolated. 
Different extraction conditions involving heating the quenched mixture under reflux in a 
methanol, water and hydrochloric acid mixture were attempted but again the desired 
products were not isolated. Different work-up conditions were tried including 
concentrating the quenched reaction mixtures and extracting the product into chloroform 
and ethyl acetate but nothing was recovered.  
When the reaction was carried out on macrocycles 113 and 117, complete decomposition 
of the starting materials was observed. 
It was decided that the best course of action could be to do no work-up at all. After 
quenching the excess borane, the reaction mixture was concentrated. 1H NMR spectra for 
the desired products showed the expected peaks although not necessarily at the expected 
frequency (Figures 18 and 19 – some impurities are present as these are crude reaction 
mixtures). For compound 111, the expected 1H NMR signals of the corresponding amine 
would be a singlet corresponding to a CH2N peak and two triplets corresponding to a 
CH2N peak and a CH2S peak. For compound 112, the expected 1H NMR signals for the 
corresponding amine would be three triplets corresponding to two CH2N peaks and a CH2S 
peak as well as a quintuplet/multiplet signifying the CH2. It should be pointed out that it 
was impossible to obtain mass spectra for these supposedly reduced macrocycles.  
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Figure 18 
Figure 19 
The next step of the reaction sequence was carried out. Using ethylene oxide, the addition 
of the 2-hydroxyethyl arms was attempted.115 Again 1H NMR spectra suggested that the 
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desired 2-hydroxyethylated compounds may have been synthesised yet it was still 
impossible to obtain mass spectra. It was decided to try and chlorinate the 2-hydroxyethyl 
arms using thionyl chloride – this should produce a solid that could be purified by 
recrystallisation. However when this procedure was carried out on the supposed 2-
hydroxyethylated thiaazamacrocycles, no product was isolated. It appeared that the 
reaction components had completely degraded. 
At this point it was decided to change the synthetic pathway. There was no proof that the 
intermediates were being produced. It was disappointing that this pathway resulted in 
failure as there does appear to be literature precedent. 
6.2 Tosyl-protected Macrocycle Strategy 
It was decided to try and synthesise some tosyl-protected thiaazamacrocycles as this 
synthesis pathway had been highly successful for the production of the azamacrocycles115 
and the oxaazamacrocycles.116 Characterisation of intermediates should confirm or exclude 
the presence of the desired compounds from the previous pathway. As explained 
previously, extreme care would need to be exercised to ensure that no sulfur mustard 
intermediates were formed (Figure 20). 
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Figure 20 
6.2.1 Formation of Tosyl-protected Macrocycles 
In order to synthesise the tosyl-protected macrocycles the precursors needed to be 
prepared. To produce the two thia-diazamacrocycles (S,N,N), the diaminothiol 116 which 
was synthesised for the amide synthetic pathway and the necessary diols were tosyl-
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protected using standard conditions (Scheme 38). 1,2-Ethanediol 118 and 1,3-propanediol 
119 were protected using tosyl chloride and pyridine.128 The protection of diaminothiol 116 
required a vigorously stirred reaction mixture of toluene-4-sulfonyl chloride in diethyl 
ether and sodium hydroxide solution.165 For the thia-triazamacrocycle (S,N,N,N), the tosyl 
protected diethanolamine 80 synthesised in Chapter 5 was used as well as the tosyl 
protected diaminothiol 122. 
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Scheme 38 
For the ‘pseudo-cis’-dithia-diazamacrocycles (S,S,N,N), a new diaminodithiol 123 required 
to be synthesised but there was literature precedent for the synthesis of this compound.166 
Cysteamine hydrochloride 114 was reacted with 1,2-dichloroethane in a sodium butoxide 
solution (Scheme 39). This dithiadiamine 123 was then tosyl protected using the same 
conditions described for 122.165 
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Scheme 39 
The cyclisations took place under the phase-transfer conditions previously described in 
Chapter 5 (Scheme 40 and 41).126 
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Scheme 40 
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Scheme 41 
For the ‘pseudo-trans’-dithia-diazamacrocycle (S,N,S,N), a different approach was required 
to avoid using a sulfur mustard. The precursor was prepared by reacting the corresponding 
tosyl protected diol 80 with thiourea producing the dithiol 130160a that reacted with the 
tosyl protected diaminothiol 122 (Scheme 42). The cyclisation was unsuccessful using 
phase-transfer conditions126 but a trace amount of desired product 131 was obtained using 
standard Richman-Atkins conditions.123 
NTsS
STsN
S NHTsTsHN
N
Ts
SHHSN
Ts
OTsTsO
S NHTsTsHN
NTsS
STsN
Cs2CO3
DMF
3%
Bu4NBr
toluene
LiOH 2.5% aq
H2N NH2
S
EtOH
NaHCO380 130
131
131
122
122
 
Scheme 42 
Therefore it was decided to carry on with the other five macrocycles (125-129) to complete 
the synthesis pathway. It should be noted that the yields for cyclisation to 128 and 129 
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were disappointing when compared to those for the azamacrocycles and 
oxaazamacrocycles. 
6.2.2 Tosyl Deprotection of Macrocycles 
As explained before, the procedures used to de-tosylate macrocycles are harsh and low 
yielding. It was decided to investigate the reaction conditions for de-tosylating 
thiaazamacrocycles. There was literature precedent for the removal of tosyl groups from 
thiaazamacrocycles.133 The first method attempted used Birch reduction conditions. The 
tosyl-protected macrocycle 126 was reacted with a lithium and ammonia mixture in 
tetrahydrofuran (Scheme 43). Unfortunately no product was isolated. 
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Scheme 43 
It was then decided to use the HBr-AcOH mixture discussed previously.133 The tosyl-
protected macrocycle 126 was heated under reflux for two days in an HBr-AcOH and 
phenol mixture (Scheme 44). The free amine was isolated in a number of ways. The first 
involved an ion-exchange column, however this was extremely low yielding and the 
product was not pure. The product could not be separated from the crude mixture by 
Kugelrohr distillation. Dean-Stark conditions were employed and the hydrobromide salt 
and sodium hydroxide were heated under reflux overnight in toluene. Upon concentration 
of the solvent the product 132 was obtained.  
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Scheme 44 
However the crude mixture appeared to contain more than one product. As the compound 
is very polar, purification is difficult. Compound 132 is so polar that it would not pass 
through a silica column. Alumina column chromatography would be a good alternative as 
the concept of reverse phase chromatography is used. The product was separated quickly 
Jennifer M. Wilson, 2007   Chapter 6, 82 
and efficiently providing the desired compound. This technique proved extremely 
successful for obtaining the pure free amine macrocycle 132. 
Figure 21 shows the yields achieved for the five substrates (132-136). This reaction is 
generally not high yielding and starting materials (tosylated macrocycle) were sometimes 
recovered. However it was felt that as long as the desired free bases were obtained in pure 
form, the yields were sufficient. 
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Figure 21 
It should be pointed out that 1H NMRs collected for the free bases (132 and 133) were 
compared with the 1H NMRs shown in Figures 18 and 19. It was determined that the 
desired compounds had not been synthesised using the amide synthetic pathway and wny 
further research hwould involve the tosyl-protected macrocycles. 
6.2.3 Addition of 2-Hydroxyethyl Arms 
The next step of the synthesis involved the addition of the carbon chain that would make 
up the 2-carbon link required for optimum DNA cross-linking. This was achieved by 
reacting the free amines (132-136) with ethylene oxide as described before although it was 
necessary to change the reaction conditions required for the azamacrocycles and 
oxaazamacrocycles.115 Instead of carrying out the reaction in water, ethanol was used as the 
reaction solvent (Scheme 45). Although the reaction mixture was initially cooled to 0 oC, it 
was allowed to return to room temperature and the mixture was stirred overnight in a 
sealed reaction vessel. 
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Scheme 45 
When this reaction was carried out for the synthesis of the azamacrocycles and the 
oxaazamacrocycles, no purification was required as the desired pure compounds were 
isolated with no by-products present. In the case of the thiaazamacrocycles, 1H NMR 
spectra showed the presence of other peaks. It is likely these are polymerised or over-
alkylated products. Alumina column chromatography was used once again to purify the 
compounds and all five substrates (137-141) were successfully isolated (Figure 22). 
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6.2.4 Chlorination of Macrocycles – Mustard Formation 
All that remained was the final chlorination step that would produce the desired alkylating 
agents as hydrochloride salts. The protonated nitrogens should prevent aziridinium ion 
formation. 
The 2-hydroxyethylated macrocycles (137-141) were reacted overnight in thionyl chloride 
at 50 oC (Scheme 46).115 Normally a white solid is isolated after extraction and purification 
but with every reaction attempted, a brown viscous oil was recovered. Numerous attempts 
were made to try and isolate a pure product but nothing was successful. 1H NMR spectra 
showed that no expected peaks were present, and it appeared that degradation had 
occurred. 
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Scheme 46 
It was extremely disappointing to discover that the chlorinations were unsuccessful, 
particularly as the synthesis pathway to the 2-hydroxyethylated thiaazamacrocycles had 
been arduous and difficult throughout with unexpected purification required at each step. 
The synthesis of the azamacrocycles and the oxaazamacrocycles had been less 
complicated. Without the chlorinated mustards it was clearly impossible to synthesise the 
desired alkylating agents and corresponding prodrugs. 
6.2.5 Carbamate Formation 
It was decided to try and synthesise a selection of carbamates from the range of 2-
hydroxyethylated thiaazamacrocycles (137-141) that had been successfully synthesised.137 
Although it was highly probable that the carbamates would be too stable to be efficient 
alkylating agents due to biological testing carried out previously, synthesis of copper(II) 
complexes could be attempted to see if the sulfur coordinates to the copper better than with 
the oxygen-containing macrocycles. Anti-parasite testing would also be carried out to 
determine whether the thiaazamacrocycles (137-141) are more cytotoxic than the 
azamacrocyclic carbamates (84-91) thus providing the prospect of a new molecular 
skeleton to develop anti-parasitic drugs. 
The 2-hydroxyethylated macrocycle 137 was heated under reflux with 4-nitrophenyl 
isocyanate and dibutyl tin diacetate in DCM overnight (Scheme 47).137 Unfortunately the 
only product that was isolated was the corresponding hydrolysed isocyanate as seen before 
during the azamacrocyclic carbamate (84-91) synthesis. Several different reaction 
conditions were investigated as had been required during the synthesis of azamacrocyclic 
carbamates but nothing proved successful. 
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Scheme 47 
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It was decided to leave this area of the project and concentrate on the synthesis of 
compounds that would prove to be biologically active. 
6.3 Conclusions 
It was extremely frustrating that none of the desired final compounds could be synthesised. 
A possible explanation to the problem was discovered; Hartley and co-workers had 
investigated the synthesis of thioacetals as pathway intermediates due to the fact that 
carbonyl groups can be successfully masked to allow synthetic change to other parts of the 
molecule.167 It was discovered that a 1,3-dithiane displaces tosylate by a 5-exo-tet 
cyclisation to give a bicyclic sulfonium salt which was isolable (Scheme 48).168 This was 
verified by X-ray crystallography. 
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Scheme 48 
It was suggested that a similar mechanism could be occurring with the chlorinated 
thiaazamacrocyclic mustards. A favoured 6-exo-tet cyclisation mechanism could happen 
forming a strained structure that then broke apart resulting in the degradation of the 
macrocycle. 
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Scheme 49 
Despite not achieving the aims of the project, a reliable synthetic pathway has been 
developed that allows the preparation of pure thiaazamacrocycles as free bases. 
Functionalisation has also been added to the thiaazamacrocycles in the form of 2-
hydroxyethyl arms. 
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7 Synthesis of Substituted Macrocycles 
As stated before, Reid had investigated the synthesis of aromatic-substituted 
azamacrocycles.117 By using a two-step iron templated synthesis (Figure 23),169 a range of 
20 compounds was produced and several of these compounds displayed excellent results 
when tested against Trypanosoma brucei. 
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Figure 23 
7.1 Synthesis of an Alkyl Substituted Azamacrocycle 
It would be beneficial to synthesise an alkyl substituted macrocycle to discover whether it 
possesses different biological activity as this would aid the design and development of new 
anti-parasite drugs. It was decided to attempt the synthesis of a macrocycle 142 with a 
methyl group attached as this is the simplest alkyl group and if the synthesis was successful 
it would provide a pathway for the synthesis of a range of compounds with different alkyl 
substituents. 
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7.1.1 Template Synthesis 
It was decided to attempt a template synthesis as discussed previously in Chapter 5 for the 
synthesis of cyclen 70.121 If successful this would provide a short route for the multigram 
preparation of the susbstituted macrocycle. 
The first step of the reaction was the synthesis of bisimidazoline 72 by treating 
triethylenetetraamine 71 (TETA) with dimethylformamide dimethyl acetal (Scheme 50). 
The desired product 72 was obtained in crystalline form in moderate yield and was reacted 
with 1,2-dibromopropane to form the carbon skeleton of the macrocycle. The 1H NMR 
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spectrum showed the disappearance of the bisimidazoline so the reaction was carried onto 
the next step. Alkaline hydrolysis should remove the two carbon infrastructure leaving the 
desired product 142. Unfortunately no product 142 or any starting material was recovered; 
the harsh reaction conditions must have broken down the reagents. It is unknown whether 
the macrocyclic skeleton was formed at all. 
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Scheme 50 
7.1.2 High Dilution Amide Synthesis 
7.1.2.1 Formation of Macrocycle 
Reid also carried out some research into the synthesis of enantiomerically pure substituted 
macrocycles.117 By adapting this line of research, the synthesis of the methyl substituted 
macrocycle 142 should be possible. Stetter and Mayer in 1961 had synthesised dione 144 
by reacting diacid chloride 143 with ethylenediamine (Scheme 51).170 
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Scheme 51 
By substituting 1,2-diaminopropane for the ethylenediamine, it would be possible to 
synthesise a compound with the molecular skeleton of the desired target compound. 
Reduction of the carbonyl groups and removal of the tosyl groups would produce the 
methyl-susbtituted macrocycle 142 as a free base (Figure 24). 
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Figure 24 
The first stage of the reaction pathway was the synthesis of the diacid chloride 143.170 This 
was achieved in a four step process (Scheme 52). Tosyl-protected ethylenediamine 145 
(prepared quantitatively from ethylenediamine using toluene-4-sulfonyl chloride and 
pyridine), was reacted with methyl bromoacetate in a sodium methoxide solution to give 
diester 146. The diacid 147 was obtained by heating 146 under reflux with acetic acid and 
hydrochloric acid. The desired intermediate 143 was obtained by heating diacid 147 under 
reflux in thionyl chloride. 
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Scheme 52 
The next step of the pathway was the key cyclisation reaction.170 The original procedure 
used benzene as the solvent for this reaction. However this reaction requires high dilution 
conditions so for health and safety reasons dichloromethane was substituted for the 
benzene. The diacid chloride 143 and 1,2-diaminopropane were added dropwise 
simultaneously and the desired product 148 precipitated from the reaction mixture 
(Scheme 53). 
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Scheme 53 
7.1.2.2 Formation of Free Base 
The next step of the pathway required the removal of the tosyl groups and the reduction of 
the carbonyl groups. A procedure was found that claimed to use lithium aluminium hydride 
to remove tosyl protecting groups from cyclen 70.171 It was thought that this method could 
be used to reduce the carbonyl groups and remove the tosyl groups in one step. The 
reaction was carried out by heating the macrocycle 148 under reflux in THF with lithium 
aluminium hydride for three days (Scheme 54). However the conditions were too harsh 
and the macrocycle was destroyed. 
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Scheme 54 
It was decided to use milder conditions to reduce the carbonyl groups and then the tosyl 
groups would be removed using de-tosylation methods well known in the Robins group. 
The carbonyl groups were successfully reduced using a 1M borane in tetrahydrofuran 
solution followed by hydrolysis using conc. hydrochloric acid yielding the desired 
compound 149 (Scheme 55).172 
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Scheme 55 
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Only one step remained to complete the synthesis of the methyl-substituted macrocycle 
142. The de-tosylation step used to obtain cyclen 70 was attempted. The hydrobromide salt 
was formed followed by formation of the free base under Dean-Stark conditions but 
attempts to isolate the desired compound were unsuccessful.173 Use of other established de-
tosylation techniques were also unsuccessful (e.g. HBr-AcOH 45%).133 
It was decided to abandon this synthesis as the desired alkylated compound had not been 
produced and other areas of research were producing better results. It was hoped that more 
success would be had synthesising substituted thiaazamacrocycles. 
7.2 Synthesis of Aromatic-Substituted Thiaaza-
macrocycles 
Reid had synthesised a range of azamacrocycles based on the cyclen skeleton.117 It would 
be interesting to investigate whether the cytotoxicity of the compounds changes depending 
on the presence of different heteroatoms in the macrocyclic structure. As work was already 
being carried out trying to synthesise thiaazamacrocycles for use as alkylating agents, it 
seemed prudent to synthesise a range of substituted thiaazamacrocycles (Figure 25). 
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Figure 25 
It was decided to attempt the synthesis of the substituted thiaazamacrocycles using the iron 
templated synthesis that had been successful for Reid.169 It is well-documented that 
triethylene tetraamine (TETA) 71 can form complexes (cis-[MLCl2]) with first-row 
transition metals.174 It was unknown whether the iron would complex to the ligand if any 
sulfur atoms were present.  
7.2.1 Synthesis of a Substituted Dithia-diazamacrocycle 
7.2.1.1 Iron Templated Synthesis 
The reaction was attempted using the dithiadiamine 123 synthesised previously (Chapter 
6). Diamine 123 was reacted with ferric chloride and methanol to form the diimine 
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(Scheme 56). Commercial phenyl glyoxal monohydrate was added. In order to isolate the 
desired compound, sodium borohydride was added to reduce the iron(III) to iron(II). An 
acidic work-up removed the coordinated iron leaving the free base.169 When Reid 
synthesised the azamacrocycles, there were specific colour changes associated with the 
different stages of the reaction, however these were not observed when attempting the 
synthesis of the thiaazamacrocycle. The 1H NMR spectrum of the crude product looked 
promising. However it was soon discovered that cyclisation had not occurred and reduced 
starting materials were obtained from the mixture, thus explaining the ‘positive’ 1H NMR 
spectrum. 
S NH
NHS
R
S N
NS
R
Fe
Cl
Cl
Fe
NH
NH
S Cl
S Cl
R
O
H
O
1. NaBH4
2. H3O+
3. OH-S NH2
NH2S
FeCl3
MeOH
123
 
Scheme 56 
7.2.1.2 Future Work - High Dilution Amide Synthesis 
It was disappointing that the iron templated synthesis was unsuccessful and due to time 
constraints more research was not carried out in this area of the project. However upon 
reflection, there is another route that could be followed to synthesise a substituted dithia-
diazamacrocycle. 
The high dilution route described previously to synthesise the methyl-substituted 
azamacrocycle 142 failed due to the presence of the tosyl-protecting groups which could 
not be removed under standard conditions. However if the same pathway was applied in 
the instance of the dithia-diazamacrocycles, there would be no tosyl groups present 
(Scheme 57). 
The dithia-diacid 150 is commercially available. This would be transformed to the diacid 
chloride 151 which should then undergo cyclisation under high dilution conditions to form 
the macrocycle 152.170 Reduction conditions have already been investigated during the 
synthesis of the methyl-substituted azamacrocycle,172 so the carbonyl groups should be 
reduced leaving the desired substituted thiaazamacrocycle 153 as the free base. 
Jennifer M. Wilson, 2007   Chapter 7, 92 
S NH
NHS
R
S NH
NHS
R
O
O
Cl S
O
S Cl
O
HO S
O
S OH
O
SOCl2
H2N NH2
R
NEt3, DCM
150 151 152
153
 
Scheme 57 
This three step synthesis if successful would provide a means to synthesise a range of 
substituted dithia-diazamacrocycles simply and quickly, allowing an investigation into the 
development of better and more potent anti-parasitic drugs. 
7.2.2 Synthesis of a Substituted Thia-triazamacrocycle 
It is thought that one of the reasons the iron templated synthesis was unsuccessful for the 
dithia-diaazamacrocycles was that the two sulfur atoms did not coordinate strongly to the 
iron centre. It was hoped that if only one sulfur was present, coordination would still occur 
with the three nitrogen atoms (Scheme 58). 
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Scheme 58 
In order to test this theory, the sulfur-containing triamine 154 needed to be synthesised. 
There is literature precedent for the synthesis of this compound.163c,175 A procedure was 
attempted using the thia-diamine 116 already synthesised (Scheme 59). 2-
Chloroethylamine hydrochloride and caesium hydroxide monohydrate were reacted with 
the thia-diamine 116 in DMF – the literature quoted good yields for this reaction.175 
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Scheme 59 
Several attempts were made to reproduce the literature results but unfortunately it was 
impossible to synthesise the thia-triamine 154. Without this intermediate the reaction 
pathway could not be continued. 
7.3 Conclusions 
The desired substituted macrocycles could not be obtained by the routes and procedures 
tried. Further research needs to be carried out to obtain the desired target compounds. As 
discussed previsouly it is thought that the substituted dithiadiazamacrocycle (S,S,N,N) 
would be synthesised using the pathway discussed. These compounds would allow an 
investigation into cytotoxicity and a structure-activity relationship could be established 
leading to a better understanding of the drug’s interactions in the body as well as allowing 
the design and development of more potent and efficient anti-parasitic agents.  
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8 Synthesis of HDM2 Inhibitors 
8.1 Introduction – p53: ‘Guardian of the Genome’ 
p53 was discovered in 1979176 and voted ‘molecule of the year 1993’ by Science 
magazine.177 It has been identified as an important tumour suppressor gene, hence the 
description ‘guardian of the genome’.178 50% of all tumours possess a mutated form of the 
p53 protein – it is the most frequently altered gene in cancers. The other 50% of tumours 
possess ‘wild-type’ p53 which is inactivated by a variety of methods.  p53 stands for the 53 
kDa gene product found in cells that are infected with a virus.179 
In the body, the p53 protein activates the transcription of specific genes by forming a 
tetramer that binds to the DNA sequence.  p53 uses two different mechanisms for tumour 
suppression although both processes produce the same result which is the prevention of 
harmful gene mutations being passed onto daughter cells. Firstly, p53 responds to DNA-
damaging environmental stresses by stopping the cell cycle; DNA replication is halted 
allowing the damaged DNA to be repaired.  Secondly, p53 can also initiate apoptosis 
(programmed cell death) as shown in Figure 26.180 
 
Figure 26 - Roles of p53180 
Cancer can occur in cells where mutated p53 exists and apoptosis cannot occur – thus the 
damaged DNA replication occurs resulting in the development of a tumour.  p53 mutations 
are largely found in the hydrophobic region of the protein which is the site of DNA 
binding.  Due to the loss of active p53, the cancer is also less responsive to radiotherapy or 
chemotherapy. This genetic mutation can be inherited as a disease known as Li-Fraumeni 
syndrome – the sufferer inherits only one functional copy of p53.181 
However, in healthy cells, the levels of p53 have to be kept to a minimum to allow the 
normal running of the cell, e.g. growth and replication.  This function is carried out by the 
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HDM2 protein (Human Double Minute-2), which forms an auto-regulatory feedback loop 
with p53.  HDM2 is the product of a p53 inducible gene.182 p53 initiates HDM2 
transcription and HDM2 inhibits p53 in three ways.  HDM2 can bind to the transactivation 
domain of p53, which blocks the transcription of genes. Also HDM2 contains a sequence 
of amino acids that is similar to the nuclear export ‘signal’ that exists in vital proteins. 
Therefore binding the HDM2 to p53 induces the eviction of the complex from the nucleus 
to the cytoplasm where normal cell functions cannot be carried out.  Finally, HDM2 is also 
an ubiquitin ligase protein – p53 becomes ‘tagged’ with a ubiquitin molecule and this 
targets p53 for degradation by proteasomes in the cell.  It can be seen that HDM2 regulates 
the stability of p53 as in Figure 27 (HDM2 is represented by MDM2 – Mouse Double 
Minute-2).183 
 
Figure 27 - Regulation of p53 by MDM2 
However in certain circumstances, e.g. when a cell is put under oncogenic stress, HDM2 
activity must be inhibited to allow p53 levels to increase and the cell will undergo DNA 
repair or apoptosis.  This can be achieved in several ways. The DNA damage can initiate 
phosphorylation of several amino acids in p53, which prevents binding with HDM2.  
Secondly, the activation of oncogenes (cancer causing cells) results in the expression of a 
protein known as Auxin Response Factor (ARF). This ADP ribosylation factor protein 
binds to HDM2 using a site remote from the p53 binding site resulting in a conformational 
change in the HDM2 protein preventing binding and ubiquitylation on p53.182 
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8.1.1 Using HDM2 As A Therapeutic Target 
In some tumours, the p53 function is disrupted due to genetic mutations of p53.  However 
other tumours possess ‘wild type’ p53 – this type of p53 has lost the ability to respond to 
oncogenic stress due to over-expression of HDM2.  Thus the chance of forming a tumour 
is increased by the inhibition of p53 stabilisation. Generally soft tissue tumours, 
osteocarcinomas and oesophagal carcinomas demonstrate the highest frequency of HDM2 
amplification.184 In fact it is thought that these types of cancers require HDM2 over-
expression for tumour survival. Therefore, HDM2-inhibiting drugs should cause 
stabilisation of p53 and induce apoptosis in cancer cells. 
Past investigation into inhibitors of non-enzyme protein-protein interactions has not proved 
successful.185 An investigation into the p53-HDM2 complex had to be carried out before 
inhibitors of HDM2 could be developed.186 Protein crystallography was used to determine 
the structure of the complex of HDM2 with peptides of the p53-binding domain.  The 
results showed that HDM2 has a deep hydrophobic cleft constructed of α-helices and β-
sheets. The HDM2 cleft is filled with three amino acid side chains from the hydrophobic 
face of p53 (Phe 19, Try 23 and Leu 26) – the p53 forms an amphipathic α-helix with one 
side hydrophobic and one hydrophilic.  Van der Waals interactions and steric 
complementarity constitute the main sources of attraction between p53 and HDM2. 
 
Figure 28 - Hydrophobic Pocket in HDM2 
Figure 28 shows the HDM2 NH2 terminal in blue with its twisted ‘trough’ type structure. 
The p53 peptide, shown in yellow, may bind to the HDM2 as an α-helix. A shows the 
HDM2-p53 complex with the floor of the HDM2 cleft in the plane of the picture. B shows 
the complex rotated 90o, looking down the helical axis of p53. C shows the complex 
rotated 90o from the vertical axis of B.185 
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8.1.2 Inhibitors Of The HDM2-p53 Complex 
p53 derived peptides inhibit the interaction between p53 and HDM2.  However peptides 
are not useful as drugs as stomach acid and hydrolytic enzymes hydrolyse the peptides too 
easily.187  
Inhibitors should be designed to mimic p53.  The reason for this is that only HDM2 has 
structurally well-defined binding sites whereas p53 can undergo structural change, e.g. 
phosphorylation or change of conformation can occur due to stress and p53 is composed of 
a single short stretch of amino acids.  The interactions between p53 and HDM2 consist of 
three hydrogen bonds and the contact surface area is small.  Therefore a low molecular 
weight inhibitor may work which also favours an oral administration for the drug. 
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Several compounds have been identified as small molecule HDM2 antagonists. These 
include the chalcones 155 that are based on phenoxy-acetic acid derivatives and 
phenoxymethyl tetrazole derivatives.188 The chalcones were first reported in 1999 and  bind 
in the hydrophobic pocket of HDM2 showing IC50 values within the µM range. Zhao and 
co-workers prepared non-peptidic polycyclic antagonists 156 which have shown moderate 
affinity for HDM2 and initiate p53-controlled apoptosis in tumour cell lines.189 During a 
library screening, the nonapeptide chlorofusin 157 was identified as an inhibitor but due to 
the high molecular mass and complex structure it is an unsuitable drug candidate.190 
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However, the molecule could prove useful for future drug design. The stereochemistry of 
C-4, C-8 and C-9 is as shown or inverted and the asterisks denote two stereocentres where 
one is R and the other is S. 
Three years ago, Roche published the structure of three cis-imidazoline based compounds 
158-160, known as the Nutlins – named after the Nutley inhibitor.185 The compounds were 
synthesised as racemic mixtures and were separated using chiral columns.  One enantiomer 
of the products formed had potent binding activity, whereas the other enantiomer was 
found to be 150 times less active. 
Bindings of these compounds to the p53 binding site were proven by X-ray crystal 
structures.  An in vivo study of these compounds on mice with human tumour xenografts 
showed 90% inhibition of tumour growth after 20 days compared to the control.  More 
importantly no side effects such as weight loss or abnormalities were observed.185 
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At the same time a small molecule called RITA 161 (Reactivation of p53 and Induction of 
Tumour cell Apoptosis) was discovered by workers at the Karolinska Institute in Sweden 
during a library screen.191 Again this compound could serve as a lead compound for future 
drug design. 
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8.2 Aims Of The Project 
A high throughput assay to identify low molecular weight inhibitors of HDM2 was 
developed by Professor Karen Vousden FRS and her team from the Cancer Research UK 
Beatson laboratories together with Dr Allan Weissman from the National Cancer Institute 
and Igen Pharmaceuticals in the USA.192 The screen was carried out in tumours containing 
wild-type p53 and a library of 10,000 compounds was tested. Forty compounds were found 
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to inhibit HDM2 autoubiquitylation by more than 50%. The compounds 162-164 were 
identified after additional in vitro gel-based assays.193 The compounds all contain a 5-
deazaflavin structural motif. 
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A ‘library’ of new analogues of these compounds has already been synthesised and 
tested.194 The biological results showed that the para-substituted compounds are favoured 
over the meta-substituted. 
As work has been carried out concerning the phenyl substituent,194 it was decided to focus 
on the 7-position of the heterocycle (Scheme 60).  An amino group instead of the nitro 
group at C-7 on compound 165 would produce a more water-soluble compound 166, which 
should be more suited for a drug that has to be taken orally or intravenously. This amino 
group could then be treated with sodium nitrite and acid to form a diazonium salt 167 
which should lead to the synthesis of further compounds such as the cyano derivative 168. 
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Scheme 60 
All compounds synthesised up to this point had contained a 7-nitro group.194 It could not be 
ruled out that part of the mechanism of action of these compounds involved the nitro group 
and oxidative stress processes.195 In order to investigate the structure-activity relationship 
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of the 5-deazaflavins, compounds containing different functional groups would be 
prepared. The size of the binding pocket could also be investigated by synthesising 
deazaflavins with different aromatic rings such as quinoline. 
8.3 Synthesis of Deazaflavins 
Retrosynthesis of the 5-deazaflavin skeleton 165 by disconnection of the central ring 
produces two fragments consisting of a 6-anilinouracil compound 169 and a substituted 
nitrobenzaldehyde 170. Further disconnection of 169 produces 6-chlorouracil 171 and 
aniline 172 (Scheme 61). Analogues are easily prepared by using substituted derivatives of 
these synthons. 
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Scheme 61 
6-Chlorouracil 171 is a commercial compound, however due to problems with the supplier 
it was necessary to synthesise the starting material. This was successfully achieved from 
2,4,6-trichloropyrimidine 173 as shown in Scheme 62.196 
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Scheme 62 
The first coupling reaction involved reacting 6-chlorouracil 171 with aniline 172 (Scheme 
63). Diversity can be added to the synthesis by using substituted anilines. The two 
reactants were melted together at 170 oC for 20 minutes producing a white solid in good 
yield.197 Nucleophilic substitution occurs at the 6-position of the uracil – the presence of the 
Jennifer M. Wilson, 2007   Chapter 8, 101 
chlorine encourages this reaction. The reaction is similar to nucleophilic aromatic 
substitution as the intermediate formed is stabilised by the presence of the electronegative 
element. However the reaction is more like a 1,4-carbonyl addition. The second step of the 
synthesis involved the condensation of the secondary amine 169 with 2-chloro-5-
nitrobenzaldehyde 170 (Scheme 63).197 Water was then added resulting in the precipitation 
of the desired product 165.  
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Scheme 63 
The mechanism of the reaction is shown in Scheme 64. Nucleophilic aromatic substitution 
occurs before the condensation reaction takes place.198 SNAr occurs because SN2 will not 
occur at sp2 hybridised orbitals and it highly unlikely that an SN1 reaction would occur as it 
would involve unaided loss of the leaving group and the formation of an aryl cation with 
an empty sp2 hybridised orbital outside of the benzene ring and a full p-orbital inside the 
ring. SNAr involves addition of the nucleophile followed by loss of the leaving group. The 
presence of an electron withdrawing group positioned ortho- or para- to the ring aids the 
reaction as electrons can be delocalised around the aromatic ring. 2-Chloro-5-
nitrobenzaldehyde possesses two electron withdrawing groups, therefore it reacts readily 
with the secondary amine. 
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Scheme 64 
A small library of derivatives was synthesised using the previously discussed method.197 
The results are summarised in Figure 29. The quoted yields are for the two successive 
steps. 
HN
N N
O
O
NO2
Cl
174 (40%)
HN
N N
O
O
Cl
175 X = H (79%)
176 X = o-Cl (22%)
177 X = p-Cl (28%)
178 X = p-CH3 (40%)
HN
N N
O
O Cl
179 (60%)
HN
N N N
O
O
HN
N N
O
O
CF3
X
180 X = p-Cl  (36%)
181 X = p-CH3 (36%)
182 (62%)
X
 
Figure 29 
It was possible to grow crystals of 181 and an X-ray crystal structure was obtained (Figure 
30). As expected the lower aromatic ring is twisted out of the plane of the deazaflavin 
system. 
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Figure 30 
As discussed previously it was desirable to synthesise an amino derivative 166 as this 
would produce a precursor to many different analogues. Unfortunately it was not possible 
to reduce the nitro compound 165 although several different methods were tried. Firstly a 
reduction using iron powder and hydrochloric acid199 was attempted but the desired product 
was undetectable in the 1H NMR spectrum. A radical method using samarium and 1,1’-
dioctadecyl-4,4’-bipyridinium dibromide200 also failed – the starting material was 
recovered. A method using formic acid, triethylamine and 10% palladium on carbon201 also 
proved unsuccessful. It was thought that these reactions were unsuccessful due to the 
limited solubility of the nitro compound 165. 
It was then decided to use Buchwald-Hartwig aminations202 to introduce the amino moiety 
using compound 179 which had been synthesised using the established pathway previously 
discussed. Compound 179 was reacted with diethylamine, palladium diacetate, tri-tert-
butylphosphine, sodium tert-butoxide and toluene (Scheme 65). 
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Scheme 65 
Unfortunately only starting material was recovered. It was decided to attempt a microwave 
technique using diethylamine, potassium tert-butoxide and DMSO.203 Again only starting 
material was recovered. 
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It was then thought that the chlorine atom of 179 could be substituted with an azide anion 
(Scheme 66). This involves nucleophilic aromatic substitution as discussed previously.198 
The azide would provide the opportunity to add functionality onto the molecule. 
Unfortunately this reaction was not successful.204 
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Scheme 66 
As attempts to reduce the nitro group on the 5-deazaflavin had proved unsuccessful it was 
decided to use a preformed amino-chlorobenzaldehyde (Scheme 67). This compound 
should react with the anilinouracil to produce the desired compound although it would 
have to be prepared as there are no commercial amino-chlorobenzaldehydes available.  
5-Amino-2-chlorobenzoic acid 183 was transformed into 184 using a one-pot procedure to 
add the methyl ester group and Boc protect the amine.205 Conditions for the reduction of 
184 to 185 were investigated.206 A procedure using lithium aluminium hydride and THF 
was successful. 
At first it had been assumed that the methyl ester 184 could be directly reduced to form the 
aldehyde compound 186, however it was impossible to isolate the pure aldehyde.205 
Therefore it was decided to form the alcohol 185 and then oxidise the primary alcohol to 
the corresponding aldehyde 186. 
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Scheme 67 
Unfortunately, it proved impossible to oxidise the alcohol 185 to aldehyde 186. Numerous 
attempts were made, none of which produced the desired compound.207 This was 
disappointing as there only remained two steps to produce the desired amino compound – 
the coupling of 168 and 186 followed by Boc-deprotection should produce 166. 
8.4 Biological Test Results 
All synthesised compounds were tested at the Beatson Oncology Laboratories, Glasgow. 
All the compounds were analysed for their ability to stabilise endogenous HDM2 and p53 
in primary human pigment epithelial cells (RPE). Several of the compounds showed 
activity in the stabilisation of p53 comparable to compound 162. Three of the analogues, 
174, 177 and 178 demonstrated stronger p53 stabilisation and activity at lower 
concentrations than compound 162. Generally stabilisation of p53 is accompanied by the 
activation of DNA damage-induced kinases – p53 becomes phosphorylated at serine 15. 
However in this case there was no clear indication that phosphorylation had occurred on 
the p53 stabilised by the 5-deazaflavins. This shows that the compounds stabilise p53 by 
inhibition of HDM2 as opposed to the activation of a DNA damage response.  
The original lead compounds 162-164 contain a nitro group that could be reduced to a nitro 
anion radical in biological systems. This radical then interacts with DNA to induce DNA 
damage. However the results from compounds 174, 177 and 178 argue against this notion. 
More interesting was the fact that analogues without the nitro group retained biological 
activity. The results are summarised in Table 7. These compounds 176-178 contained a 6-
chloro group instead of the 7-nitro group. 
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Compound 1 µM 5-10 µM 
165 ND - 
174 + ++ 
175 ND - 
176 - + 
177 + ++ 
178 + ++ 
179 ND - 
180 - - 
181 - - 
182 ND - 
Table 7. Stabilisation of p53 measured by Western blotting in RPE cells treated with the 
analogues at the indicated concentrations for 24 hours. Results of the three experiments are 
summarised to indicate no elevation of p53 levels (-); increase in p53 with that seen with 5 
µM compound 162 (+); or increase in p53 levels in excess of that seen with 5 µM 
compound 162 (++). ND, not determined. 
8.5 Conclusions 
By consideration of the test results obtained, it has been determined that the compounds 
must have certain structural characteristics in order to be good inhibitors of HDM2. For 
example there must be a substituent on the aromatic ring of the fused cyclic system. 
The most important new finding is that the nitro group present in the three original 
compounds 162-164 is not essential for stabilisation and activation of p53.  
The R substituent on the phenyl ring must be in the ortho or para position and requires 
some bulk, e.g. a methyl group or a chlorine atom is adequate although a bromine atom 
appears to be too big. This work has been published as part of a wider study of these types 
of compounds.208 
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Figure 31 
If any further work is carried out on this project it would be beneficial to complete the 
synthesis of the amino-derivative as this compound would allow an investigation into the 
mode of action of the deaazaflavins. 
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9 Experimental 
9.1 General Experimental Details 
All reactions were carried out under an inert atmosphere unless otherwise stated, using 
oven-dried or flame-dried glassware. Solutions were added via syringe unless otherwise 
stated. Tetrahydrofuran and diethyl ether were freshly distilled from sodium-
benzophenone; dichloromethane, toluene, dimethylformamide and pyridine were distilled 
from calcium hydride prior to use. Petroleum ethers refer to the fraction boiling at 40-60 
oC. Brine refers to a saturated sodium chloride solution. Reagents were obtained from 
Aldrich Chemical Company (Gillingham, Dorset, UK), Alfa Aesar Lancaster (Morecambe, 
Lancs, UK) or Alfa Aesar Avocado (Heysham, Lancs, UK) and used without further 
purification unless otherwise stated. Purification by column chromatography was carried 
out using Fischer Silica 60A silica gel (mesh size 35-70 µm) as the stationary phase. 
Melting points were measured using Gallenkamp apparatus and are uncorrected. IR spectra 
were recorded using Golden Gate, nujol or KBr on a JASCO FT/IR 410 spectrometer. 
NMR spectra were recorded using a Bruker AV400 or DPX/400 spectrometer. Chemical 
shifts are given in ppm relative to trimethylsilane. Chemical shifts in 13C NMR spectra are 
given in ppm relative to CDCl3 as internal standard (77.0 ppm). All NMR J values are 
given in Hz. Mass spectra were recorded on a JEOL JMS700 spectrometer.  
9.2 Experimental to Chapter 5 
9.2.1 General Procedures (A-C) 
General procedure A – Copper complex formation: A stirred solution of macrocycle (1 
eq) and methanol/water mixture (5:1) was added to a round-bottomed flask fitted with a 
water-cooled condenser. Anhydrous copper (II) chloride (1 eq) was added and the reaction 
mixture was heated to 50 oC for 10 min. A blue or green solid precipitated on cooling and 
was collected by filtration. 
General procedure B – Method 1 for synthesis of carbamates: A stirred solution of 
1,4,7,10-tetra(2-hydroxyethyl)-1,4,7,10-tetraazacyclododecane (1 eq) and pyridine (5 mL) 
was prepared. Isocyanate (eq) was added and the reaction mixture was stirred for 18 h at 
RT. The pyridine was removed by rotary evaporator and the beige solid was filtered and 
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washed with diethyl ether (20 mL). White crystals were obtained by recrystallising from 
hot methanol. 
General procedure C – Method 2 for synthesis of carbamates: A stirred solution of 
alcohol (1 eq), dibutyl tin diacetate (3 drops) and dichloromethane (10 mL) was prepared. 
Isocyanate (0.88 mL, 9.28 mmol) was added and the reaction mixture was stirred and 
heated under reflux for 24 h. The solvent was concentrated and the residue was filtered and 
washed with diethyl ether (20 mL). The crude product was recrystallised from ethyl acetate 
and hexane. 
General procedure D – Acylation of azamacrocycles: A stirred solution of cyclen (1 eq) 
and dichloromethane (5 mL) was prepared and cooled to 0 oC in an ice bath. Triethylamine 
(4 eq) was added. Once all the reactants had dissolved, chloroacetyl chloride or 
bromoacetyl bromide (4 eq) was added. The reaction mixture was stirred for 20 min at 0 oC 
then allowed to return to RT and stirred for 16 h. The dark brown solution was washed 
with water (2 x 25 mL). The organic layer was dried (MgSO4) and concentrated leaving a 
dark brown oil that was purified by column chromatography (eluant: 
dichloromethane/methanol 97/3). 
9.2.2 Experimental Details 
N,N’,N’’-Tri(toluene-4-sulfonyl)diethylene triamine 78209 
N
Ts
NHTsTsHN
 
A stirred solution of diethylene triamine (21.7 mL, 0.20 mol) and distilled water (125 mL) 
was prepared. Sodium hydroxide pellets (24.0 g, 0.6 mol) were added and the temperature 
was kept below 40 °C. Diethyl ether (125 mL) was added and the reaction mixture was 
stirred vigorously. Toluene-4-sulfonyl chloride (114.5 g, 0.6 mol) was added, the 
temperature was kept below 20 °C during addition. The reaction mixture was cooled to 0 
°C and stirred for one hour. The white precipitate was filtered and washed with diethyl 
ether (250 mL). Recrystallisation from chloroform gave the desired product (112.6 g, 
99%). mp 176-178 °C (lit. 177-179 °C); 1H NMR (400 MHz, CDCl3): 2.50 (9H, s, CH3), 
2.63 (2H, t, J 6.0 Hz, 2 x NH), 3.14-3.22 (8H, m, 4 x CH2), 7.29-7.38 (6H, m, 6 x ArH), 
7.64 (2H, d, J 8.4 Hz, 2 x ArH), 7.77-7.87 (4H, m, 4 x ArH); m/z (FAB): 566 (MH+, 99%), 
412 (71), 227 (53), 154 (50), 136 (35), 92 (31). 
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N,O,O’-Tri(toluene-4-sulfonyl)diethanolamine 80210 
N
Ts
OTsTsO
 
A stirred solution of toluene-4-sulfonyl chloride (114.5 g, 0.6 mol) and dichloromethane 
(140 mL) was prepared and cooled to 0 °C. Diethanolamine (19.2 mL, 0.2 mol), 
benzyltriethylammonium chloride (18.2 g, 80.0 mmol) and 30% NaOH solution (24.0 g in 
150 mL distilled water) were added whilst stirring vigorously. The reaction mixture was 
allowed to return to room temperature and was stirred for another hour. The reaction 
mixture was poured onto distilled water (300 mL). The organic phase was separated and 
washed with distilled water (3 x 150 mL). The organic phase was dried (MgSO4), filtered 
and concentrated. The viscous oil was placed on a vacuum line to eliminate any presence 
of solvent. The product crystallised over a period of 2 weeks (102.9 g, 91%). mp 97-99 °C 
(lit. 101-103 °C); 1H NMR (400 MHz, CDCl3): 2.45 (3H, s, CH3), 2.49 (6H, s, 2 x CH3), 
3.40 (4H, t, J 6.0 Hz, 2 x CH2N), 4.14 (4H, t, J 6.0 Hz, 2 x CH2O), 7.31-7.34 (2H, m, 2 x 
ArH), 7.38 (4H, d, J 8.0 Hz, 4 x ArH), 7.63 (2H, d, J 8.4 Hz, 2 x ArH), 7.78 (4H, d, J 8.0 
Hz, 4 x ArH); m/z (CI): 568 (MH+, 13%), 432 (12), 396 (12), 242 (100), 157 (35). 
1,4,7,10-Tetra(toluene-4-sulfonyl)-1,4,7,10-tetraazacyclododecane 76123 
NTsTsN
TsN NTs
 
Method 1: A mixture of toluene (200 mL), tetrabutylammonium bromide (0.81 g, 2.5 
mmol) and 2.5% LiOH solution (2.56 g in 100 mL distilled water) was heated under reflux 
conditions. N,N’,N’’-Tri(toluene-4-sulfonyl)diethylene triamine (5.65 g, 10 mmol),  
N,O,O’-tri(toluene-4-sulfonyl)diethanolamine (5.68 g, 10 mmol) and toluene (400 mL) 
were added in small portions. The reaction mixture was heated under reflux overnight. The 
reaction mixture was cooled and the white precipitate was filtered and washed with 
methanol (100 mL) giving a white solid. (5.42 g, 69%). mp 276-279 oC (lit. 278-280 oC); 
1H NMR (400 MHz, CDCl3): 2.47 (12H, s, 4 x CH3), 3.45 (16H, bs, 8 x CH2), 7.34 (8H, d, 
J 7.0 Hz, 8 x ArH), 7.66 (8H, d, J 7.0 Hz, 8 x ArH); m/z (FAB): 789  (MH+, 99%), 633 
(40), 477 (16), 323 (20), 253 (37), 154 (38), 92 (54). 
Method 2: A stirred solution of N,N’,N’’-tri(toluene-4-sulfonyl)diethylene triamine (8.0 g, 
11 mmol), caesium carbonate (13.68 g, 42 mmol) and DMF (300 mL) was prepared. 
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N,O,O’-Tri(toluene-4-sulfonyl)diethanolamine (5.68 g, 11 mmol) was dissolved in DMF 
(125 mL) and added to a dropping funnel. The contents of the dropping funnel were added 
dropwise over a period of 3 h. The reaction mixture was stirred for 5 d at room 
temperature. The DMF was removed using a pump-assisted rotary evaporator. The residue 
was taken up in dichloromethane (150 mL) and distilled water (150 mL). The aqueous 
layer was extracted with dichloromethane (100 mL). The combined organic phases were 
washed with brine (150 mL), dried (MgSO4) and concentrated. The light brown residue 
was recrystallised from methanol (5.25 g, 47%). Spectroscopic data as described above.  
1,4,7,10-Tetraazacyclododecane 70 – Cyclen211 
NHHN
HN NH
 
Method 1: A stirred solution of 1,4,7,10-tetra(toluene-4-sulfonyl)-1,4,7,10-
tetraazacyclododecane (5.42 g, 6.87 mmol), phenol (12.80 g, 0.14 mol) and HBr-AcOH 
45% (270 mL) was prepared. The round bottomed flask was fitted with a water-filled 
condenser and an air condenser. This allows the evolving HBr gas to escape to the top of 
the fume hood. The reaction mixture was heated under reflux for 3 d. The reaction mixture 
was cooled and the acetic acid was removed under vacuum. The residue was taken up in 
toluene (4 x 30 mL) to azeotrope off all traces of acetic acid on the rotary evaoporator. The 
dark purple residue was dissolved in distilled water (150 mL) and dichloromethane (75 
mL) was added. The layers were separated and the aqueous layer was washed with 
dichloromethane (4 x 75 mL). The aqueous layer was concentrated yielding a brown 
residue which was purified by an anion exchange column. The column was prepared using 
Amberlite IRA-400 resin. Distilled water (200 mL), potassium hydroxide (50 mL, 10 % 
solution) and distilled water (350 mL) were passed down the column until pH 7 was 
achieved. The crude residue was dissolved in a minimum volume of distilled water and 
loaded onto the column. Water was eluted through the column until the pH dropped from 
11 to 7. The aqueous eluant was concentrated. Methanol (4 x 25 mL) was added to 
azeotrope off all traces of water. The product was recrystallised from hot toluene yielding a 
white powder (0.54 g, 46%). mp 98-100 oC (lit. 110-113 °C); 1H NMR (400 MHz, D2O): 
2.48 (16H, bs, 8 x CH2); m/z (CI): 173 (MH+, 61%), 113 (8), 97 (9), 79 (100). 
Method 2: A stirred solution of 1,4,7,10-tetrakis-(toluene-4-sulfonyl)-1,4,7,10-
tetraazacyclododecane (9.66 g, 12.66 mmol) and conc. sulfuric acid (25 mL) was prepared 
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and stirred at 110 oC for 40 h. The brown/black solution was poured into a conical flask 
and cooled in an ice bath. Distilled water (20 mL) was added slowly. Potassium hydroxide 
(45 g) pellets were added until the pH was 13. Ethanol (150 mL) was added and the 
mixture was filtered. The solid residue was washed with ethanol (5 x 20 mL) and the 
filtrate was concentrated. The residue was taken up in the minimum volume of 1 M 
hydrochloric acid (40 mL) and dichloromethane (30 mL) was added. The layers were 
separated and the aqueous layer was washed with dichloromethane (4 x 30 mL). The pH 
was raised to 13 by adding potassium hydroxide pellets. This was extracted with 
chloroform (4 x 25 mL). The organic layers were combined, dried (K2CO3) and 
concentrated yielding a yellow solid (0.28 g, 13%). Spectroscopic data as described above. 
Method 3 : Conc. sulphuric acid (11 mL) was heated to 165 °C. 1,4,7,10-Tetra(toluene-4-
sulfonyl)-1,4,7,10-tetraazacyclododecane (1.20 g, 2.42 mmol) was added in a single 
portion and the solution was stirred until the reaction mixture had turned black. The 
reaction mixture was cooled by transferring the mixture into a Buchner flask and 
submersing this flask in cold water. This mixture was added dropwise to ethanol (36 mL) 
that was stirred. The precipitate was the polyhydrosulfate salt. Diethyl ether (27 mL) was 
added and the solution was cooled to 0 °C in an ice bath. The solid was filtered and 
dissolved in the minimum volume of hot water (7 mL), and an equivalent volume of HBr 
(48% aq, 7 mL) was added. Overnight the tetrahydrobromide salt crystallised. This was 
filtered and washed with hydrobromic acid (5 mL) and ethanol (5 mL). The white crystals 
were dried under high vaccuum. The crystals were then added to a round-bottomed flask 
charged with toluene (20 mL), distilled water (5 mL) and sodium hydroxide pellets (0.4 g, 
10 mmol). Dean-Stark apparatus was fitted and the reaction mixture was heated under 
reflux for 24 h. The toluene solution was then filtered and concentrated yielding white 
crystals. (0.97 g, 88%). Spectroscopic data as described above. 
1,4,7,10-Tetra(2-hydroxyethyl)-1,4,7,10-tetraazacyclododecane 83115 
NN
N N
OHHO
HO OH
 
1,4,7,10-Tetraazacyclododecane (0.97 g, 5.63 mmol) and  distilled water (9.7 mL) were 
added to a round-bottomed flask fitted with an dropping funnel and a cooling finger. 
Ethylene oxide (2.48 g, 56.3 mmol) and distilled water (1.9 mL) were added to the reaction 
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mixture dropwise. The reaction mixture was stirred for 2 h and the temperature was kept 
below 5 °C. The water and excess ethylene oxide were removed by rotary evaporator, 
yielding white crystals (2.10 g, 100%). mp 67-69 °C (no lit. mp available); 1H NMR (400 
MHz, CDCl3): 2.42 (8H, t, J 4.8 Hz, 4 x CH2N), 2.46 (16H, bs, 8 x CH2N), 3.55 (8H, t, J 
4.8 Hz, 4 x CH2O); m/z (FAB): 349 (MH+, 99%), 305 (18), 248 (4), 175 (9), 154 (14), 89 
(15). 
1,4,7,10-Tetra(2-chloroethyl)-1,4,7,10-tetraazacyclododecane dihydrochloride 58115  
NN
N N
ClCl
Cl Cl
.2HCl
 
1,4,7,10-Tetra(2-hydroxyethyl)-1,4,7,10-tetraazacyclododecane (100 mg, 1.43 mol) and 
thionyl chloride (25 mL, 5 mL/100 mg tetraol) were added to a round-bottomed flask fitted 
with a water-cooled condenser and this was heated at 50 oC overnight. The excess thionyl 
chloride was removed by rotary evaporator. The desired product was recrystallised from 
hot propan-2-ol (48 mg, 34%). mp 206-208 oC (no lit. mp available); 1H NMR (400 MHz, 
D2O): 3.28 (16H, bs, 8 x CH2N), 3.38 (8H, bs, 4 x CH2N), 3.84-3.90 (8H, m, 4 x CH2Cl); 
m/z (FAB): 423 [(M-2Cl)H+, 35Cl, 100%], 421 (79), 387 (22), 359 (17), 211 (26), 106 (38). 
1,4,7,10-Tetra(2-chloroethyl)-1,4,7,10-tetraazacyclododecane [Cu(II)]Cl2 64115 
NN
N N
ClCl
Cl Cl
+Cl-
Cu
Cl
 
Using general procedure A, 64 was synthesised from 1,4,7,10-tetra(2-chloroethyl)-
1,4,7,10-tetraazacyclododecane dihydrochloride 58 (20 mg, 40 mmol), as blue crystals (21 
mg, 100%), m/z (FAB): 483 [(M-2Cl)+, 35Cl, 60%].  
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1,4,7,10-Tetra(phenylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 84 
NN
N N
OO
O O
N
O
H
N
O
H
N
O
H
N
O
H
 
Using general procedure B, 84 was synthesised from 1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.1 g, 0.29 mmol) and phenyl isocyanate (1.09 mL, 10 
mmol), as white crystals (0.24 g, 100%). mp 150-152 oC; νmax (KBr)/cm-1: 3296 (NH), 
2944 (CH), 1696 (CO), 1228, 797; 1H NMR (400 MHz, D6-DMSO): 2.62 (24H, bs, 12 x 
CH2N), 4.10 (8H, t, J 6.0 Hz, 4 x CH2O), 6.50 (4H, t, J 8.0 Hz, 4 x ArH), 7.24 (8H, t, J 8.0 
Hz, 8 x ArH), 7.45 (8H, d, J 8.0 Hz, 8 x ArH), 9.56 (4H, bs, 4 x NH); 13C NMR (100 MHz, 
D6-DMSO): 52.4 (CH2), 53.8 (CH2), 62.1 (CH2), 122.3 (CH), 128.6 (CH), 128.7 (CH), 
128.8 (CH), 129.0 (CH), 134.8 (C), 153.5 (C); m/z (FAB): 825.4296 (MH+, C44H57N8O8 
requires 825.4299), 511 (4), 358 (95), 307 (11), 155 (100), 109 (29).  
1,4,7,10-Tetra(isopropylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 85 
NN
N N
OO
O O
N
O
H
N
O
H
N
O
H
N
O
H
 
Using general procedure B, 85 was synthesised from 1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.2 g, 0.58 mmol) and isopropyl isocyanate (0.91 mL, 
9.28 mmol), as white crystals (0.24 g, 60%).
 
Found: C, 55.8; H, 9.4; N, 16.3. C36H64N8O8 
requires C, 55.8; H, 9.5; N, 16.1%; mp 141-143 oC; νmax (KBr)/cm-1: 3279 (NH), 2969 
(CH) 1684 (CO), 1539; 1H NMR (400 MHz, D6-Acetone): 1.00 (24H, d, J 6.8 Hz, 8 x 
CH3), 2.45 (24H, bs, 12 x CH2N), 3.59-3.64 (4H, m, 4 x CH), 3.94 (8H, t, J 6.0 Hz, 4 x 
CH2O); 13C NMR (100 MHz, D6-DMSO): 22.5 (CH3), 42.2 (CH), 52.7 (CH2), 54.0 (CH2), 
61.6 (CH2), 155.3 (C); m/z (FAB): 689 (MH+, 100%), 586 (10), 503 (18), 331 (85), 174 
(54), 131 (100), 90 (79), 72 (37).  
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1,4,7,10-Tetra(propylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 86 
N
NN
N
O N
O
O N
H
O
H
ON
O
H
ON
O
H
 
Using general procedure C, 86 was synthesised from 1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.2 g, 0.58 mmol) and propyl isocyanate (0.88 mL, 
9.28 mmol), as white crystals (0.16 g, 41%). mp 142-144 oC; νmax (KBr)/cm-1: 3312 (NH), 
2960 (CH), 1686 (CO), 1548, 1272, 1008, 668; 1H NMR (400 MHz, D6-Acetone): 0.91 
(12H, t, J 7.4 Hz, 4 x CH3), 1.48-1.57 (8H, m, 4 x CH2), 2.65 (24H, bs, 12 x CH2N), 3.09 
(8H, t, J 7.0 Hz, 4 x CH2N), 4.10 (8H, t, J 6.0 Hz, 4 x CH2O); 13C NMR (100 MHz, D6-
DMSO): 11.2 (CH3), 22.7 (CH2), 42.0 (CH2), 52.6 (CH2), 54.0 (CH2), 61.8 (CH2) 156.2 
(C); m/z (FAB): 689.4922 (MH+, C32H65N8O8 requires 689.4925), 433 (4%), 331 (2), 289 
(20), 146 (100).  
1,4,7,10-Tetra(4-methoxyphenyl)aminocarbonyloxyethyl-1,4,7,10-
tetraazacyclododecane 87 
NN
N N
O N
O
H
O N
O
H
ON
O
H
ON
O
H
MeO
MeO OMe
OMe
 
Using general procedure C, 87 was synthesised from 1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.2 g, 0.58 mmol) and 4-methoxyphenyl isocyanate 
(3.0 mL, 23.2 mmol), as white crystals (0.55 g, 56%). mp 166-168 oC; νmax (KBr)/cm-1: 
3294 (NH), 2957 (CH), 1698 (CO), 1509, 1240, 827; 1H NMR (400 MHz, D6-DMSO): 
2.06 (24H, bs, 12 x CH2N), 3.24 (12H, bs, 4 x OCH3), 3.65 (8H, bs, 4 x CH2O), 6.38 (8H, 
d, J 9.0 Hz, 8 x ArH), 6.90 (8H, d, J 9.0 Hz, 8 x ArH), 8.89 (4H, bs, 4 x NH); 13C NMR 
(400 MHz, D6-DMSO): 52.5 (CH2), 53.8 (CH2), 55.1 (CH3), 62.0 (CH2), 113.8 (CH), 119.9 
(CH), 132.2 (C), 153.7 (C), 154.7 (C); m/z (FAB): 945.4724 (MH+, C48H65N8O12 requires 
945.4722), 779 (4%), 695 (3), 459 (4) 338 (5), 238 (22), 170 (51), 87 (100).  
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1,4,7,10-Tetra(4-bromophenyl)aminocarbonyloxyethyl-1,4,7,10-
tetraazacyclododecane 88 
NN
N N
O N
O
H
O N
O
H
ON
O
H
ON
O
H
Br
Br Br
Br
 
Using general procedure C, 88 was synthesised from 1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.1 g, 0.29 mmol) and 4-bromophenyl isocyanate (2.30 
g, 11.6 mmol), as white crystals (0.21 g, 64%). mp 212-214 oC; νmax (KBr)/cm-1: 3303 
(NH), 2833 (CH), 1709 (CO), 1393, 1227, 820; 1H NMR (400 MHz, D6-DMSO): 2.50 
(24H, bs, 12 x CH2N), 4.11 (8H, t, J 6.0 Hz, 4 x CH2O), 7.41-7.46 (16H, m, 16 x ArH), 
8.86 (4H, s, 4 x NH); 13C NMR (100 MHz, D6-DMSO): 52.4 (CH2), 53.8 (CH2), 62.3 
(CH2) 113.4 (C), 120.2 (CH), 131.5 (CH), 138.9 (C), 153.4 (C); m/z (FAB): 1143 [MH+ 
(81Br), 4%], 1141 [MH+ (79Br), 5%], 371 (5), 253 (9), 170 (100), 87 (95).  
1,4,7,10-Tetra(2-nitrophenyl)aminocarbonyloxyethyl-1,4,7,10-tetraazacyclododecane 
89 
NN
N N
O N
O
H
O N
O
H
ON
O
H
ON
O
H
NO2 O2N
O2NNO2
 
Using general procedure C, 89 was synthesised from 1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.1 g, 0.29 mmol) and 2-nitrophenyl isocyanate (0.48 
g, 2.90 mmol), as a pale yellow solid (0.18 g, 64%). mp 82-84 oC; νmax (KBr)/cm-1: 3350 
(NH), 2359 (CH), 1718 (CO), 1428, 1237, 743; 1H NMR (400 MHz, D6-DMSO): 2.59 
(24H, bs, 12 x CH2N), 4.11 (8H, bs, 4 x CH2O), 7.28 (4H, t, J 8.0 Hz, 4 x ArH), 7.66 (4H, 
t, J 8.0 Hz, 4 x ArH), 7.73 (4H, d, J 8.0 Hz, 4 x ArH), 7.96 (4H, d, J 8.0 Hz, 4 x ArH), 9.77 
(4H, bs, 4 x NH); 13C NMR (100 MHz, D6-DMSO): 52.6 (CH2), 53.6 (CH2), 63.2 (CH2), 
123.8 (CH), 124.2 (CH), 125,7 (CH), 132.5 (C), 134.4 (CH), 140.7 (C), 153.4 (C); m/z 
(FAB): 1006 (MH+, 97%), 842 (100), 826 (13), 678 (43), 660 (16), 490 (18), 326 (12), 232 
(32), 158 (48), 81 (100).  
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1,4,7,10-Tetra(3-nitrophenyl)aminocarbonyloxyethyl-1,4,7,10-tetraazacyclododecane 
90 
NN
N N
O N
O
H
O N
O
H
ON
O
H
ON
O
H
O2N NO2
NO2O2N
 
Using general procedure C, 90 was synthesised from 1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.1 g, 0.29 mmol) and 3-nitrophenyl isocyanate (0.48 
g, 2.9 mmol), as a pale yellow solid (0.14 g, 46%). mp 151-153 oC; νmax (KBr)/cm-1: 3389 
(NH), 2797 (CH), 1720 (CO), 1526, 1081, 735; 1H NMR (400 MHz, D6-DMSO): 2.61 
(24H, bs, 12 x CH2N), 4.14 (8H, t, J 6.0 Hz, 4 x CH2O), 7.47-7.56 (4H, m, 4 x ArH), 7.80-
7.96 (12H, m, 12 x ArH), 10.09 (4H, bs, 4 x NH); 13C NMR (100 MHz, D6-DMSO): 52.6 
(CH2), 53.7 (CH2), 62.6 (CH2), 121.9 (CH), 122.3 (CH), 128.9 (CH), 133.7 (CH), 146.4 
(C), 146.7 (C), 151.4 (C); m/z (FAB): 1005.3709 (MH+, C44H53N12O16 requires 
1005.3702), 391 (3), 322 (3), 238 (30), 170 (64), 87 (100).  
1,4,7,10-Tetra(4-nitrophenyl)aminocarbonyloxyethyl-1,4,7,10-tetraazacyclododecane 
91 
NN
N N
O N
O
H
O N
O
H
ON
O
H
ON
O
H
O2N
O2N NO2
NO2
 
Using general procedure C, 91 was synthesised from 1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.1 g, 0.29 mmol) and 4-nitrophenyl isocyanate (0.48 
g, 2.9 mmol), as a bright yellow solid (0.18 g, 60%). mp 179-181 oC; νmax (KBr)/cm-1: 
3323 (NH), 2831 (CH), 1728 (CO), 1329, 855; 1H NMR (400 MHz, D6-DMSO): 2.60 
(24H, bs, 12 x CH2N), 4.14 (8H, bs, 4 x CH2O), 7.64 (8H, d, J 8.8 Hz, 8 x ArH), 8.12 (8H, 
d, J 8.8 Hz, 8 x ArH), 10.30 (4H, s, 4 x NH); 13C NMR (100 MHz, D6-DMSO): 52.6 
(CH2), 53.7 (CH2), 62.6 (CH2), 117.5 (CH), 124.9 (CH), 141.5 (C), 145.7 (C), 153.1 (C); 
m/z (FAB): 1005.3697 (MH+, C44H53N12O16 requires 1005.3702), 990 (3), 824 (2), 782 (1), 
628 (1), 560 (1), 475 (1), 322 (3), 238 (17), 170 (100), 87 (100). 
Jennifer M. Wilson, 2007   Chapter 9, 118 
1,4,7,10-Tetra(phenylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 
[Cu(II)]Cl2 92 
NN
N N
OO
O O
N
O
H
N
O
H
N
O
H
N
O
H
+Cl-
Cu
Cl
 
Using general procedure A, 92 was synthesised from 1,4,7,10-
tetra(phenylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 84 (0.24 g, 0.29 
mmol), as light blue crystals (0.28, 100%). mp 176-178 oC; νmax (KBr)/cm-1: 3185 (NH), 
2291, 1716 (CO), 1270, 1086; m/z (FAB): 887 ([M-2Cl]+, 100%), 826 (8), 768 (18), 750 
(8), 410 (14), 367 (11), 185 (33), 94 (89), 71 (22). UV(H2O): λmax - 616 nm, εcoeff - 202 L 
cm-1 mol-1. 
1,4,7,10-Tetra(isopropylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 
[Cu(II)]Cl2 93 
Cl-
N
NN
N
O N
O
O N
H
O
H
ON
O
H
ON
O
H
Cu
Cl
 
Using general procedure A, 93 was synthesised from 1,4,7,10-
tetra(isopropylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 85 (0.24 g, 0.35 
mmol), as green crystals (0.17 mg, 58%). mp 201-203 oC; νmax (KBr)/cm-1: 3341 (NH), 
2968 (CH), 1699 (CO), 1250, 1094; m/z (FAB): 751.4142 ([M-2Cl]+, C32H64N8O8Cu 
requires 751.4143), 688 (15%), 331 (13), 221 (15), 174 (17), 131 (100), 90 (38), 72 (20); 
UV(H2O): λmax - 614 nm, εcoeff - 375 L cm-1 mol-1.  
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1,4,7,10-Tetra(propylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 
[Cu(II)]Cl2 94 
Cl-
N
NN
N
O N
O
O N
H
O
H
ON
O
H
ON
O
H
Cu
Cl
 
Using general procedure A, 94 was synthesised from 1,4,7,10-
tetra(propylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 86 (0.16 g, 0.24 
mmol), as green crystals (0.13 g, 64%). mp 66-67 oC; νmax (KBr)/cm-1: 3336 (NH), 2964 
(CH), 1706 (CO), 1539, 1263; m/z (FAB): 752 ([M-2Cl]+, 100%), 688 (10), 667 (8), 221 
(12), 131 (20); UV(H2O): λmax - 614 nm, εcoeff - 375 L cm-1 mol-1.  
1,4,7,10-Tetra(4-methoxyphenylaminocarbonyloxyethyl)-1,4,7,10-
tetraazacyclododecane [Cu(II)]Cl2 95 
NN
N N
O N
O
H
O N
O
H
ON
O
H
ON
O
H
MeO
MeO OMe
OMe
Cu
Cl
+Cl-
 
Using general procedure A, 95 was synthesised from 1,4,7,10-tetra(4-
methoxyphenylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 87 (0.3 g, 0.32 
mmol), as green crystals (78.0 mg, 23%). mp 186-188 oC; νmax (KBr)/cm-1: 3234 (NH), 
2942 (CH), 1721 (CO), 1511, 1221, 827; m/z (FAB): 1042.2632 ([M-Cl]+, 
C48H64N8O12Cu35Cl requires 1042.2628), 307 (22%), 155 (100), 109 (20); UV(H2O): λmax - 
604 nm, εcoeff - 381 L cm-1 mol-1.  
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1,4,7,10-Tetra(4-bromophenyl)aminocarbonyloxyethyl-1,4,7,10-
tetraazacyclododecane [Cu(II)]Cl2 96 
NN
N N
O N
O
H
O N
O
H
ON
O
H
ON
O
H
Br
Br Br
Br
Cu
Cl
+Cl-
 
Using general procedure A, 96 was synthesised from 1,4,7,10-tetra(4-
bromophenylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 88 (0.1 g, 80 µmol), 
as blue crystals (40 mg, 39%). mp 212-214 oC; νmax (KBr)/cm-1: 3333 (NH), 3102 (CH), 
1723 (CO), 1537, 1219, 881; m/z (FAB): 1238 [(M-2Cl)+, 79Br2, 81Br2, 100%], 1002 (5), 
557 (10), 336 (15); UV(H2O): λmax: 786 nm, εcoeff: 1793 L cm-1 mol-1.  
1,4,7,10-Tetra(2-nitrophenyl)aminocarbonyloxyethyl-1,4,7,10-tetraazacyclododecane 
[Cu(II)]Cl2 97 
NN
N N
O N
O
H
O N
O
H
ON
O
H
ON
O
H
Cu
Cl
+Cl-
NO2
NO2
O2N
O2N
 
Using general procedure A, 97 was synthesised from 1,4,7,10-tetra(2-
nitrophenylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 89 (0.1 g, 90 µmol), 
as green crystals (40 mg, 39%). mp 149-151 oC; νmax (KBr)/cm-1: 3363 (NH), 1735 (CO), 
1512, 1340, 739; m/z (FAB): 1102 [(M-Cl)+, 35Cl, 3%], 903 (5), 209 (20), 158 (100), 81 
(55); UV(H2O): λmax - 623 nm, εcoeff - 1026 L cm-1 mol-1. 
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1,4,7,10-Tetra(3-nitrophenyl)aminocarbonyloxyethyl-1,4,7,10-tetraazacyclododecane 
[Cu(II)]Cl2 98 
NN
N N
O N
O
H
O N
O
H
ON
O
H
ON
O
H
Cu
Cl
+Cl-O2N NO2
NO2O2N
 
Using general procedure A, 98 was synthesised from 1,4,7,10-tetra(3-
nitrophenylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 90 (0.1 g, 90 µmol), 
as turquoise crystals (76 mg, 74%). mp 222-223 oC; νmax (KBr)/cm-1: 2959 (NH), 1718 
(CO), 1427, 1089, 735; m/z (FAB): 1102 [(M-Cl)+, 35Cl, 1.7%] 235 (8), 158 (100), 81 
(100); UV(H2O): λmax - 623 nm, εcoeff - 935 L cm-1 mol-1. 
[1,4,7,10-Tetra(4-nitrophenyl)aminocarbonyloxyethyl-1,4,7,10-tetraazacyclododecane 
[Cu(II)]Cl2 99 
NN
N N
O N
O
H
O N
O
H
ON
O
H
ON
O
H
O2N
O2N NO2
NO2
Cu
Cl
+Cl-
 
Using general procedure A, 99 was synthesised from 1,4,7,10-tetra(4-
nitrophenylaminocarbonyloxyethyl)-1,4,7,10-tetraazacyclododecane 91 (0.1 g, 90 µmol), 
as green crystals (81 mg, 80%). mp 156-157 oC; νmax (KBr)/cm-1: 2448, 1734 (CO), 1508, 
1111, 853. m/z (FAB): 1102 [(M-Cl)+, 35Cl, 1.3%], 232 (22), 81 (100); UV(H2O): λmax - 
623 nm, εcoeff - 935 L cm-1 mol-1. 
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1,4,7,10-Tetra(2-hydroxyethyl)-1,4,7,10-tetraazacyclododecane [Cu(II)]Cl2 100 
Cl-
N
NN
N
OH
OH
HO
HO
Cu
Cl
 
Using general procedure A, 100 was synthesised from 1,4,7,10-tetra(2-hydroxyethyl)-
1,4,7,10-tetraazacyclododecane 83 (0.2 g, 0.57 mmol), as bright blue crystals (49.0 mg, 
18%) mp 234-236 oC; νmax (KBr)/cm-1: 3554, 3235, 1621, 1440, 1085, 1015; m/z (FAB): 
411.2036 [(M-2Cl)+, C16H36N4O4Cu requires 411.2033], 349 (6%), 247 (5), 90 (5); 
UV(H2O): λmax – 602 nm, εcoeff – 371 L cm-1 mol-1. 
1,4,7,10-Tetrachloroacetyl-1,4,7,10-tetraazacyclododecane 101 
N
NN
N
Cl
Cl
Cl
Cl
O
OO
O
 
Using general procedure D, 101 was synthesised from 1,4,7,10-tetraazacyclododecane 
(0.50 g, 2.9 mmol) and chloroacetyl chloride (1.39 mL, 17 mmol), as a beige solid (0.11 g, 
10%). mp 72-74 oC; νmax (KBr)/cm-1: 3450, 1786, 1653 (CO), 1423, 1131, 791. 1H NMR 
(400 MHz, CDCl3): 3.74 (8H, s, 4 x CH2), 4.26 (16H, s, 8 x CH2N); 13C NMR (100 MHz, 
CDCl3): 39.7 (CH2), 52.5 (CH2), 170.5 (C); m/z (FAB): 477.0612 (MH+, 35Cl, 
C16H25N4O4Cl6 requires 477.0630), 441 (22), 401 (7), 281 (12), 256 (8), 207 (11), 179 
(66), 148 (15), 75 (100). 
1,4,7,10-Tetrabromoacetyl-1,4,7,10-tetraazacyclododecane 102 
N
NN
N
Br
Br
Br
Br
O
OO
O
 
Using general procedure D, 102 was synthesised from 1,4,7,10-tetraazacyclododecane 
(0.50 g, 2.9 mmol) and bromoacetyl bromide (1.51 mL, 17 mmol), as a brown oil (0.18 g, 
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11%). νmax (KBr)/cm-1: 3444, 2957 (CH), 1732, 1645 (CO), 1174; 1H NMR (400 MHz, 
CDCl3): 3.64 (8H, s, 4 x CH2), 3.88 (16H, s, 8 x CH2N). 13C NMR (100 MHz, CDCl3): 
25.7 (CH2), 53.5 (CH2), 171.3 (C); m/z (FAB): 652.8601 (MH+, C16H2579Br4N4O4 requires 
652.8609), 577 (20%), 329 (15), 219 (20), 165 (28), 71 (47). 
1,4-Bis(2-o-nitrophenylaminocarbonyloxyethyl)piperazine 103 
N N
O
N
O
HO
N
O
H
O2N NO2
 
 
Using general procedure C, 103 was synthesised from 1,4-bis(2-hydroxyethyl)piperazine 
(0.2 g, 1.15 mmol) and 2-nitrophenyl isocyanate (0.57 g, 3.45 mmol), as white crystals 
(0.36 g, 68%). mp 134-136 oC; νmax (KBr)/cm-1: 3072 (NH), 2826 (CH), 1742 (CO), 1236, 
785; 1H NMR (400 MHz, D6-DMSO): 2.50 (8H, s, 4 x CH2N), 2.55 (4H, t, J 5.5 Hz, 2 x 
CH2N), 4.17 (4H, t, J 5.5 Hz, 2 x CH2O), 7.30-7.34 (2H, m, 2 x ArH), 7.62-7.71 (4H, m, 4 
x ArH), 7.95 (2H, dd, J 8.2, 1.4 Hz, 2 x ArH), 9.91 (2H, bs, 2 x NH); 13C NMR (100 MHz, 
D6-DMSO): 52.8 (CH2), 56.3 (CH2), 62.3 (CH2), 124.3 (CH), 124.5 (CH), 125.2 (CH), 
132.0 (C), 134.1 (CH), 141.5 (C), 153.5 (C); m/z (FAB): 503.1886 (MH+, C22H27N6O8 
requires 503.1890), 238 (9%), 170 (71), 87 (100).  
1,4-Bis(2-m-nitrophenylaminocarbonyloxyethyl)piperazine 104 
N N
O
N
O
HO
N
O
H
O2N NO2
 
 
Using general procedure C, 104 was synthesised from 1,4-bis(2-hydroxyethyl)piperazine 
(0.20 g, 1.15 mmol) and 3-nitrophenyl isocyanate (0.57 g, 3.45 mmol), as a yellow solid 
(0.30 g, 55%). mp 152-154 oC; νmax (KBr)/cm-1: 3385 (NH), 2821 (CH), 1742 (CO), 1277, 
779; 1H NMR (400 MHz, D6-DMSO): 2.47 (8H, s, 4 x CH2N), 2.59 (4H, t, J 5.4 Hz, 2 x 
CH2N), 4.23 (4H, t, J 5.4 Hz, 2 x CH2O), 7.58 (2H, t, J 8.2 Hz, 2 x ArH), 7.80-7.88 (4H, 
m, 4 x ArH), 8.47 (2H, s, 2 x ArH), 10.26 (2H, bs, 2 x NH); 13C NMR (100 MHz, D6-
DMSO): 52.8 (CH2), 56.4 (CH2), 61.7 (CH2), 112.0 (CH), 116.9 (CH), 124.1 (CH), 130.2 
(CH), 140.5 (C), 148.1 (C), 153.5 (C); m/z (FAB): 503.1891 (MH+, C22H27N6O8 requires 
503.1890), 238 (14%), 170 (78), 87 (100). 
Jennifer M. Wilson, 2007   Chapter 9, 124 
1,4-Bis(2-p-nitrophenylaminocarbonyloxyethyl)piperazine 105137 
N N
O
N
O
HO
N
O
H
O2N NO2
 
 
Using general procedure C, 105 was synthesised from 1,4-bis(2-hydroxyethyl)piperazine 
(0.20 g, 1.15 mmol) and 4-nitrophenyl isocyanate (0.57 g, 3.45 mmol), as a yellow solid 
(0.49 g, 90%). mp 212-214 oC (lit. m.p. 215-217 oC); 1H NMR (400 MHz, D6-DMSO): 
2.33-2.37 (8H, m, 4 x CH2N), 3.46 (4H, t, J 5.2 Hz, 2 x CH2N), 4.37 (4H, t, J 5.2 Hz, 2 x 
CH2O), 7.73 (4H, d, J 9.4 Hz, 4 x ArH), 8.22 (4H, d, J 9.4 Hz, 4 x ArH), 9.74 (2H, bs, 2 x 
NH); m/z (FAB): 503 (MH+, 20%), 238 (11), 170 (75), 87 (100). 
1,4-Bis(2-p-methoxyphenylaminocarbonyloxyethyl)piperazine 106 
N N
O
N
O
HO
N
O
H
MeO OMe
 
 
Using general procedure C, 106 was synthesised from 1,4-bis(2-hydroxyethyl)piperazine 
(0.20 g, 1.15 mmol) and 4-methoxyphenyl isocyanate (0.44 mL, 3.45 mmol) as a white 
solid (0.51 g, 99%). mp 155-157 oC; νmax (KBr)/cm-1: 3323 (NH), 2812 (CH), 1690 (CO), 
1219, 826; 1H NMR (400 MHz, D6-DMSO): 2.44 (8H, bs, 4 x CH2N), 2.55 (4H, t, J 5.6 
Hz, 2 x CH2N), 3.69 (6H, s, 2 x OCH3), 4.15 (4H, t, J 5.6 Hz, 2 x CH2O), 6.85 (4H, d, J 9.0 
Hz, 4 x ArH), 7.35 (4H, d, J 9.0 Hz, 4 x ArH), 9.48 (2H, bs, 2 x NH); 13C NMR (100 MHz, 
D6-DMSO): 52.9 (CH2), 55.1 (CH3), 56.6 (CH2), 61.1 (CH2), 113.9 (CH), 119.8 (CH), 
132.2 (C), 132.9 (C), 153.6 (C); m/z (FAB): 473.2398 (MH+, C24H33N4O6 requires 
473.2400), 238 (11%), 170 (68), 87 (100). 
1,2-Tetra(2-hydroxyethyl)ethylenediamine 108212 
N N
HO
HO OH
OH
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Ethylenediamine (0.56 mL, 8.32 mmol) and water (50 mL) were added to a round-
bottomed flask fitted with an dropping funnel and a cooling finger. Ethylene oxide (9.11 
mL, 0.17 mol) and water (20 mL) were added to the reaction mixture dropwise. The 
reaction stirred for two hours with the temperature kept under 5 oC. The water and excess 
ethylene oxide were removed by rotary evaporator, yielding a colourless oil (1.43 g, 73%). 
1H NMR (CDCl3, 400 MHz): 2.64 (8H, t, J 4.7 Hz, 4 x CH2N), 2.68 (4H, s, 2 x CH2N), 
3.68 (8H, t, J 4.7 Hz, 4 x CH2N), 3.76 (4H, s, 4 x OH); m/z (FAB): 237 (MH+, 100%), 177 
(5), 155 (32), 133 (40), 119 (22), 90 (8). 
9.3 Experimental to Chapter 6 
9.3.1 General Procedures (A-F) 
General procedure A – Synthesis of macrocycles (amide bond formation): A stirred 
solution of triethylamine (2 eq) and dichloromethane (100 mL) was prepared. Diamine (1 
eq) in dichloromethane (50 mL) and thiodiglycolic acid chloride (1 eq) in dichloromethane 
(50 mL) were added dropwise using syringe pumps over a period of 5 h. The beige 
precipitate was filtered off, washed with dichloromethane (100 mL) and recrystallised from 
methanol. 
General procedure B – Tosylation of diols: A stirred solution of toluene-4-sulfonyl 
chloride (2 eq) and dry pyridine (10 mL) was prepared in an ice bath at 0 oC. Diol (1 eq) 
and dry pyridine (25 mL) were added dropwise. The reaction mixture was stirred for 1 h at 
0 oC then allowed to return to RT and stirred for 3 h. The reaction mixture was poured onto 
distilled water (150 mL). The white precipitate was filtered off and yielded white crystals 
from hot ethanol. 
General procedure C – Tosylation of diamines: A solution of diamine (1 eq), sodium 
hydroxide (2.1 eq) and distilled water (100 mL) was prepared. A solution of toluene-4-
sulfonyl chloride (2.1 eq) and diethyl ether (100 mL) was added. The reaction mixture was 
stirred at room temperature for 24 h. The layers were separated and the aqueous layer was 
washed with chloroform (2 x 75 mL). The organic layers were combined, dried and 
concentrated yielding a brown viscous oil which was purified using column 
chromatography (eluant: dichloromethane/methanol 95/5). 
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General prodecure D – Synthesis of tosyl-protected macrocycles (phase transfer 
cyclisation conditions): A mixture of toluene (200 mL), tetrabutylammonium bromide 
(0.25 eq) and 2.5% lithium hydroxide solution solution (50 mL) was heated under reflux. 
Tosyl-protected diamine (1 eq) and tosyl-protected diol (1 eq) and toluene (400 mL) were 
added in small portions. The reaction mixture was heated under reflux overnight. After 
cooling, the organic layer was separated and concentrated and the white solid was filtered 
and recrystallised from methanol. 
General procedure E – Detosylation of macrocycles: A solution of tosyl-protected 
macrocycle (1 eq), phenol (10 eq) and HBr-AcOH 45% (5 mL per 100 mg) was prepared 
and stirred at 80 oC for 3 d. An air condenser was placed on top of the water condenser to 
ensure safe passage of the evolved HBr to the top of the fumehood. The reaction mixture 
was cooled and concentrated. The dark brown residue was azeotroped using toluene (4 x 
15 mL) to remove all traces of acetic acid. The dark brown residue was dissolved in 
dichloromethane (30 mL) and distilled water (30 mL) was added. The layers were 
separated and the aqueous layer was washed with dichloromethane (4 x 15 mL). The 
aqueous layer was concentrated. The resulting orange residue was dissolved in distilled 
water (5 mL) and sodium hydroxide (10 eq) was added. The flask was topped up with 
toluene and the resulting mixture was azeotroped using Dean-Stark apparatus until all the 
water
 
had been removed. The toluene was decanted off and concentrated. The crude 
product was purified using alumina column chromatography (eluant: 
dichloromethane/methanol 95/5) yielding a transparent oil. 
General procedure F – Hydroxyethylation of macrocycles: A stirred solution of 
macrocycle (1 eq) and ethanol (5 mL) was prepared and cooled to 0 oC using an ice bath. 
Ethylene oxide (5 eq per NH) was added dropwise using a cooling finger and addition 
funnel. The reaction mixture was sealed, allowed to return to room temperature and stirred 
overnight. The reaction mixture was concentrated. The crude product was purified using 
alumina column chromatography (eluant: dichloromethane/methanol 95/5). 
9.3.2 Experimental Details 
Thiodiglycolic acid chloride 110 
Cl S Cl
OO
 
Jennifer M. Wilson, 2007   Chapter 9, 127 
A mixture of thiodiglycolic acid (15.0 g, 0.1 mol) and thionyl chloride (150 mL, 2.1 mol), 
was stirred overnight at RT. Excess thionyl chloride was removed under vacuum. The 
cream coloured solid was used in the next reaction without purification assuming 100% 
conversion. 
1-Thia-4,7-diazacyclononane-3,7-dione 111 
HN NH
S OO
 
Using general procedure A, 111 was synthesised from ethylene diamine (1.78 mL, 26.7 
mmol) and thiodiglycolic acid chloride 110 (5.0 g, 26.7 mmol), as a beige solid (4.65 g, 
100%). mp 162-164 oC; νmax (KBr)/cm-1: 2930 (NH), 1661 (CO), 1249, 794; 1H NMR (400 
MHz, D2O): 3.08 (4H, s, 2 x CH2N), 3.19 (4H, s, CH2S); 13C NMR (100 MHz, D2O): 36.6 
(CH2), 37.3 (CH2), 177.8 (C).  
1-Thia-4,8-diazacyclodecane-3,9-dione 112160c 
HN NH
S OO
 
Using general procedure A, 112 was synthesised from 1,3-diaminopropane (2.23 mL, 26.7 
mmol) and thiodiglycolic acid chloride 110 (5.0 g, 26.7 mmol), as a beige solid (5.03 g, 
100%). mp 188-189 oC (lit. > 200 oC); νmax (KBr)/cm-1: 2365 (NH), 1700 (CO), 1206, 814; 
1H NMR (400 MHz, D2O): 1.87-1.95 (2H, m, CH2), 2.95 (4H, t, J 7.8 Hz, 2 x CH2N), 3.19 
(4H, s, CH2S); 13C NMR (100 MHz, D2O): 24.9 (CH2), 36.6 (CH2), 37.3 (CH2), 177.8 (C). 
1-Thia-4,7,10-triazacyclododecane-3,11-dione 113 
HNS
NH HN
O
O
 
Using general procedure A, 113 was synthesised from diethylene triamine (1.73 mL, 16.0 
mmol) and thiodiglycolic acid chloride 110 (3.0 g, 16.0 mmol), as white crystals (3.49 g, 
100%). mp 49-51 oC; νmax (KBr)/cm-1: 2922 (NH), 2121, 1601 (CO), 1218, 872; 1H NMR 
(400 MHz, D2O): 2.76 (4H, t, J 6.2 Hz, 2 x CH2N), 2.96 (4H, t, J 6.2 Hz, 2 x CH2N), 3.10 
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(4H, s, 2 x CH2S); 13C NMR (100 MHz, D2O): 37.3 (CH2), 38.8 (CH2), 45.1 (CH2), 177.7 
(C). 
Bis(2-aminoethyl)sulfide 116164 
H2N
S NH2
 
A stirred solution of sodium (0.60 g, 25.9 mmol) and ethanol (100 mL) was prepared. 
Cysteamine hydrochloride (1.0 g, 8.62 mmol) was added and the reaction mixture was 
heated under reflux for 30 min. 2-Chloroethylamine hydrochloride (0.98 g, 8.62 mmol) 
was added. The reaction mixture was heated under reflux for a further 2 h. The reaction 
mixture was cooled and the precipitated sodium chloride was filtered off and the filtrate 
was concentrated yielding the product as a pale yellow oil (0.92 g, 89%). 1H NMR (400 
MHz, CDCl3): 1.21 (4H, bs, 2 x NH2), 2.55 (4H, t, J 6.5 Hz, 2 x CH2S), 2.82 (4H, t, J 6.5 
Hz, CH2N); m/z (EI): 121 (MH+, 100%), 104 (60), 71 (33). 
1,7-Dithia-4,10-diazacyclododecane-3,11-dione 117 
HNS
NH S
O
O
 
Using general procedure A, 117 was synthesised from bis(2-aminoethyl)sulfide (1.29 g, 
10.7 mmol) and thiodiglycolic acid chloride 110 (2.0 g, 10.7 mmol), as white crystals (2.37 
g, 94%). mp 131-133 oC; νmax (KBr)/cm-1: 3567 (NH), 1595 (CO), 1388 (CH); 1H NMR 
(400 MHz, D2O): 2.65 (4H, t, J 6.6 Hz, 2 x CH2N), 2.99-3.02 (8H, m, 4 x CH2S); 13C 
NMR (100 MHz, D2O): 27.8 (CH2), 37.3 (CH2), 38.1 (CH2), 177.6 (CO). 
1,2-Ethanediol ditosylate 120213 
TsO OTs
 
Using general procedure B, 120 was synthesised from 1,2-ethanediol (3.14 mL, 56 mmol), 
as white crystals (19.16 g, 92%). mp 122-124 oC (lit. 123-125 oC); 1H NMR (400 MHz, 
CDCl3): 2.45 (6H, s, 2 x CH3), 4.18 (4H, s, 2 x CH2), 7.33 (4H, d, J 8.4 Hz, 4 x ArH), 7.72 
(4H, d, J 8.4 Hz, 4 x ArH); m/z (FAB): 371 (MH+, 57%). 
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1,3-Propanediol ditosylate 121214 
OTsTsO
 
Using general procedure B, 121 was synthesised from 1,3-propanediol (4.75 mL, 65.7 
mmol), as white crystals (19.3 g, 83%). mp 90-92 oC (lit. 91-93 oC); 1H NMR (400 MHz, 
CDCl3): 2.01 (2H, quin, J 6.0 Hz, CH2), 2.47 (6H, s, 2 x CH3), 4.07 (4H, t, J 6.0 Hz, 2 x 
CH2N), 7.36 (4H, d, J 8.0 Hz, 4 x ArH), 7.76 (4H, d, J 8.0 Hz, 4 x ArH); m/z (FAB): 385 
(MH+, 100%). 
N,N’-Bis(toluene-4-sulfonyl)-bis(2-aminoethylsulfide) 122165 
S NHTsTsHN
 
Using general procedure C, 120 was synthesised from bis(2-aminoethylsulfide) 116 (4.0 g, 
33 mmol), as a brown viscous oil (12.7 g, 89%). 1H NMR (400 MHz, CDCl3): 2.45 (6H, s, 
2 x CH3), 2.57 (4H, t, J 6.4 Hz, 2 x CH2S), 3.09 (4H, q, J 6.4 Hz, 2 x CH2N), 5.28 (2H, t, J 
6.4 Hz, 2 x NH), 7.37 (4H, d, J 6.2 Hz, 4 x ArH), 7.76 (4H, d, J 6.2 Hz, 4 x ArH); m/z 
(FAB): 429 (MH+, 100%), 386 (5), 258 (4), 199 (35), 156 (25), 140 (15), 93 (12). 
1,8-Diamino-3,6-dithiaoctane 123166 
S S NH2
H2N
 
 
A stirred solution of sodium (4.14 g, 0.18 mol) and tert-butanol (100 mL) was prepared 
and heated under reflux. Cysteamine hydrochloride (10.00 g, 88.0 mmol) was added and 
the reaction mixture was stirred for 30 min. 1,2-Dichloroethane (3.47 mL, 44.0 mmol) and 
tert-butanol (25 mL) were added dropwise and the reaction mixture was stirred for 3 h. 
After cooling, the precipitated NaCl was filtered off and the filtrate was concentrated. 
Kugelrohr distillation isolated the pure product as a pale yellow oil that solidified upon 
standing (7.31 g, 92%). 1H NMR (400 MHz, CDCl3): 1.33 (4H, bs, 4 x NH), 2.65 (4H, t, J 
6.5 Hz, 2 x CH2N), 2.74 (4H, s, 2 x CH2S), 2.87 (4H, t, J 6.5 Hz, 2 x CH2S). m/z (CI): 181 
(MH+, 100%), 164 (9), 136 (33), 104 (70), 76 (7). 
1,8-Bis(toluene-4-sulfonyl)-1-8-diamino-3,6-dithiaoctane 124 
S S NHTsTsHN
 
Jennifer M. Wilson, 2007   Chapter 9, 130 
 
Using general procedure C, 124 was synthesised from 1,8-diamino-3,6-dithiaoctane 123 
(5.0 g, 27.7 mmol), as a brown solid (13.0 g, 96%). mp 87-88 oC; νmax (KBr)/cm-1: 3239 
(NH), 2922 (CH), 1596, 1424; 1H NMR (400 MHz, CDCl3): 2.41 (6H, s, 2 x  CH3), 2.66-
2.99 (8H, m, 2 x CH2S, 2 x CH2S), 3.14 (4H, q, J 6.2 Hz, 2 x CH2N), 5.28 (2H, t, J 6.2 Hz, 
2 x NH), 7.34 (4H, d, J 8.1 Hz, 4 x ArH), 7.78 (4H, d, J 8.1 Hz, 4 x ArH); 13C NMR (100 
MHz, CDCl3): 21.6 (CH3), 31.6 (CH2), 32.1 (CH2), 42.5 (CH2), 127.1 (CH), 129.8 (CH), 
126.8 (C), 143.7 (C); m/z (FAB): 489.1006 (MH+, C20H29N2O4S4 requires 489.1010), 258 
(100%), 199 (40). 
4,7-Bis(toluene-4-sulfonyl)-1-thia-4,7-diazacyclononane 125165 
TsN NTs
S
 
Using general procedure D, 125 was synthesised from N,N’-bis(toluene-4-sulfonyl)-bis(2-
aminoethyl)sulfide (2.0 g, 4.67 mmol) 122 and 1,3-ethanediol ditosylate 120 (1.8 g, 4.67 
mmol), as a white solid (1.6 g, 74%). mp 270-272 oC (lit. 276-279 oC); 1H NMR (400 
MHz, CDCl3): 2.43 (6H, s, 2 x CH3), 3.13 (4H, bs, CH2N), 3.37 (4H, s, CH2N), 3.51 (4H, 
bs CH2S), 7.53 (4H, d, J 8.4 Hz, 4 x ArH), 7.73 (4H, d, J 8.4 Hz, 4 x ArH); m/z (FAB): 455 
(MH+, 100%), 395 (3), 299 (35), 199 (4), 155 (32), 137 (32), 93 (35), 90 (34). 
4,8-Bis(toluene-4-sulfonyl)-1-thia-4,8-diazacyclodecane 126160a 
TsN NTs
S
 
Using general procedure D, 126 was synthesised from N,N’-bis(toluene-4-sulfonyl)-bis(2-
aminoethylsulfide) 122 (2.0 g, 4.67 mmol) and 1,3-propanediol ditosylate 121 (1.8 g, 4.67 
mmol), as a white solid (2.2 g, 100%). mp 204-205 oC (lit. 285-287 oC – large difference 
could be due to different polymorph); 1H NMR (400 MHz, CDCl3): 2.36-2.42 (2H, m, 
CH2), 2.44 (6H, s, 2 x CH3), 3.08 (4H, t, J 4.8 Hz, 2 x CH2N), 3.14 (4H, t, J 6.0 Hz, 2 x 
CH2N), 3.33 (4H, t, J 4.8 Hz, 2 x CH2S), 7.34 (4H, d, J 8.0 Hz, 4 x ArH), 7.67 (4H, d, J 8.0 
Hz, 4 x ArH); m/z (FAB): 469 (MH+, 100%), 313 (55), 242 (100), 199 (14), 156 (20), 143 
(14), 93 (27). 
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4,7,10-Tris(toluene-4-sulfonyl)-1-thia-4,7,10-triazacyclododecane 127 
TsN
TsNNTs
S
 
 
Using general procedure D, 127 was synthesised from N,N’-bis(toluene-4-sulfonyl)-bis(2-
aminoethyl)sulfide 122 (2.0 g, 4.67 mmol) and N,O,O’-tris(toluene-4-
sulfonyl)diethanolamine 80 (2.7 g, 4.67 mmol), as white crystals (2.5 g, 82%). mp 184-186 
oC; νmax (KBr)/cm-1: 3433, 2924 (CH2), 1334, 1150; 1H NMR (400 NMR, CDCl3): 2.45 
(9H, s, 3 x CH3), 3.00 (4H, t, J 5.2 Hz, 2 x CH2S), 3.43 (12H, bs, 6 x CH2N), 7.34 (6H, d, J 
8.0 Hz, 4 x ArH), 7.68 (6H, d, J 8.0 Hz, 6 x ArH); 13C NMR (100 MHz, CDCl3): 21.6 
(CH3), 31.7 (CH2), 50.9 (CH2), 52.2 (CH2), 127.6 (CH), 129.9 (CH), 134.2 (C), 144.1 (C); 
m/z (FAB): 652.1647 (MH+, C29H38N3O6S4 requires 652.1643), 592 (20%), 496 (40), 253 
(73), 156 (40), 93.0 (85). 
7,10-Bis(toluene-4-sulfonyl)-1,4-dithia,7,10-diaazacyclododecane 128 
SS
NTsTsN
 
Using general procedure D, 128 was synthesised from 1,8-bis(toluene-4-sulfonyl)-1,8-
diamino-3,6-dithiaoctane 124 (2.0 g, 4.09 mmol) and 1,2-ethanediol ditosylate 120 (1.52 g, 
4.09 mmol), as white crystals (0.70 g, 33%). mp 176-178 oC; νmax (KBr)/cm-1: 3088, 2893 
(CH), 1536, 1333, 1166; 1H NMR (400 MHz, CDCl3): 2.38 (6H, s, 2 x CH3), 2.78 (4H, s, 2 
x CH2S), 2.83 (4H, t, J 6.2 Hz, 2 x CH2S), 3.33 (4H, t, J 6.2 Hz, 2 x CH2N), 3.42 (4H, s, 2 
x CH2N), 7.24 (4H, d, J 8.0 Hz, 4 x ArH), 7.63 (4H, d, J 8.0 Hz, 4 x ArH); 13C NMR (100 
MHz, CDCl3): 21.6 (CH3), 31.8 (CH2),  43.9 (CH2),  50.7 (CH2), 52.2 (CH2), 127.6 (CH), 
129.9 (CH), 134.4 (C), 143.9 (C); m/z (FAB): 515.1159 (MH+, C22H31N2O4S4 requires 
515.1167), 487 (84%), 455 (100), 395 (28), 359 (28), 116 (37), 88 (94). 
7,11-Bis(toluene-4-sulfonyl)-1,4-dithia-7,11-diazacyclotridecane 129 
NTsTsN
S S
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Using general procedure D, 129 was synthesised from 1,8-bis(toluene-4-sulfonyl)-1,8-
diamino-3,6-dithiaoctane 124 (2.0 g, 4.09 mmol) and 1,3-propanediol ditosylate 121 (1.57 
g, 4.09 mmol), as a white solid (0.97 g, 45%). mp 52-54 oC; νmax (KBr)/cm-1: 3435, 2924 
(CH), 1597, 1339, 1157; 1H NMR (400 MHz, CDCl3): 1.89-1.95 (2H, m, CH2), 2.38 (6H, 
s, 2 x CH3), 2.68 (4H, s, 2 x CH2S), 2.76-2.80 (4H, m, 2 x CH2S), 3.10-3.18 (8H, m, 4 x 
CH2N), 7.27 (4H, d, J 8.2 Hz, 4 x ArH), 7.61 (4H, d, J 8.2 Hz, 4 x ArH); 13C NMR (100 
MHz, CDCl3): 19.7 (CH3), 26.6 (CH2), 28.5 (CH2), 29.3 (CH2), 46.5 (CH2),  47.5 (CH2), 
125.2 (CH), 128.0 (CH), 133.1 (C), 141.2 (C); m/z (FAB): 529.1326 (MH+, C23H33N2O4S4 
requires 529.1323), 469 (44%), 409 (25), 373 (40), 214 (50), 156 (35), 93 (100). 
N-(Toluene-4-sulfonyl)-3-azapentane-1,5-dithiol 130160a 
N
Ts
SHHS
 
 
A stirred solution of N,O,O’-tris(p-tolylsulfonyl)diethanolamine (5.85 g, 10.3 mmol) and 
anhydrous ethanol (40 mL) was prepared. Thiourea (1.72 g, 22.6 mmol) was added and the 
mixture was heated under reflux conditions overnight. The reaction mixture was 
concentrated and taken up in saturated sodium hydrogen cabronate solution (20 mL) and 
heated under reflux conditions for 3 h. After cooling, 6 N hydrochloric acid was added 
dropwise until the pH of the reaction mixture was 7. The aqueous solution was extracted 
with dichloromethane (3 x 50 cm3). The organic layers were combined, dried (MgSO4) and 
concentrated. The crude product was purified using flash column chromatography (eluant: 
dichloromethane/methanol 99:1) yielding a transparent oil (1.98 g, 66%). 1H NMR (400 
MHz, CDCl3): 1.36 (2H, t, J 8.5 Hz, 2 x SH), 2.37 (3H, s, CH3), 2.64-2.69 (4H, m, 2 x 
CH2S), 3.21 (4H, t, J 7.5 Hz, 2 x CH2N), 7.26 (2H, d, J 8.1 Hz, 2 x ArH), 7.63 (2H, d, J 8.1 
Hz, 2 x ArH); m/z (FAB): 292 (MH+, 100%), 258 (95), 244 (47), 232 (22), 199 (13), 173 
(36), 156 (47), 140 (15), 104 (25), 93 (91).  
4,10-Bis(toluene-4-sulfonyl)-1,7-dithia-4,10-diaazacyclododecane 131 
NTsS
STsN
 
Using general procedure D, 131 was synthesised from N,N’-bis(toluene-4-sulfonyl)-bis(2-
aminoethyl)sulfide 122 (3.41 g, 6.0 mmol) and N-(toluene-4-sulfonyl)-3-azapentane-1,5-
dithiol 130 (1.75g, 6.0 mmol), as white crystals (0.07 g, 3%). mp 164-166 oC; νmax 
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(KBr)/cm-1: 3417, 1667, 1327, 1077; 1H NMR (400 MHz, CDCl3): 2.36 (6H, s, 2 x CH3), 
2.86 (8H, t, J 6.6 Hz, 4 x CH2S), 3.28 (8H, t, J 6.6 Hz, 4 x CH2N), 7.25 (8H, d, J 8.2 Hz, 8 
x ArH), 7.61 (8H, d, J 8.2 Hz, 8 x ArH); 13C NMR (100 MHz, CDCl3): 21.6 (CH3), 31.5 
(CH2),  50.6 (CH2), 127.3 (CH), 129.9 (CH), 135.1 (C), 143.9 (C); m/z (FAB): 515.1178 
(MH+, C22H31N2O4S4 requires 515.1167), 359 (13%), 258 (17), 199 (28), 155 (85), 137 
(58). 
1-Thia-4,8-diazacyclodecane 132215 
NHHN
S
 
 
Using general procedure E, 132 was synthesised from 4,8-bis(toluene-4-sulfonyl)-1-thia-
4,8-diazacyclodenane 126 (0.5 g, 1.07 mmol), as a transparent oil (25.3 mg, 93%). 1H 
NMR (400 NMR, CDCl3): 1.51-1.62 (2H, m, CH2), 2.59-2.81 (12H, m, 4 x CH2N, 2 x 
CH2S); m/z (CI): 161 (MH+, 100%), 135 (22), 127 (18), 101 (17), 87 (10), 75 (5). 
1-Thia-4,7-diazacyclononane 133162 
NHHN
S
 
 
Using general procedure E, 133 was synthesised from 4,7-bis(toluene-4-sulfonyl)-1-thia-
4,7-diazacyclononane 125 (0.5 g, 1.10 mmol), as a transparent oil (0.04 g, 31%). 1H NMR 
(400 NMR, CDCl3): 1.96 (2H, bs, 2 x NH), 2.67-2.71 (8H, m, 2 x CH2N, 2 x CH2S), 2.87 
(4H, t, J 5.2 Hz 2 x CH2N); m/z (CI): 147 (MH+, 100%), 145 (7), 113 (4), 85 (4), 69 (4). 
1-Thia-4,7,10-triazacyclododecane 134 
NH
NHHN
S
 
 
Using general procedure E, 134 was synthesised from 4,7,10-tris(toluene-4-sulfonyl)-1-
thia-4,7,10-triazacyclododecane 127 (0.5 g, 0.77 mmol), as a white solid (0.04 g, 32%). mp 
58-60 oC; νmax (KBr)/cm-1: 3405 (NH), 2923 (CH), 1576, 1457; 1H NMR (400 NMR, 
CDCl3): 2.62-2.65 (4H, m, 2 x CH2), 2.68-2.71 (4H, m, 2 x CH2), 2.74-2.80 (8H, m, 4 x 
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CH2); 13C NMR (100 MHz, CDCl3): 32.4 (CH2), 45.7 (CH2), 45.9 (CH2), 47.4 (CH2); m/z 
(FAB): 190.1376 (MH+, C8H19N3S requires 190.1378), 113 (12%), 85 (50), 69 (72).  
1,4-Dithia-7,10-diazacyclododecane 135159 
SS
NHHN
 
Using general procedure E, 135 was synthesised from 7,10-bis(toluene-4-sulfonyl)-1,4-
thia-7,10-diazacyclododecane 128 (0.5 g, 0.97 mmol), as a yellow oil (0.025 g, 13%). 1H 
NMR (400 NMR, CDCl3): 2.68-2.72 (4H, m, 2 x CH2S), 2.75 (4H, s, 2 x CH2S), 2.81 (4H, 
s, 2 x CH2N), 2.82-2.85 (4H, m, 2 x CH2N); m/z (CI): 207 (MH+, 100%), 179 (2), 145 (2), 
113 (9), 103 (3), 85 (3), 69 (3).  
1,4-Dithia-7,11-diazacyclotridecane 136159 
NHHN
S S
 
 
Using general procedure E, 136 was synthesised from 7,11-bis(toluene-4-sulfonyl)-1,4-
thia-7,11-diazacyclotridecane 129 (0.5 g, 0.94 mmol), as a transparent oil (0.07 mg, 35%). 
1H NMR (400 NMR, CDCl3): 1.77 (2H, quin, J 5.4 Hz, CH2), 2.72-2.75 (4H, m, 2 x 
CH2S), 2.78-2.81 (8H, m, 2 x CH2S, 2 x CH2N), 2.83-2.86 (4H, m, 2 x CH2N), 3.77 (2H, 
bs, 2 x NH); m/z (CI): 221 (MH+, 100%), 193 (2), 157 (2), 127 (9), 99 (4), 85 (6), 71 (5).  
4,7-Bis(2-hydroxyethyl)-1-thia-4,7-diazacyclononane 137162 
NN
S
OHHO
 
 
Using general procedure E, 137 was synthesised from 1-thia-4,7-diazacyclononane 133 
(40.0 mg, 0.27 mmol), as a transparent oil (24.2 mg, 39%). 1H NMR (400 NMR, CDCl3): 
2.66-2.99 (8H, m, 2 x CH2S, 2 x CH2N), 2.71-2.74 (4H, m, 2 x CH2N), 2.78-2.81 (4H, m, 2 
x CH2N), 3.55 (4H, t, J 5.0 Hz, 2 x CH2O); m/z (CI): 235 (MH+, 100%), 190 (1), 176 (2), 
135 (3), 90 (10), 76 (7).  
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4,8-Bis(2-hydroxyethyl)-1-thia-4,8-diazacyclodecane 138 
N N
S
OHHO
 
Using general procedure E, 138 was synthesised from 1-thia-4,8-diazacyclodenane 132 
(83.1 mg, 0.52 mmo), as a transparent oil (17.5 mg, 14%). νmax (KBr)/cm-1: 3381 (OH), 
2946, 1655, 1458, 1049; 1H NMR (400 NMR, CDCl3): 1.56 (2H, quin, J 6.5 Hz, CH2), 
2.48-2.51 (8H, m, 2 x CH2S, 2 x CH2N), 2.63 (8H, m, 4x CH2N), 3.50 (4H, t, J 5.0 Hz, 2 x 
CH2O); 13C NMR (100 MHz, CDCl3): 25.2 (CH2), 30.8 (CH2), 52.1 (CH2), 53.5 (CH2), 
55.8 (CH2), 59.2 (CH2); m/z (CI): 249 (MH+, 7%), 243 (4), 216 (10), 90 (65).  
4,7,10-Tris(2-hydroxyethyl)-1-thia-4,7,10-triazacyclododecane 139 
NS
NN
OH
OHHO
 
 
Using general procedure E, 139 was synthesised from 1-thia-4,7,10-triazacyclododecane 
134 (0.14 g, 0.74 mmol), as a transparent oil (0.14 g, 61%). νmax (KBr)/cm-1: 3360 (OH), 
2812, 1654, 1452, 1070;  1H NMR (400 NMR, CDCl3): 2.45 (4H, t, J 4.6 Hz, 2 x CH2S), 
2.54 (8H, bs, 4 x CH2N) 2.66 (10H, bs, 5 x CH2N), 3.56 (4H, t, J 5.0 Hz, 2 x CH2O); 13C 
NMR (100 MHz, CDCl3): 28.5 (CH2), 50.9 (CH2), 51.8 (CH2), 54.2 (CH2), 56.8 (CH2), 
59.4 (CH2); m/z (CI): 322.2159 (MH+, C14H32N3O3S requires 322.4922), 221 (5%), 154 
(10), 88 (15).  
7,10-Bis(2-hydroxyethyl)-1,4-dithia-7,10-diazacyclododecane 140 
SS
NN
OHHO
 
 
Using general procedure E, 140 was synthesised from 1,4-dithia-7,10-diazacyclododecane 
135 (25.0 mg, 0.12 mmol), as a transparent oil (38.6 mg, 100%). νmax (KBr)/cm-1: 3386 
(OH), 2809, 1451 (CH2), 1059; 1H NMR (400 NMR, CDCl3): 2.49 (4H, t, J 4.8 Hz, 2 x 
CH2S), 2.60 (4H, s, 2 x CH2S) 2.67-2.73 (8H, m, 4 x CH2N), 2.86 (4H, s, 2 x CH2N), 3.56 
(4H, t, J 4.8 Hz, 2 x CH2O); 13C NMR (100 MHz, CDCl3): 28.6 (CH2), 29.9 (CH2), 50.8 
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(CH2), 54.2 (CH2), 56.4 (CH2), 59.5 (CH2); m/z (CI): 295 (MH+, 100%), 201 (10), 172 
(35), 71 (10). 
7,11-Bis(2-hydroxyethyl)-1,4,-dithia-7,11-diazacyclotridecane 141 
NN
S S
HO OH
 
Using general procedure E, 141 was synthesised from 1,4-dithia-7,11-diazacyclotridecane 
136 (70.0 mg, 0.32 mmol), as a transparent oil (27.5 mg, 28%). 1H NMR (400 NMR, 
CDCl3): 1.65 (2H, quin, J 6.5 Hz, CH2), 2.50-2.56 (8H, m 4 x CH2S), 2.68 (8H, bs, 4 x 
CH2N), 2.76 (4H, bs, 2 x CH2N), 3.52 (4H, t, J 5.2 Hz, 2 x CH2O); 13C NMR (100 MHz, 
CDCl3): 25.2 (CH2), 30.6 (CH2), 32.6 (CH2), 52.2 (CH2), 53.9 (CH2), 56.3 (CH2), 58.8 
(CH2); m/z (CI): 309.1668 (MH+, C13H29N2O2S2 requires 309.1670), 215 (25%). 
9.4 Experimental to Chapter 7 
1,1-Ethylenedi-2-imidazoline 72121 
NN
N N
 
N,N’-Dimethylformamide dimethyl acetal (10.9 mL, 82 mmol) was added to 
triethylenetetraamine (6.1 mL, 41 mmol) and the mixture was heated under reflux for 1 h. 
Excess solvent was removed under vacuum and the white/yellow residue was recrystallised 
from tetrahydrofuran to give the desired product as white crystals (3.15 g, 46%). m.p. 107-
108 oC (lit. 107-109 oC); 1H NMR (CDCl3, 400 MHz): 3.16 (4H, t, J 9.6 Hz, 2 x CH2N), 
3.20 (4H, s, 2 x CH2), 3.78 (4H, t, J 9.6 Hz, 2 x CH2N) 6.74 (2H, s, 2 x CH); m/z (EI): 166 
(M+, 55%), 165 (16), 124 (7), 84 (34), 83 (100), 56 (100). 
N,N’-Bis(toluene-4-sulfonyl)-ethylenediamine-N,N’-diacetic acid-dimethyl ester 146170 
TsNNTs
OMe
O
MeO
O
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Sodium (0.25 g, 10.9 mmol) was dissolved in absolute methanol (14 mL) in a 3-necked 
flask. N,N’-Bis(toluene-4-sulfonyl)-ethylenediamine (2.0 g, 5.4 mmol) was added. The 
mixture was stirred and heated under reflux for 2 h. The methanol was removed by 
distillation and the residue was dried under vacuum. The powder was added portionwise 
over 30 min to a stirred ice-cooled flask of methyl bromoacetate (4.1 mL, 43.4 mmol). 
After stirring for 30 min at RT, the excess methyl bromoacetate was removed under 
vacuum. A mixture of chloroform (10 mL) and water (10 mL) was added to the residue. 
The chloroform layer was washed with water (2 x 10 mL) before drying over calcium 
chloride. The solution was filtered and concentrated. The product was recrystallised from 
methanol (1.05 g, 40%). mp 123-125 oC (lit. 124-126 oC); 1H NMR (400 MHz, CDCl3): 
2.36 (6H, s, 2 x CH3), 3.41 (4H, s, 2 x CH2), 3.55 (6H, s, 2 x OCH3), 4.00 (4H, s, 2 x CH2), 
7.24 (8H, d, J 8.0 Hz, 4 x ArH), 7.63 (8H, d, J 8.0 Hz, 4 x ArH); m/z (CI): 513 (MH+, 
98%), 453 (35), 357 (21), 270 (13), 256 (35), 156 (23), 93 (30). 
N, N’-Bis(toluene-4-sulfonyl)-ethylenediamine-N,N’-diacetic acid 147170 
TsNNTs
OH
O
HO
O
 
A mixture of N,N’-bis(toluene-4-sulfonyl)-ethylenediamine-N,N’-diacetic acid-dimethyl 
ester (0.64 g, 1.24 mmol), acetic acid (5.2 mL) and conc. hydrochloric acid (1.3 mL) was 
stirred and heated under reflux for 12 h. The resulting white crystals were filtered and 
rinsed with acetic acid (2 x 3 mL) before drying under vacuum (0.80 g, 70%). mp 240-242 
oC (lit. 228-229 oC); 1H NMR (400 MHz, DMSO): 2.41 (6H, s, 2 x CH3), 3.27 (4H, s, 2 x 
CH2), 3.98 (4H, s, 2 x CH2), 7.41 (8H, d, J 8.0 Hz, 4 x ArH), 7.66 (8H, d, J 8.0 Hz, 4 x 
ArH), 12.77 (2H, s, 2 x OH); m/z (FAB): 485 (MH+, 17%), 439 (5), 285 (6), 238 (24), 170 
(21), 87 (100). 
N,N’-Bis(toluene-4-sulfonyl)-N,N’-ethanediyl-bis-glycyl chloride 143170 
TsNNTs
Cl
O
Cl
O
 
N,N’-Bis(toluene-4-sulfonyl)-ethylenediamine-N,N’-diacetic acid (0.51 g, 1.06 mmol) and 
thionyl chloride (5.4 mL, 74.2 mmol) were stirred and heated using a water bath at 80 oC 
for 5 h. The reaction mixture was concentrated and the crude product was recrystallised 
from benzene (special permission was given to use benzene) yielding fluffy white crystals 
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(0.55 g, 86%). mp 127-129 oC (lit. 223-224 oC); 1H NMR (D6-DMSO, 400 MHz): 2.40 
(6H, s, 2 x CH3), 3.25 (4H, s, 2 x CH2), 3.98 (4H, s, 2 x CH2), 7.39 (4H, d, J 8.1 Hz, 4 x 
ArH), 7.65 (4H, d, J 8.1 Hz, 4 x ArH). 
4,7-Bis(toluene-4-sulfonyl)-2-methyl-1,4,7,10-tetraazacylcododecane -2,9-dione 148 
NHTsN
NHTsN
O
O
 
A stirred solution of triethylamine (0.86 mL, 6.17 mmol) and dichloromethane (140 mL) 
was prepared. Over a period of 6 h, N,N’-bis(toluene-4-sulfonyl)-N,N’-ethanediyl-bis-
glycyl chloride (1.61 g, 3.1 mmol) in dichloromethane (37.5 mL) and 1,2-diaminopropane 
(0.26 mL, 3.09 mmol) in dichloromethane (37.5 mL) were added using 2 syringe pumps. 
The reaction mixture was then stirred for an additional 2 h. The white precipitate was 
filtered off (0.78 g, 48%). mp ≥360 oC; νmax (KBr)/cm-1: 3212 (NH), 3090 (CH), 1644 
(CO), 1350, 1162, 822, 550. 1H NMR (D6-DMSO, 400 MHz): 0.98 (3H, d, J 6.8 Hz, CH3), 
2.42 (6H, s, 2 x CH3), 2.66-2.77 (4H, m, 2 x CH2N), 3.21-3.47 (4H, m, 2 x CH2), 3.97-4.02 
(3H, m, CH, CH2), 7.47 (4H, d, J 7.6 Hz, 4 x ArH), 7.65 (4H, d, J 7.6 Hz, 4 x ArH); 13C 
NMR (D6-DMSO, 100 MHz): 16.5 (CH3), 19.7 (CH3), 42.9 (CH2), 43.4 (CH), 45.9 (CH2), 
51.9 (CH2), 52.1 (CH2), 125.8 (CH), 128.6 (CH), 133.3 (C), 142.3 (C), 164.7 (C), 165.3 
(C). m/z (FAB): 523.1679 (MH+, C23H29N4O6S2 requires 523.1685), 367 (14%), 239 (22) 
170 (45), 87 (100). 
4,7-Bis(toluene-4-sulfonyl)-2-methyl-1,4,7,10-tetraazacyclododecane 149 
NHTsN
NHTsN
 
A stirred solution of 4,7-bis(toluene-4-sulfonyl)-2-methyl-1,4,7,10-tetraazacyclododecane -
2,9-dione (0.2 g, 0.38 mmol) and tetrahydrofuran (10 mL) was prepared and cooled using 
an ice bath. Borane in tetrahydrofuran (3.64 mL, 38.0 mmol) was added dropwise. The 
reaction mixture was heated under reflux for 3 d. Methanol was added dropwise to quench 
the reaction. The reaction mixture was concentrated. The minimum volume of ethanol was 
added to dissolve the brown residue. 6M Hydrochloric acid (2 mL) was added and the 
reaction mixture was heated under reflux overnight. The mixture was cooled using an ice 
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bath and the resulting white precipitate was filtered off and dried (0.11 g, 59%). mp 216-
218 oC; νmax (KBr)/cm-1: 3612 (NH), 2974 (CH), 2369, 1596 (CO), 1332, 1155; 1H NMR 
(D6-DMSO, 400 MHz): 1.57 (3H, bs, CH3), 2.44 (6H, s, 2 x CH3), 2.88-2.91 (2H, m, CH2), 
2.97-3.01 (2H, m, CH2), 3.19-3.38 (3H, m, CH, CH2), 3.90 (1H, bs, CH), 4.02 (2H, bs, 
CH2), 4.24 (1H, bs, CH2), 7.53 (4H, d, J 7.6 Hz, 4 x ArH), 7.72 (4H, d, J 7.6 Hz, 4 x ArH), 
9.46 (1H, bs, NH), 10.02 (1H, bs, NH); 13C NMR (D6-DMSO, 100 MHz): 15.1 (CH), 19.0 
(CH3), 38.7 (CH2), 39.3 (CH2), 41.8 (CH2), 43.9 (CH3), 46.7 (CH2), 47.0 (CH2), 49.9 
(CH2), 125.7 (CH), 128.1 (CH), 129.2 (C), 142.6 (C); m/z (EI): 494.2018 (M+, 
C23H34N4O4S2 requires 494.2021), 424 (30%), 339 (28), 296 (44), 91 (100). 
9.5 Experimental to Chapter 8 
9.5.1 General Procedures (A & B) 
General procedure A – Synthesis of aminouracils: 6-Chlorouracil (1 eq) and aniline (3 
eq) were heated at 170 °C under nitrogen for 20 min. The mixture was cooled and diethyl 
ether (15 mL) was added. The mixture was sonicated for 15 min. The white suspension 
was filtered and washed with distilled water (15 mL), methanol (15 mL) and diethyl ether 
(15 mL). The white solid was placed in a desiccator and dried overnight using silica and 
P2O5. 
General procedure B – Synthesis of deazaflavins: A suspension of aminouracil (0.30 g, 
1.40 mmol) and DMF (15 mL) was prepared. A 2-chloro-5-nitrobenzaldehyde (0.33 g, 1.7 
mmol) was added and the reaction mixture was heated at 110 °C for 90 min under nitrogen. 
The yellow transparent solution was cooled and distilled water (25 mL) was added. The 
resulting precipitate was filtered and washed with water (15 mL). The yellow solid was 
placed in a desiccator and dried overnight using silica and P2O5 
9.5.2 Experimental Details 
6-Chlorouracil 171196 
N
N Cl
O
H
O
H
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2,4,6-Trichloropyrimidine (15 g, 8.2 mmol) was added to a stirring solution of sodium 
hydroxide (13.2 g, 0.328 mol) and distilled water (135 mL). The reaction mixture was 
heated under reflux for one hour. The solution was cooled and the pH was adjusted to ~2-3 
using conc. hydrochloric acid (18 mL). The mixture was stored at 0 °C overnight. The 
white precipitate was filtered and recrystallised from water (9.1g, 71%). mp 287-289 °C 
(lit. 300 °C); 1H NMR (400 MHz, D6-DMSO): 5.76 (1H, s, 5-H), 11.33 (1H, s, NH), 12.09 
(1H, s, NH); m/z (FAB): 147 (MH+, 35Cl, 86%), 119 (2), 113 (12), 79 (100). 
6-Phenylamino-1H-pyrimidine-2,4-dione 169 
N
N N
H
O
H
O
H
 
Using general procedure A, 169 was synthesised from 6-chlorouracil 171 (1.0 g, 6.82 
mmol) and aniline (1.8 mL, 20 mmol), as a white solid (1.2 g, 84%). mp 332-333 °C; 
Found: C, 59.1; H, 4.4; N, 20.4. C10H9N3O2 requires C, 59.1; H, 4.5; N, 20.7.; νmax 
(neat)/cm-1:  3414 (NH), 1818 (CO), 1807 (CO);  1H NMR (400 MHz, D6-DMSO): 4.70 
(1H, s, 5-H), 7.15-7.23 (3H, m, 3 x ArH), 7.40 (2H, t, J 7.8 Hz, 2 x ArH), 8.28 (1H, s, NH), 
10.20 (1H, s, NH), 10.50 (1H, s, NH); 13C NMR (100 MHz, D6-DMSO): 75.8 (CH), 122.7 
(CH), 124.7 (CH), 129.4 (CH), 137.9 (C), 150.8 (C), 152.2 (C), 164.4 (C). m/z (FAB): 204  
(MH+, 20%), 158 (40), 81 (100). 
6-(2-Chlorophenylamino)-1H-pyrimidine-2,4-dione 
N
N N H
O
H
O
H Cl
3'
4'
5'
6'
 
Using general procedure A, 6-(2-chlorophenylamino)-1H-pyrimidine-2,4-dione was 
synthesised from 6-chlorouracil 171 (1.0 g, 6.82 mmol) and 2-chloroaniline (2.15 mL, 20.5 
mmol), as a white solid. mp 321-323 oC (decomp); Found: C, 50.4; H, 3.3; N, 17.5, 
C10H8ClN3O2 requires C, 50.5; H, 3.4; N, 17.7; νmax (neat)/cm-1: 3202 (NH), 1731 (CO), 
1632 (C=C), 1540, 1480, 1224, 1078, 796, 736 ; 1H NMR (400 MHz, D6-DMSO): 4.37 
(1H, s, 5-H), 7.29 (1H, ddd, J 8.0, 8.0, 1.6 Hz, 4’-H), 7.41 (1H, ddd, J 8.0, 8.0, 1.3 Hz, 5’-
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H), 7.46 (1H, dd, J 8.0, 1.6 Hz, 6’-H), 7.59 (1H, dd, J 8.0, 1.3 Hz, 3’-H), 8.10 (1H, s, NH) 
10.38 (1H, s, NH), 10.55 (1H, s, NH); 13C NMR (100 MHz, D6-DMSO): 76.1 (CH), 126.8 
(CH), 127.4 (CH), 128.2 (CH), 128.4 (C), 130.1 (CH), 134.4 (C), 150.7 (C), 152.1 (C), 
164.2 (C); m/z (CI): 238 (MH+, 35Cl, 91%) 204 (8), 147 (10), 79 (100).  
6-(4-Chlorophenylamino)-1H-pyrimidine-2,4-dione 
N
N N H
O
H
O
H
Cl
 
Using general procedure A, 6-(4-chloro-phenylamino)-1H-pyrimidine-2,4,dione was 
synthesised from 6-chlorouracil 171 (1.0 g, 6.82 mmol) and 4-chloroaniline (2.61 g, 20.5 
mmol), as a white solid (0.97 g, 60%). mp 344-346 oC (decomp); Found: C, 50.3; H, 3.2; 
N, 17.4, C10H8ClN3O2 requires C, 50.5; H, 3.4; N, 17.7; νmax (KBr)/cm-1:  3195 (NH), 1754 
(CO), 1616 (C=C), 1488, 1298, 788, 752 ; 1H NMR (400 MHz, D6-DMSO): 4.73 (1H, s, 5-
H), 7.23 (2H, d, J 8.6 Hz, 2 x ArH), 7.43 (2H, d, J 8.6 Hz, 2 x ArH), 8.42 (1H, s, NH), 
10.32 (1H, s, NH), 10.55 (1H, s, NH); 13C NMR (100 MHz, D6-DMSO): 76.6 (CH), 124.1 
(CH), 128.2 (C), 129.3 (CH), 137.1 (C), 150.9 (C), 151.9 (C), 164.4 (C); m/z (CI): 238 
(MH+, 35Cl, 4%), 157 (60), 79 (100).  
6-(4-Methylphenyl)-1H-pyrimidine-2,4-dione 
N
N N H
O
O
H
H
CH3
 
Using general procedure A, 6-(4-methylphenyl)-1H-pyrimidine-2,4-dione was synthesised 
from 6-chlorouracil 171 (1.0 g, 6.82 mmol) and 4-tolylaniline (2.19 g, 20.0 mmol), as a 
white solid (1.35 g, 91%) mp 321-323 oC; Found: C, 60.7; H, 5.1; N, 19.1, C11H11N3O2 
requires C, 60.8; H, 5.1; N, 19.3; νmax (KBr)/cm-1: 3273 (NH), 2764, 1772 (CO), 1634 
(C=C) 1446, 822, 786; 1H NMR (400 MHz, D6-DMSO): 2.29 (3H, s, CH3), 4.61 (1H, s, 5-
H), 7.10 (2H, d, J 8.4 Hz, 2 x ArH), 7.20 (2H, d, J 8.4 Hz, 2 x ArH), 8.23 (1H, s, NH), 
10.18 (1H, s, NH), 10.45 (1H, s, NH); 13C NMR (100 MHz, D6-DMSO): 20.4 (CH3), 75.2 
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(CH), 123.1 (CH), 129.8 (CH), 134.1 (C), 135.1 (C), 150.8 (C), 152.5 (C), 164.3 (C); m/z 
(EI): 217 (M+, 10%), 154 (8), 78 (90), 63 (100), 45 (26). 
10-Phenyl-7-nitro-10H-pyrimido[4,5-b]quinoline-2,4-dione 165 
N
N
O
H
O N
NO2
10 9
8
7
654
3
2
1
 
 Using general procedure B, 165 was synthesised from 6-phenylamino-1H-pyrimidine-2,4-
dione (0.3 g, 1.47 mmol), and 2-chloro-5-nitrobenzaldehyde (0.33 g, 1.78 mmol), as a 
yellow solid (413 mg, 84%). mp >380 °C; Found: C, 60.7; H, 2.8; N, 16.4, C17H10N4O4 
requires C, 61.1; H, 3.0; N, 16.7; νmax (neat)/cm-1: 3220 (NH), 1722 (CO), 1610; 1H NMR 
(400 MHz, D6-DMSO): 6.87 (1H, d, J 9.6 Hz, 9-H), 7.47-7.75 (2H, m, 2 x ArH), 7.65-7.75 
(3H, m, 3 x ArH), 8.45 (1H, dd, J 9.2, 2.4 Hz, 8-H), 9.23 (1H, d, J 2.4 Hz, 6-H), 9.31 (1H, 
s, 5-H), 11.32 (1H, s, NH); 13C NMR (100 MHz, D6-DMSO): 117.5 (C), 118.5 (CH), 120.4 
(C), 127.2 (CH), 128.3 (2 CH), 128.4 (2 CH), 129.7 (CH), 130.4 (CH), 137.2 (C), 142.1 
(C), 145.1 (C), 156.3 (C), 159.5 (C), 161.4 (C); m/z (FAB): 335 (MH+, 13%), 232 (15), 157 
(80), 80 (100). 
10-(2-Chlorophenyl)-7-nitro-10H-pyrimido[4,5-b]quinoline-2,4-dione 174 
N
N
N
NO2
O
H
O
Cl
 
Using general procedure B, 174 was synthesised from 6-(2-chlorophenylamino)-1H-
pyrimidine-2,4-dione (0.1 g, 0.42 mmol) and 2-chloro-5-nitrobenzaldehyde (94 mg, 0.5 
mmol), as a yellow solid (101 mg, 66%). mp 326-328 oC; νmax (KBr)/cm-1: 3144 (NH), 
2826, 1683 (CO), 1617, 1340, 1218, 825, 796; 1H NMR (400 MHz, D6-DMSO): 6.88 (1H, 
d, J 9.6 Hz, 9-H), 7.56-7.70 (3H, m, 3 x ArH), 7.81-7.89 (1H, m, ArH), 8.48 (1H, dd, J 9.6, 
2.8 Hz, 8-H), 9.27 (1H, s, 5-H), 9.32 (1H, d, J 2.8 Hz, 6-H), 11.43 (1H, s, NH); 13C NMR 
(100 MHz, D6-DMSO): 117.2 (C), 117.7 (CH), 120.4 (C), 127.5 (CH), 129.0 (CH), 129.5 
(CH), 130.4 (CH), 130.9 (CH), 131.6 (C), 131.9 (CH), 134.2 (C), 142.7 (CH), 143.3 (C). 
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143.8 (C), 156.2 (C), 158.8 (C), 161.1 (C); m/z (FAB): 369.0391 (MH+, C17H1035ClN4O4 
requires 369.0388), 232 (20%), 158 (40), 81 (100). 
6-Chloro-10-phenyl-10H-pyrimido[[4,5-b]quinoline-2,4-dione 175 
N
N
O
H
O N
Cl
 
Using general procedure B, 175 was synthesised from 6-phenylamino-1H-pyrimidine-2,4-
dione (0.15 g, 0.74 mmol) and 2,6-dichlorobenzaldehyde (0.26 g, 1.50 mmol), as a yellow 
solid (0.22 g, 92%). mp (decomp) 338-340 °C; νmax (neat)/cm-1: 3381 (NH), 3234 (NH), 
1702 (CO), 1669 (CO);  1H NMR (400 MHz, D6-DMSO): 6.70 (1H, dd, J 8.0, 1.2 Hz, 8-
H), 7.43-7.45 (2H, m, 7-H, 9-H), 7.63-7.71 (5H, m, 5 x ArH), 9.04 (1H, s, 5-H), 11.27 (1H, 
s, NH); 13C NMR (100 MHz, D6-DMSO): 116.7 (C), 116.8 (CH), 118.4 (C), 124.9 (2 CH), 
128.3 (CH), 129.5 (2 CH), 130.3 (CH), 133.7 (C), 135.2 (CH), 136.5 (CH), 137.6 (C), 
143.1 (C), 156.3 (C), 158.5 (C), 161.6 (C); m/z (FAB): 324.0536 (MH+, C17H1135ClN3O2 
requires 324.0540), 292 (20%), 80 (100). 
6-Chloro-10-(2-chlorophenyl)-10H-pyrimido[4,5-b]quinoline-2,4-dione 176 
N
N
N
O
H
O
Cl
Cl
 
Using general procedure B, 176 was synthesised from 6-(2-chlorophenylamino)-1H-
pyrimidine-2,4-dione (0.3 g, 1.26 mmol) and 2-chloro-6-fluorobenzaldehyde (0.24 g, 1.51 
mmol), as a yellow solid (55 mg, 36%). mp 305-307 oC; νmax (KBr)/cm-1: 3142 (NH), 
2801, 1709 (CO), 1685 (C=C), 1607, 1219, 794, 769; 1H NMR (400 MHz, D6-DMSO): 
6.72 (1H, d, J 10.8 Hz, 9-H), 7.62-7.66 (1H, m, 8-H), 7.67-7.79 (4H, m, 4 x ArH), 7.85-
7.96 (1H, m, 7-H), 9.89 (1H, s, 5-H), 10.33 (1H, s, NH); 13C NMR (100 MHz, D6-DMSO): 
115.9 (CH), 116.5 (C), 118.4 (C), 125.4 (CH), 129.5 (CH), 130.4 (CH), 130.8 (CH), 131.0 
(C), 131.7 (C), 134.1 (C), 134.5 (C), 135.9 (CH), 137.2 (C), 141.9 (C), 156.2 (C), 157.9 
(C), 161.3 (C); m/z (CI): 358.0151 (MH+, C17H1035Cl2N3O2 requires 358.0150), 128 (10%), 
79 (100).  
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6-Chloro-10-(4-chlorophenyl)-10H-pyrimido[4,5-b]quinoline-2,4-dione 177 
N
N
N
O
H
O
Cl
Cl
 
Using general procedure B, 177 was synthesised from 6-(4-chlorophenylamino)-1H-
pyrimidine-2,4,dione (0.3 g, 1.26 mmol) and 2-chloro-6-fluorobenzaldehyde (0.24 g, 1.51 
mmol), as a yellow solid (0.28 g, 63%). mp 220-222 oC (decomp); νmax (KBr)/cm-1: 3254 
(NH), 1667 (C=C), 1602 (C=C), 1363, 1245, 797, 747; 1H NMR (400 MHz, D6-DMSO): 
6.55 (1H, d, J 8.8 Hz, 9-H), 7.50 (2H, d, J 8.4 Hz, 2 x ArH), 7.59-7.65 (2H, m, 7-H, 8-H), 
7.79 (2H, d, J 8.4 Hz, 2 x ArH), 9.07 (1H, s, 5-H), 11.29 (1H, s, NH); 13C NMR (100 MHz, 
D6-DMSO): 116.7 (C), 116.8 (CH), 118.5 (C), 124.9 (CH), 130.3 (CH), 130.4 (CH), 133.8 
(C), 134.2 (C), 135.3 (CH), 136.3 (C), 136.7 (CH), 142.9 (C). 156.2 (C), 158.6 (C), 161.5 
(C); m/z (FAB): 358.0152 (MH+, C17H1035Cl2N3O2 requires 358.0150), 232 (8%), 158 
(100), 81 (100). 
5-Chloro-10-(4-methylphenyl)-10H-pyrimido[4,5-b]quinoline-2,4-dione
 
178 
N
N N
O
H
O
CH3
Cl
 
Using general procedure B, 178 was synthesised from 6-p-tolylamino-1H-pyrimidine-2,4-
dione (0.1 g, 0.46 mmol) and 2-chloro-6-fluorobenzaldehyde (87 mg, 0.55 mmol), as a 
yellow solid (69 mg, 44%). mp >360 oC; νmax (KBr)/cm-1: 3131 (NH), 3000, 2803, 1707 
(CO), 1656 (C=C), 1221, 796, 740; 1H NMR (400 MHz, D6-DMSO): 2.49 (3H, s, CH3), 
6.75 (1H, d, J 9.2 Hz, 9-H), 7.30 (2H, d, J 8.2 Hz, 2 x ArH), 7.50 (2H, d, J 8.2 Hz, 2 x 
ArH), 7.66-7.73 (2H, m, 7-H, 8-H), 9.02 (1H, s, 5-H), 11.24 (1H, s, NH); 13C NMR (100 
MHz, D6-DMSO): 20.8 (CH3), 116.9 (CH), 118.4 (C), 124.8 (CH), 125.3 (C), 127.9 (CH), 
130.7 (CH), 133.7 (C), 134.9 (C), 135.1 (CH), 136.4 (CH), 139.1 (C) 143.3 (C), 156.3 (C), 
158.6 (C), 161.6 (C); m/z (FAB): 338.0700 (MH+, C18H1335ClN3O2 requires 338.0696), 232 
(20%), 158 (65), 81 (100). 
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8-Chloro-10-phenyl-10H-pyrimido[4,5-b]quinoline-2,4-dione 179 
N
N
O
H
O N Cl
 
Using general procedure B, 179 was synthesised from 6-phenylamino-1H-pyrimidine-2,4-
dione (0.15 g, 0.74 mmol) and 2,4-dichlorobenzaldehyde (0.26 g, 1.50 mmol), as a yellow 
solid (0.17 g, 71%). mp (decomp) 370-372 °C; Found: C, 62.8; H, 3.1; N, 12.8, 
C17H11ClN3O2 requires C, 63.1; H, 3.1; N, 13.0; νmax (neat)/cm-1: 3335 (NH), 3145 (NH), 
1700 (CO), 1659 (CO);  1H NMR (400 MHz, D6-DMSO): 6.50 (1H, d, J 1.6 Hz, 9-H), 
7.38-7.40 (2H, m, 2 x ArH), 7.52 (1H, dd, J 8.8, 2 Hz, 7-H), 7.57-7.65 (3H, m, 3 x ArH), 
8.22 (1H, d, J 8.8 Hz, 6-H) 9.08 (1H, s, 5-H), 11.10 (1H, s, NH); 13C NMR (100 MHz, D6-
DMSO): 115.9 (C), 116.1 (CH), 119.8 (C), 124.7 (CH), 128.3 (CH), 129.6 (C), 130.4 
(CH), 133.2 (CH), 137.1 (C), 139.3 (C), 141.7 (CH), 142.5 (C), 156.3 (C), 158.5 (C), 158.8 
(C), 161.7 (C); m/z (FAB): 324 (MH+, 35Cl, 100%) 281 (7), 232 (12), 157 (25), 80 (50). 
10-(4-Chlorophenyl)-7-trifluoromethyl-10H-pyrimido[4,5-b]quinoline-2,4-dione 180 
N
N N
O
H
O
CF3
Cl
 
Using general procedure B, 180 was synthesised from 6-(4-chlorophenylamino)-1H-
pyrimidine-2,4,dione (0.3 g, 1.26 mmol) and 2-chloro-5-(trifluoromethyl)benzaldehyde 
(0.22 mL, 1.51 mmol), as a yellow solid (0.40 g, 83%). mp 342-343 oC; νmax (KBr)/cm-1: 
3155 (NH), 2825, 1690 (C=C), 1618, 1337, 1276, 831, 797; 1H NMR (400 MHz, D6-
DMSO): 6.97 (1H, d, J 9.2 Hz, 9-H), 7.54 (2H, d, J 8.6 Hz, 2 x ArH), 7.79 (2H, d, J 8.6 
Hz, 2 x ArH), 8.01 (1H, dd, J 9.2, 2.0 Hz, 8-H), 8.54 (1H, d, J 1.2 Hz, 6-H), 9.22 (1H, s, 5-
H), 11.27 (1H, s, NH); 13C NMR (400 MHz, D6-DMSO): 117.0 (C), 118.4 (CH), 120.6 
(C), 123.3 (C), 124.9 (CF3, J 33 Hz), 128.9 (CH), 130.5 (CH), 131.2 (CH), 132.8 (CH), 
134.3 (C), 136.1 (C), 142.1 (CH), 143.6 (C). 156.3 (C), 159.8 (C), 161.5 (C); 19F NMR 
(376 MHz, D6-DMSO): -60.7 (CF3); m/z (FAB): 392.0413 (MH+, C18H1035ClF3N3O2 
requires 392.0414), 349 (15%), 81 (30). 
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10-p-tolyl-6-trifluoromethyl-10H-pyrimido-[4,5-b]quinoline-2,4-dione 181 
N
N N
O
H
O
CH3
CF3
 
Using general procedure B, 181 was synthesised from 6-p-tolylamino-1H-pyrimidine-2,4-
dione (0.1 g, 0.46 mmol) and 2-chloro-5-(trifluoromethyl)benzaldehyde (80 µmol, 5.52 
mmol), as a yellow solid (67 mg, 40%). mp >360 oC; νmax (KBr)/cm-1: 3145 (NH), 3006, 
1714 (CO), 1670 (C=C), 1333, 1212, 796; 1H NMR (400 MHz, D6-DMSO): 2.47 (3H, s, 
CH3), 6.90-6.93 (1H, d, J 9.2 Hz, 9-H), 7.32 (2H, d, J 8.2 Hz, 2 x ArH), 7.50 (2H, d, J 8.2 
Hz, 2 x ArH), 7.99-8.02 (1H, dd, J 9.2, 2.0 Hz, 8-H), 9.22 (1H, bs, 6-H), 10.33 (1H, s, 5-
H), 11.23 (1H, s, NH); 13C NMR (100 MHz, D6-DMSO): 20.8 (CH), 117.0 (CH), 118.5 
(CH), 120.5 (C), 124.4 (CF3, J 33 Hz), 128.0 (CH), 128.8 (CH), 130.3 (CH), 130.8 (CH), 
134.7 (C), 139.1 (C), 141.9 (CH), 143.9 (C). 156.4 (C), 159.3 (C), 161.6 (C); 19F NMR 
(367 MHz, D6-DMSO): -60.7 (CF3); m/z (FAB): 372.0966 (MH+, C19H13F3N3O2 requires 
372.0960), 232 (20%), 158 (40), 81 (100). 
12-Phenyl-12H-1,3,11,12-tetraaza-naphthacene-2,4-dione 182 
N
N
O
H
O N N
 
Using general procedure B, 182 was synthesised from 6-phenylamino-1H-pyrimidine-2,4-
dione (0.2 g, 0.98 mmol) and 2-chloro-3-quinolinecarboxaldehyde (0.23 g, 1.18 mmol), as 
a yellow solid (0.24 g, 74%). mp (decomp) 353–355 °C; Found: C, 70.5; H, 3.5; N, 16.3, 
C20H12N4O2 requires C, 70.6; H, 3.5; N, 16.5; νmax (neat)/cm-1: 3368 (NH), 3230 (H), 1713 
(CO), 1628 (C=C aromatic); 1H NMR (400 MHz, D6-DMSO): 7.40-7.42 (2H, m, 7-H, 10-
H), 7.56-7.58 (1H, m, ArH), 7.62-7.68 (4H, m, 4 x ArH), 7.85-7.87 (1H, m, 8-H), 8.31 
(1H, d, J 7.6 Hz, 9-H), 9.21 (1H, s, 6-H), 9.34 (1H, s, 5-H), 11.3 (1H, s, NH). m/z (FAB): 
341 (MH+, 1%) 232 (30), 157 (100), 80 (100). 
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5-tert-Butoxycarbonylamino-2-chlorobenzoic acid methyl ester 184 
N
H
O
OCl
O
O
 
2-Chloro-5-amino-benzoic acid (1.97 g, 11.5 mmol) was dissolved in methanol (22 mL) 
under a nitrogen atmosphere and cooled to 0 oC using an ice bath. Trimethylsilyl chloride 
(2.93 mL, 22.9 mmol) was added dropwise to the lilac coloured solution. After 1 h, the 
reaction mixture was returned to RT and stirred overnight. Triethylamine (3.19 mL, 22.9 
mmol) and di-tert-butyl dicarbonate (2.75 mL, 12.6 mmol) were added dropwise to the 
grey reaction mixture and this was stirred for 2 h. The brown reaction mixture was 
concentrated. The greenish residue was dissolved in diethyl ether (30 mL) and filtered to 
remove the precipitate (triethylamine salt). The filtrate was concentrated and purified using 
column chromatography (eluant: pet ether/ethyl acetate 60/40) yielding a white solid (3.30 
g, 51%). mp 99-100 oC; νmax (KBr)/cm-1: 3356, 2969 (NH), 1725, 1699 (CO), 1528, 1310, 
1231, 1060, 972; 1H NMR (400 MHz, CDCl3): 1.45 (9H, s, 3 x CH3), 3.90 (3H, s, OCH3), 
6.51 (1H, s, NH), 7.28 (1H, d, J 8.8 Hz, ArH), 7.41 (1H, dd, J 8.8, 2.8 Hz, ArH), 7.76 (1H, 
d, J 2.8 Hz, ArH). 13C NMR (100 MHz, CDCl3): 27.4 (CH3), 28.3 (CH3), 52.5 (CH), 120.9 
(CH), 122.4 (CH), 127.3 (C), 130.2 (C), 131.5 (CH), 137.1 (C), 152.4 (C), 165.8 (C); m/z 
(EI): 285.0767 (M+, C13H1635ClNO4 requires 285.0768), 229 (35%), 185 (30), 83 (20), 57 
(100). 
 (1-Chloro-2-hydroxymethyl-4-tert-butoxycarbonylamino)benzene 185 
NHBocHO
Cl
 
A suspension of lithium aluminium hydride (0.177 g, 4.62 mmol) in tetrahydrofuran (10 
mL) was prepared and cooled to 0 oC using an ice bath. 5-tert-Butoxycarbonylamino-2-
chlorobenzoic acid methyl ester was added in small portions. The reaction mixture was 
heated at 40 oC for 2 d. The reaction mixture was quenched by the careful addition of 
water. Diethyl ether was added and the layers were separated. The aqueous layer was 
washed with diethyl ether (3 x 20 mL). The combined organic layers were washed with 
water (3 x 20 mL), dried (MgSO4), concentrated and purified using column 
chromatography eluant: petroleum ether/ethyl acetate 70/30 yielding a pale yellow solid 
(1.18 g, 42%). mp 66-68 oC; νmax (KBr)/cm-1: 3287, 2812 (NH), 1608 (CO), 1238, 1056, 
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873; 1H NMR (400 MHz, CDCl3): 2.86 (9H, s, 3 x CH3), 4.68 (2H, s, CH2), 6.49 (1H, dd, J 
8.4, 2.8 Hz, 6-ArH), 6.72 (1H, d, J 2.8 Hz, 2-ArH), 7.05 (1H, d, J 8.4 Hz, 5-ArH), 7.25 
(1H, s, NH); 13C NMR (100 MHz, CDCl3) 30.8 (CH3), 63.2 (CH2), 77.3 (C), 112.5 (CH), 
112.6 (CH), 120.2 (C), 129.8 (CH), 138.6 (C), 148.3 (C); m/z (EI): 257.0816 (M+, 
C12H1635ClNO3 requires 257.0819), 201 (100%), 157 (92), 57 (100). 
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9.6 Biological Testing 
9.6.1 Biological Testing Chapter 5 
9.6.1.1 DNA Cross-linking Activity of Macrocyclic Mustards 
The method used was the agarose gel cross-link assay.151a pBR322 plasmid DNA was 
linearised by digestion with HinDIII and dephosphorylated by treatment with bacterial 
alkaline phosphatase. The DNA was 5’-end labeled using T4 polynucleotide kinase and [γ-
32P] ATP (5000 Ci/mmol, Amersham, UK). Following precipitation and removal of 
unincorporated ATP, the DNA was resuspended in sterile double-distilled water at 1 
mg/mL. Approximately 10 ng of labeled DNA were used for each experimental point. 
Reactions with drug were performed in 25 mM triethanolamine, 1 mM EDTA (pH 7.2) at 
37 oC for 2 h. Reactions were terminated by the addition of a greater than equal volume of 
stop solution (0.6 M sodium acetate, 20 mM EDTA, 100 µg/mL tRNA) and the DNA was 
precipitated by the addition of 3 vols 95% ethanol. Following centrifugation and removal 
of supernatant, the DNA pellet was dried by lyophilisation. Samples were dissolved in 10 
µL strand separation buffer (30% DMSO, 1mM EDTA, 0.04% bromophenol blue, 0.04% 
xylene cyanol), heated at 90 oC for 2 min and chilled immediately in an ice-water bath 
prior to loading. Control undenatured samples were dissolved in 10 µL 6% sucrose, 0.04% 
bromophenol blue and loaded directly. Electrophoresis was performed on 20 cm long 0.8% 
submerged horizontal agarose gels at 40 V for 16 h. The gel and running buffer were 40 
mM Tris, 20 mM acetic acid and 2 mM EDTA (pH 8.1). Gels were dried at 80 oC onto one 
layer of Whatman 3 MM and one layer of DE81 filter papers on a BioRad Model 583 gel 
drier connected to a vacuum. Autoradiography was performed with Hyperfilm MP 
(Amersham, UK) at -70 oC using a DuPont-Cronex Lightening-plus intensifying screen. 
Sharper images were obtained by overnight exposure without the intensifying screen. The 
percentage double stranded (cross-linked) DNA was obtained in each lane using a BioRad 
Imaging Densitometer. 
9.6.1.2 Cytotoxicity of Macrocyclic Mustards 
The cytotoxic effects of the free ligands studied were measured against the human chronic 
myeloid leukaemia cell line K562. Cells were maintained as a suspension in RPMI 1640 
medium supplemented with 10% foetal calf serum and 2 mM glutamine at 37 oC in a 
humidified atmosphere containing 5% CO2. Following a 1 h exposure to the sample, the 
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corresponding IC50 value was determined using the MTT assay.151b,151c This is based on the 
ability of viable tumour cells to convert a yellow tetrazolium salt [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-2H-tetrazolyium bromide, MTT] into mauve formazan crystals. 
9.6.1.3 Trypanosome Cell Line 
9.6.1.3.1 Trypanosoma brucei brucei 427 
T. b. brucei EATRO (East African Trypanosomiasis Research Organisation) 427 was used 
routinely for uptake assays. These stocks were supplied by Dr M. P. Barrett, University of 
Glasgow. 
9.6.1.3.2 T. b. brucei 427 ∆Tbat1 Mutant Clone 
The ∆Tbat1(P2) null mutant clone was constructed by sequential replacement of  TbAT1 
with the neomycin and puromycin resistance markers in T. b. brucei 427. This knockout 
cell line was four-fold less sensitive to melasoprol and melarsen oxide. These stocks are 
held at the University of Glasgow. 
9.6.1.4 Growth and Maintenance of Bloodstream-Form Trypanosome Stocks 
9.6.1.4.1 In vitro culture 
Cultures were incubated in sterile culture flasks at 37 oC and 5% CO2 in HMI-9 medium 
containing 20% heat-inactivated foetal calf serum. 5 mL cultures were seeded with 200 µL 
of culture at 2 x 106 cells/mL. Cells were allowed to grow for 3 d after which they had 
reached maximum density (approximately 2 x 106 cells/mL) and were passaged again in 
the same way. 
9.6.1.5 Trypanotoxicity 
9.6.1.5.1 In vitro Toxicity Assay (Alamar Blue Assay) 
The Alamar Blue assay was used to assess toxicity in vitro.153 Doubling serial dilutions of 
test compound were set out in a 96 well plate in duplicate, in a volume of 100 µL HMI-9 
medium.154 100 µL of trypanosomes at 2 x 105 cells/mL were added to each well. After 48 
h incubation at 37 oC and 5% CO2, 10% Alamar Blue (20 µL) was added to each well and 
the plates incubated for a further 24 h. Unspecified enzymes in the live cells reduce the 
Alamar Blue to the colourless form. The concomitant change in absorption at 600 nm can 
be measured spectrophotometrically, or fluorometric measurements can be taken at 530 nm 
excitation and 590 nm emission as the amount of fluorescence detectable at these 
wavelengths increases in the reduced dye. All measurements were taken fluorometrically. 
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The EC50 value was calculated by analysing the data with the EC50 algorithm of the Grafit 
4.0 (Erithracus Software) or using Prism 3.0 (GraphPad, San Diego, CA, USA). Values 
were checked for accuracy by visually examining cell viability and motility. Each 
experiment was performed in duplicate and replicated at least once. 
9.6.1.6 Human Embryonic Kidney Cells 
Human Embryonic Kidney Cells (HEK), strain 293T, were used as the mammalian cell 
line for comparative analyses. HEK cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (Sigma) with penicillin/streptomycin (10 mg/mL), L-Glutamax (200 nM), and 
10% newborn calf serum in vented culture flasks at 37 oC in 5-10% CO2 atmosphere, 
passaging when cells on the monolayer are 80-85% confluent. The Alamar Blue assay 
protocol was modified from the one used for live trypanosomes; 100 µL of a 3 x 105 
cells/mL suspension was added to each well of a 96 well plate and incubated at 37 oC for 3 
h to allow cells to adhere to the bottom of the wells. Preparation of drug stocks in doubling 
dilution was added after the incubation period, incubated for a further 12-16 h before the 
addition of 10% Alamar Blue (20 µL). After 24 h the plates were read fluorometrically and 
visually as above. 
9.6.1.7 Fluorescence Assays 
9.6.1.7.1 Wet Slides 
A culture of the cells in HMI-9 medium was centrifuged and the excess medium poured 
off. 5.0 mL of CBSS solution was used to re-suspend the cells before centrifuging and 
pouring off excess CBSS. This process was repeated twice to wash the cells and remove 
soluble blood components. 2.0 µL of 10.0 mM fluorescent drug compounds was added to 
0.5 mL cells in CBSS solution in a 0.5 mL vial. After five min the vial was centrifuged, the 
excess solution removed, and 0.2 µL solution removed to a glass slide and a cover slip 
added. The was viewed directly through the Zeiss Axioscope FL fluorescence microscope 
using a Zeiss 02 filter at an excitation wavelength of 330 nm and an emission wavelength 
of 400 nm. Images were obtained by the same method but using an Axiovert 200M 
Fluorescence microscope. This technique was repeated to cover a 5-90 min time period. 
9.6.2 Biological Testing Chapter 8 
Protein expression levels were assessed by Western Blotting, after incubation of primary 
human pigment epithelial (RPE) cells with 1-20 µM of each compound for 24 h. Proteins 
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from whole cell extracts were separated by SDS 12% polyacrylamide gel electrophoresis 
and analysed by Western blotting with anti-p53 DO-1 (Pharmingen), anti-HDM2 
AB1/AB2 (Oncogene Science), anti-phospho-p53 (serine-15) (Cell Signaling) and anti-
21WAF1/CIP1 (Santa Cruz Biotechnology) antibodies. Blots were also probed with an anti-
Cdk4 antibody (Santa Cruz Biotechnology) to monitor protein loading. The effects of some 
of the compounds were assessed by flow cytometry. 
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9.7 Experimental Crystallography Details 
Details of data collection procedures and structure refinement are given in the following 
table. CIF data can be accessed online at http://www.chem.gla.ac.uk/~louis/data/. Single 
crystals of suitable size were attached to glass fibres using acrylic resin, and mounted on a 
goniometer head in a general position. Data was collected on an Enraf-Nonius KappaCCD 
diffractometer, running under Nonius Collect software, and using graphite monochromated 
X-radiation (λ=0.71073 Å). All data sets were collected at a temperature of 150 K using an 
Oxford Instruments Cryostream. Typically scan angles of 1-2 o were used, with integration 
times of 50-100 s per image. Precise unit cell dimensions were determined by post-
refinement of the setting angles of a large proportion of the data set. The frame images 
were integrated using Denzo(SMN)216 and the resultant raw intensity files processed using 
a locally modified version of DENZOX.217 Absorption corrections, either by Gaussian 
quadrature,218 based on the measured crystal faces, or by a semi-empirical correction219 
were applied to all data sets. Data were then sorted and merged using SORTAV.220 
Structures were solved either by Patterson interpretation (DIRDIF-99)221 or by direct 
methods (SIR92).222 Refinement with SHELXL97-2 using full-matrix least squares on F2 
and all the unique data. Neutral atom scattering forces, coefficients of anomalous 
dispersion and absorption coefficients were obtained from reference. All calculations were 
carried out using the WinGX package of crystallographic programs.223 
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Compound number 84 85 181 
Compound formula C44H56N8O8 C32H64N8O8 C19H12F3N3O2 
Compound colour colourless colourless yellow 
Mr 824.97 688.91 371.32 
Space group P21/a P21/a P-1 
Crystal system monoclinic monoclinic triclinic 
a/Å 11.0274 (5) 12.8699 (5) 10.0933 (4) 
b/Å 8.9869 (5) 9.5994 (4) 12.4331 (5) 
c/Å 21.2550 (8) 17.0767 (8) 14.8188 (6) 
β/deg 91.304 (3) 111.043 (2) 93.650 (2) 
V/Å-3 2105.87 (17) 1969.01 (15) 1736.60 (12) 
Z 2 2  4 
Dcalc/ g cm-3 1.301 1.162 1.42 
F(000) 880 752 760 
µ(Mo-Ka)/mm-1 0.091 0.084 0.116 
Crystal size/mm 0.48 x 0.41 x 0.13 0.39 x 0.35 x 0.25 0.6 x 0.4 x 0.2 
Transmission coefficients (range) 1.000-0.798 n/a n/a 
θ range/deg 2.46-26.45 1.28-26.14 1.46-26.51 
No. of data measured 21987 17875 33364 
No. of unique data 4331 3920 7137 
Rint 0.0758 n/a 0.0102 
No. of data in refinement 4331 3920 7137 
No. of refined parameters 280 218 501 
Final R[I>2σ(l)] (all data) 0.0589 0.0631 0.047 
Rw2[I>2σ(l)] (all data) 0.1194 0.0998 0.0759 
Flack parameter n/a n/a n/a 
Goodness of fit S 1.056 1.086 1.052 
Largest residuals/eÅ-3 0.31, -0.323 0.444, -0.323 0.188, -0.19 
Max shift/esd in last cycle 0.001 0.004 0.008 
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